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Preface 
This surveillance report presents information on drug-related deaths, both of addicts and non-addicts, 
that occurred during 2012 and for which Coronial inquests and similar formal investigations have been 
completed and information submitted. Its main purpose is to provide an analytical summary of data 
received, and through consistent surveillance to detect and identify emerging patterns and issues in 
respect of drug-related deaths. In this way, it contributes to the reduction and prevention of drug-
related deaths in the UK due to the misuse of both licit and illicit drugs. 
 
The Programme could not achieve its goals and objectives without the invaluable voluntary 
collaboration and co-operation of Coroners and their staff across England, Wales, Northern Ireland, 
Guernsey, Jersey, and the Isle of Man. Scottish drug-related deaths data are provided by the Scottish 
Crime and Drug Enforcement Agency. Additional data is provided by the Northern Ireland Statistics 
and Research Agency on drug-related poisonings from the General Mortality Register. The 
contributions from all these sources are important as it enables the Programme to maintain a UK-wide 
reporting and surveillance system. We thank them all for their active participation and support.  
 
The findings show a decrease in the number of reported deaths in 2012 submitted to NPSAD by 
Coroners from England, Wales, Northern Ireland and the Islands when compared to the number 
reported in last year’s report. Death notifications recorded by the Scottish Police also decreased. Part 
of the fall in Coroners’ notifications may be attributed to a lower notification rate, and changes within 
the Coronial system.  
 
As in previous years, the statistics in this report are intended to inform authorities at the local, regional 
and national levels, as well as health and other professionals about the serious consequences of drug 
abuse, especially polydrug use. 
 
The report also provides a number of indications of changes in patterns of drug-related deaths over 
time, and highlights emerging issues so that appropriate action can be considered. 
 
 
Professor Fabrizio Schifano 
Advisor to the National Programme on Substance Abuse Deaths 
International Centre for Drug Policy 
St George’s, University of London 
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Key findings for the UK and Islands 
A total of 1,613 notifications of drug-related deaths occurring in 2012 in the UK and Islands were 
submitted to the Programme prior to the publication of this Annual Report, whilst over 100 more 
deaths in the UK for 2012 have been reported since analysis began. The data presented here were 
provided by 87 of the 111 Coroners’ jurisdictions in England & Wales; an overall response rate of 
78.4%, giving very high coverage for an entirely voluntary reporting system, and for this we thank the 
Coroners for their support.  
The highest rates of drug-related deaths per 100,000 population aged 16 and over in 2012 were in the 
following DAAT areas: Liverpool (12.57); Blackburn with Darwen (11.45); Hammersmith and Fulham 
(11.34); Sunderland (10.55); and Manchester (8.79). 
The principal demographic characteristics of the decedents have remained consistent with previous 
reports, with the majority of cases male (72.2%); under the age of 45 years (67.5%); and where 
ethnicity was known, White (97.3%). 
Accidental poisoning remained the primary underlying cause of death in cases reported to NPSAD, 
accounting for 67.9% of deaths, followed by poisoning of undetermined intent (11.2%) and intentional 
self-poisoning (11.0%). Across all age groups, accidental poisoning remained the most frequent 
underlying cause of death, whilst a greater proportion of older females died of intentional self-
poisoning than males. This pattern has remained consistent across the years. 
Heroin/morphine remained the principal substance implicated in death in the UK and Islands for 2012; 
however the proportion of deaths in which the drug was implicated rose from its lowest level in 2011 
to 36.4% in 2012. This increase of 4.5% from last year contrasts with the steady decline that was 
seen between 2009 (52.5%) and 2011 (31.9%) for deaths involving this drug. Another change in the 
drug-related death trends witnessed in recent years was seen in the proportion of cases involving 
methadone: deaths in 2012 involving this substance fell to 27.6%, which is in contrast to the steady 
rise seen from 2008 to 2011 (from 22.4% to 30.8%). Deaths involving hypnotics/sedatives, such as 
benzodiazepines, continued the consistent rise seen in previous years from 21.8% in 2008 to 30.3% 
in 2012.  
The slight increase in deaths noted in last year’s report in which stimulants such as cocaine and 
ecstasy were implicated has continued into 2012 (accounting for 1.7% and 1.2% respectively, up from 
1.2% and 0.7%), whilst deaths involving amphetamines stabilised. Of particular interest is that the 
number of deaths in which cocaine was implicated was higher in Liverpool than the whole of either the 
Midlands and East of England, London, or the South of England. Taking into account the population 
size of these regions compared to Liverpool highlights the importance of this figure. 
As in 2011, 2012 saw a substantial number of deaths reported involving Novel Psychoactive 
Substances (NPS), again dominated by methcathinones such as mephedrone. Deaths involving other 
drugs of interest such as pregabalin and venlafaxine are discussed along with selected NPS in 
Chapter 8: Commentary and Emerging Themes. 
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Regional key findings 
 
England – NPSAD definition 
A total of 1,147 deaths were reported to the Programme for 2012 (1,424 in 2011). Whilst the 
demographics and substances implicated in death remained relatively stable, there was a marked 
increase in the proportion of deaths involving heroin/morphine and a modest decrease in the 
proportion involving methadone. This is a reversal in the pattern seen in recent years. As seen in 
2011, the most common prescribed medications implicated in death were anti-depressants and 
hypnotics/sedatives.  
England – Drug Strategy definition (“drug misuse”) 
A total of 865 deaths were reported for 2012 (1,026 in 2011). After the substantial reduction in the 
proportion of deaths attributed to heroin/morphine in 2011 compared to 2010 noted in last year’s 
report (45.8% to 37.9%), the proportion in 2012 rose to pre-2011 levels of 42.8%.  Heroin/morphine 
therefore remained the most frequently implicated substance in those deaths qualifying as “drug 
misuse” cases. Whilst deaths attributed to accidental poisoning remained at 2011 levels, a 3.5% 
decrease was seen in deaths attributed to intentional self-poisoning.  
Wales – NPSAD definition 
A total of 58 deaths were reported to NPSAD for 2012 (81 in 2011). Similar to what was seen in 
England, there was a substantial rise of 5.5% in the percentage of deaths attributed to 
heroin/morphine in Wales for 2012. However, in contrast to England, there was a 3.5% rise in the 
proportion of deaths in which methadone was implicated. Since 2009 the percentage of Welsh deaths 
involving methadone has increased by 19.7%. Meanwhile, the proportion of deaths involving other 
opiates/opioid analgesics more than halved, from 30.4% in 2011 to 15.1% in 2012. 
Northern Ireland – NPSAD definition 
The number of NPSAD deaths reported in 2012 was 78 (82 in 2011). As found in recent years, whilst 
heroin/morphine- and methadone-related deaths were much less prominent, other opiates/opioid 
analgesics played a much greater role in Northern Ireland (NI) than in the rest of the UK (60.8% in NI 
compared with 26.8% for the UK as a whole). 
Scotland – NPSAD definition 
The number of deaths reported to police in Scotland fell in 2012 to 326 (from 339 in 2010). Consistent 
with previous years, opiates such as methadone play a larger role in Scottish deaths reported to the 
Programme than in other regions; this may be due in part to the different definition used by the police 
in Scotland when recording the deaths. Deaths involving hypnotics/sedatives and anti-depressants 
also increased between 2011 and 2012. 
The Islands – NPSAD definition 
The Programme was notified of two deaths on the Isle of Man and two on Jersey during 2012. No 
NPSAD deaths were reported for Guernsey. 
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Introduction 
This fourteenth annual report continues the series of reports published by the National Programme on 
Substance Abuse Deaths (NPSAD). It covers deaths occurring between January and December 2012 
reported to the Programme, as well as presenting information on emerging patterns and issues that 
need monitoring. The data reported are also used to inform key public agencies, both in the UK and 
Europe, on particular drugs and their role in deaths. 
There is a chapter for each constituent part of the UK (England, Wales, Scotland, Northern Ireland 
and Guernsey, Jersey and Isle of Man) with a graphical summary on each chapter’s cover page of the 
key findings for each country. Chapter 1 provides a substantive description of the situation regarding 
drug-related deaths in England during 2012 meeting the NPSAD case definition, including data tables 
for a detailed breakdown of areas within England. Chapter 2 looks at deaths in England meeting the 
definition used for the Drug Strategy. Chapters 3 to 6 cover the other parts of the UK and Islands, with 
Chapter 7 presenting findings for the UK as a whole. A commentary on emerging issues is given in 
Chapter 8, whilst Chapter 9 highlights other issues involving the cases reported. Further details about 
the Programme are given in the appendices. 
Definitions used in this report 
An NPSAD case is defined as a death where any of the following criteria are met at a completed 
inquest, fatal accident inquiry or similar investigation: 
 One or more psychoactive substance directly implicated in death; 
 History of dependence or abuse of psychoactive drugs;  
 Presence of Controlled Drugs at post mortem; or 
 Cases with deaths directly due to drugs but with no inquest. 
 A “Drug misuse” case is defined as a death where: 
 The underlying cause of death is drug abuse or drug dependence; or  
 The underlying cause is drug poisoning and where any of the substances controlled under 
the Misuse of Drugs Act 1971 are involved. 
The cases reported to the Programme by the SCDEA are those which meet the definition used by the 
Association of Chief Police Officers (Scotland) – “where there is prima facie evidence of a fatal 
overdose of controlled drugs”. Full definitions for drug-related deaths can be found in the appendices. 
Other activities  
The Programme provides information to public consultations; parliamentary questions; and Ministerial 
briefings. For many years information has been provided to the Advisory Council on the Misuse of 
Drugs (ACMD) and the UK Drugs Early Warning System (DEWS) on substances being found in post 
mortem toxicology as well as epidemiological data relating to drug-related mortality. The analysis 
performed on the data is used along with other evidence, to inform the advice and recommendations 
given by the ACMD to Government Ministers about harms arising from drug use. The data provided 
play a vital role in the formulation of policy relating to particular drugs. Since 2012 data have been 
provided at the ACMD’s request on: 
 The presence and/or role of ‘Z’ (zaleplon, zolpidem and zopiclone) drugs in UK deaths 
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 UK deaths associated with ketamine analogues and derivatives including methoxetamine for 
the Ketamine and related matters Working Group 
 UK deaths involving tramadol 
 Novel Psychoactive Substances including benzofury and NBOMe 
Similarly, findings from the Programme’s Annual Report and research articles are used in national 
and international research. The European Monitoring Centre Drugs for and Drug Addiction has also 
used data provided by NPSAD on UK deaths where fentanyl and tramadol have been involved. 
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Chapter 1: Drug-related deaths in England using the NPSAD 
definition 
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This chapter examines drug-related deaths which occurred in England in 2012, reported 
voluntarily by Coroners. Responses were voluntarily submitted from a total of 78 out of 99 
Coroners' jurisdictions in England, giving a total coverage rate of 78.8%. This figure represents a 
remarkably high compliance rate for an entirely voluntary process, and we thank the Coroners of 
England for their continuing support. 
 
The first section in this chapter examines the overall demographics of drug-related deaths 
reported to NPSAD; examines cases that capture a range of psychoactive drugs; and covers the 
history of drug use irrespective of the cause of death. Included within this section is a 
comparison of those with a history of drug use against those without. This section highlights any 
changes between 2011 and 2012 including figures for the Drug and Alcohol Action Team areas 
and a breakdown for the English regions.  
 
Profile of NPSAD cases  
1.1 Demography 
In 2012, there were 1,147 NPSAD drug-related deaths reported to the Programme. Male cases 
accounted for 71.4%, whilst 28.6% were female (Table 1.1 and Figure 1.1). Around forty-five per 
cent (45.2%) of cases were unemployed, and over sixty per cent (64.3%) of deaths occurred 
among those less than 45 years old. Those living alone accounted for 43.6% of cases; 39.6% 
lived with others; and 2.9% were of no fixed abode.  Where ethnicity was known (n = 742), the 
vast majority were White (96.6%); with the remainder Black (1.6%); Indian (0.5%); and Pakistani 
and other ethnicities (1.2%). 
 
Table 1.1: Demographic variables for NPSAD drug-related deaths, England, 2012 
 
Variable Category Number (%) 
TOTAL  1,147 (100.0) 
Gender Male 819 (71.4) 
Female 328 (28.6) 
Employment status Employed 326 (28.4) 
Unemployed 519 (45.2) 
Childcare/house person 29 (2.5) 
Student  20 (1.7) 
Retired/invalidity/sickness 114 (9.9) 
Not known 139 (12.1) 
Living arrangements Alone 500 (43.6) 
With others 454 (39.6) 
Other 51 (4.4) 
No fixed abode 33 (2.9) 
Not known 109 (9.5) 
Ethnicity Black 12 (1.0) 
Indian 4 (0.3) 
White 717 (62.5) 
Other 9 (0.8) 
Not known 405 (35.3) 
 
1.2 Age  
Most NPSAD drug-related deaths in England during 2012 occurred amongst those aged 44 
years and under (64.3%) (Figure 1.1). The median age at death was 41 years (interquartile 
range = 16). This is consistent with the statements of Bird et al (2003) and Ghodse et al. (2009), 
that older male, White drug users are at most risk of drug-related deaths.  
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Figure 1.1: NPSAD drug-related deaths by age group and gender, England, 2012 
 
 
1.3 Location of death 
In 2012, 70.8% of cases died at the deceased’s home address or another private residential 
address; 15.5% died in hospital; 6.1% died in a public place (e.g. park or public facilities); with 
7.5% of cases dying at other or unspecified locations. 
 
1.4 Underlying cause(s) of death 
The categories of underlying cause(s) of death for coding within ICD-10 (Appendix 1) were as 
follows: 
 Accidental poisoning (X40-X47): 63.1% 
 Intentional self-poisoning (X60-X67): 13.7%  
 Poisonings of undetermined intent (Y10-Y17): 12.1% 
 Other (e.g. natural causes, drowning, hanging): 10.3% 
 Unascertained (R99): 0.8% 
 
Of the cases reported to NPSAD, a greater proportion of male deaths were attributed to 
accidental poisoning compared to female deaths (66.2% vs. 55.5%). In contrast, a 
proportionately larger number of female deaths were as a result of intentional self-poisoning 
(17.4% vs. 12.2%) and poisoning of undetermined intent (18.9% vs. 9.4%) 
 
Deaths amongst those aged 44 years and younger were attributed to accidental poisoning more 
often than older cases (68.9% vs. 52.9%). By contrast, the deaths of those aged 45 years or 
over were not only more commonly attributed to intentional self-poisoning than younger cases 
(21.7% vs. 9.2%), but also to poisoning of undetermined intent (15.1% vs. 10.4%). 
 
1.5 Manner of death  
The results for 2012 cases are as follows: 
 Accidental: 63.9% 
 Suicidal: 16.7% 
 Undetermined: 14.5% 
 Natural: 4.4% 
 Homicidal: 0.6% 
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A greater proportion of male deaths were deemed accidental compared to female deaths (67.0% 
vs. 56.1%). Conversely, there were proportionately more deaths attributed to suicide in females 
than in males (18.6% vs. 15.9%), and also deaths where the manner was undetermined (20.4% 
vs. 12.1%). 
 
The manner of death of those aged less than 45 years was deemed accidental more often than 
in older cases (71.0% vs. 51.2%). Those aged 45 years or over had proportionately more deaths 
than younger cases attributed to suicide (24.1% vs. 12.5%), and to a manner that was 
undetermined (17.3% vs. 12.9%). 
 
Psychoactive substances implicated in death  
1.6 Psychoactive substances 
Of the 1,147 NPSAD-related deaths in 2012, psychoactive drugs, including alcohol in 
combination, were directly implicated in 1,033 (90.1%). Of these, the principal substances 
implicated were heroin/morphine (35.2%); alcohol in combination with other substances (33.7%); 
other opiates/opioid analgesics (26.7%); anti-depressants (25.1%); hypnotics/sedatives (24.1%); 
methadone (22.7%); and cocaine (11.1%) shown in Table 1.6. 
 
Table 1.6: Psychoactive substances implicated in NPSAD deaths, England, 2012 
 
Drug category 
Number (%) of psychoactive 
drug cases where no other 
substance was implicated 
 
Number  (%) of 
psychoactive drug cases 
where drug was implicated 
 
TOTAL 1,033 (100.0) 
Alcohol in combination - 348 (33.7) 
Amphetamines 16 (1.5) 41 (4.0) 
Anti-depressants 48 (4.6) 259 (25.1) 
Anti-epileptics 6 (0.6) 25 (2.4) 
Anti-Parkinson’s 0 (0.0) 2 (0.2) 
Anti-psychotics 5 (0.5) 60 (5.8) 
Cannabis 2 (0.2) 24 (2.3) 
Cocaine 24 (2.3) 115 (11.1) 
Ecstasy-type drugs 19 (1.8) 38 (3.7) 
GHB/GBL 6 (0.6) 11 (1.1) 
Heroin/morphine 88 (8.5) 364 (35.2) 
Hypnotics/sedatives 24 (2.3) 249 (24.1) 
Mephedrone 1 (0.1) 13 (1.3) 
Methadone 40 (3.9) 234 (22.7) 
Other opiates/opioid 
analgesics 
47 (4.5) 276 (26.7) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in death. Not all 
cases had psychoactive substances directly implicated in death: these are excluded from this table. 
 
1.7 Psychoactive substances most frequently implicated for each age group  
As shown in Table 1.8 below, for those aged 14 years and under, ecstasy-type drugs; 
heroin/morphine; and mephedrone were each implicated once (mephedrone and ecstasy-type 
drugs in one death; heroin/morphine alone in another); whilst for 15-24 year olds, alcohol in 
combination with other drugs was the most frequently implicated psychoactive substance in their 
deaths. Heroin/morphine was identified as the psychoactive substance most frequently implicated 
in the deaths of those aged between 25-44 years, representing 67.9% of all deaths implicated to 
the drug reported in England, in 2012. Alcohol in combination was also the most frequently 
implicated psychoactive substance in the deaths of those aged 45-54 years; with anti-
depressants being the psychoactive substance implicated most often in the 55-64 years age 
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group. Hypnotics/sedatives were once again the drugs most frequently implicated in the deaths of 
those aged 65 and over.  
 
1.8 Age group with highest frequency for each psychoactive substance implicated 
As Table 1.8 below shows, alcohol in combination; amphetamines; anti-depressants; anti-
Parkinson’s; anti-psychotics; cannabis; cocaine; GHB/GBL; heroin/morphine; 
hypnotics/sedatives; methadone; and other opiates/opioid analgesics were most commonly 
implicated in the deaths of those aged between 35-44 years. Ecstasy-type drugs were again most 
commonly implicated in the deaths of the 15-24 age group. Mephedrone and anti-epileptics were 
implicated most often in the 25-34 age group. 
 
Table 1.8: Age group and psychoactive substance implicated in death, NPSAD cases, 
England, 2012 
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Alcohol in 
combination 
0 
(0.0) 
24 
(6.9) 
74 
(21.3) 
131 
(37.6) 
76 
(21.8) 
33 
(9.5) 
10 
(2.9) 
348 33.7% 
Amphetamines 0 
(0.0) 
2 
(4.9) 
9 
(22.0) 
15 
(36.6) 
12 
(29.3) 
3 
(7.3) 
0 
(0.0) 
41 4.0% 
Anti-
depressants 
0 
(0.0) 
16 
(6.2) 
41 
(15.8) 
74 
(28.6) 
67 
(25.9) 
44 
(17.0) 
17 
(6.6) 
259 25.1% 
Anti-epileptics 0 
(0.0) 
2 
(8.0) 
9 
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25 2.4% 
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Anti-psychotics 0 
(0.0) 
3 
(5.0) 
15 
(25.0) 
17 
(28.3) 
11 
(18.3) 
12 
(20.0) 
2 
(3.3) 
60 5.8% 
Cannabis 0 
(0.0) 
7 
(29.2) 
4 
(16.7) 
9 
(37.5) 
3 
(12.5) 
0 
(0.0) 
1 
(4.2) 
24 2.3% 
Cocaine 0 
(0.0) 
6 
(5.2) 
35 
(30.4) 
40 
(34.8) 
21 
(18.3) 
10 
(8.7) 
3 
(2.6) 
115 11.1% 
Ecstasy-type 1 
(2.6) 
19 
(50.0) 
7 
(18.4) 
8 
(21.1) 
3 
(7.9) 
0 
(0.0) 
0 
(0.0) 
38 3.7% 
GHB/GBL 0 
(0.0) 
1 
(9.1) 
4 
(36.4) 
6 
(54.5) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
11 1.1% 
Heroin/ 
morphine 
1 
(0.3) 
19 
(5.2) 
93 
(25.5) 
154 
(42.3) 
57 
(15.7) 
29 
(8.0) 
11 
(3.0) 
364 35.2% 
Hypnotics/ 
sedatives 
0 
(0.0) 
13 
(5.2) 
55 
(22.1) 
98 
(39.4) 
39 
(15.7) 
23 
(9.2) 
21 
(8.4) 
249 24.1% 
Mephedrone 1 
(7.7) 
2 
(15.4) 
5 
(38.5) 
2 
(15.4) 
3 
(23.1) 
0 
(0.0) 
0 
(0.0) 
13 1.3% 
Methadone 0 
(0.0) 
13 
(5.6) 
 
63 
(26.9) 
 
97 
(41.5) 
38 
(16.2) 
 
20 
(8.5) 
3 
(1.3) 
234 
 
22.7% 
Other 
opiates/opioid 
analgesics 
0 
(0.0) 
11 
(4.0) 
45 
(16.3) 
87 
(31.5) 
 
 
68 
(24.6) 
 
43 
(15.6) 
21 
(7.6) 
276 
 
 
26.7% 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not all 
cases had drugs directly implicated in death; these are excluded from this table. 
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1.9 Gender and implicated psychoactive substance 
The type of psychoactive substances implicated in fatalities is somewhat different between male 
and female cases. 
 
Among male cases in which psychoactive drugs were implicated (n = 730), the top five 
substances most frequently implicated alone or in combination, presented in numerical order 
were: 
1. Heroin/morphine (38.4%) 
2. Alcohol in combination (36.0%) 
3. Other opiates/opioid analgesics (25.5%) 
4. Methadone (24.5%) 
5. Hypnotics/sedatives (24.2%). 
 
Amongst female cases in which psychoactive drugs were implicated (n = 303), the top five 
substances most frequently implicated alone or in combination were: 
 
1. Anti-depressants (39.9%) 
2. Other opiates/ opioid analgesics (29.7%) 
3. Alcohol in combination (28.1%) 
4. Heroin/morphine (27.7%) 
5. Hypnotics/sedatives (23.8%) 
 
Comparing the type of psychoactive substances implicated in the deaths of males and females 
reveals that there is a higher proportion of male deaths compared to female deaths involving 
heroin/morphine; alcohol in combination; methadone; hypnotics/sedatives; cocaine; GHB/GBL; 
cannabis; amphetamines; anti-Parkinson’s drugs; mephedrone; and ecstasy-type drugs. 
 
Females, compared to males, show a greater proportion of deaths implicating anti-depressants; 
other opiates/opioid analgesics; anti-psychotics; and anti-epileptics.  
 
1.10 Polysubstances 
In 2012, 14.0% of the 1,033 psychoactive substance-related deaths reported to NPSAD involved 
heroin/morphine in combination with alcohol; whilst 8.5% involved heroin/morphine and 
hypnotics/sedatives combined; and 7.8% involved heroin/morphine in combination with 
methadone. Deaths involving hypnotics/sedatives with anti-depressants accounted for 7.1% of 
cases; 8.8% involved other opiates/opioid analgesics combined with alcohol; whilst 7.9% of 
deaths involved heroin/morphine and other opiates/ opioid analgesics combined. The 
combination of heroin/morphine and other opiates/opioid analgesics has fluctuated between 4% 
and 9% over the past ten years. Over the last decade alcohol in combination with two other 
stimulants constantly featured. Combinations of drugs, with or without alcohol, pose greater risks 
for mortality (Ghodse et al., 2010). 
 
In 2012, several different substance types, when implicated in combination, often featured with 
alcohol. Alcohol was implicated in 54.2% of deaths involving cannabis; 40.6% involving 
hypnotics/sedatives; 39.8% involving heroin/morphine; 38.9% involving methadone; 38.5% 
involving mephedrone; 33.0% involving other opiates/opioid analgesics; 32.8% involving anti-
depressants; and 31.3% of cases involving cocaine. 
 
1.11 Single substances 
In 2012, there were 326 (31.6%) psychoactive substance deaths in which only one of the 
following substances was implicated. Of these 326 deaths from single substances, 
heroin/morphine accounted for 26.9% of deaths; anti-depressants – 14.0%; other opiates/opioid 
analgesics – 14.4%; methadone – 12.3%; hypnotics/sedatives – 7.4%; cocaine – 7.4%; ecstasy-
type drugs – 5.8%; amphetamines – 4.9%; anti-epileptics – 1.8%; GHB/GBL – 1.8%; anti-
psychotics – 1.5%; cannabis – 0.6%; and mephedrone – 0.3%. 
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1.12 Prescribed psychoactive drugs  
In total, 655/1,147 cases (57.1%) were reported to be receiving prescribed psychoactive drugs 
at the time of their death in 2012 (Table 1.12); whilst 244 cases (21.3%) were confirmed as not 
being prescribed psychoactive medication; and 248 had unknown prescription status (21.6%). Of 
those who were prescribed psychoactive drugs (n = 655), prescribed drugs reported were: anti-
depressants (58.0%); hypnotic/sedatives (39.8%); other opiates/opioid analgesics (31.0%); anti-
psychotics (18.9%); methadone (17.9%); anti-epileptics (16.6%); heroin/morphine (6.3%); and 
anti-Parkinson’s (1.7%). ‘Polypharmacy’, i.e. multiple prescriptions of psychoactive drugs, 
occurred in 63.8% (418/655) of these cases. 
 
Age appeared to be related to whether the cases were on prescribed psychoactive medication or 
not when prescribing history was known at the time of death, with 40.6% of 15-24 year olds 
prescribed psychoactive medication; 25-34 (63.2%); 35-44 (76.4%); 45-54 (78.7%); 55-64 
(90.8%); and 65 and over (74.5%). 
 
 
Table 1.12: Prescribed psychoactive medication, NPSAD cases, England, 2012  
Drug category 
Number (%) of cases on 
prescribed 
psychoactive medication 
by drug 
Number (%) of these 
cases where same 
prescribed drug was 
implicated in death 
TOTAL 655 (100.0) - 
Anti-depressants 380 (58.0) 177 (46.6) 
Anti-epileptics 109 (16.6) 16 (14.7) 
Anti-Parkinson’s 11 (1.7) 2 (18.2) 
Anti-psychotics 124 (18.9) 44 (35.5) 
Heroin/morphine 41 (6.3) 33 (80.5) 
Hypnotic/sedatives 261 (39.8) 109 (41.8) 
Methadone 117 (17.9) 78 (66.7) 
Other opiates/opioid 
analgesics 
203 (31.0) 117 (57.6) 
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual 
and more than one substance may be implicated in a death. 
 
 
The following paragraphs further examine NPSAD deaths and the involvement of prescribed 
medication. 
 
Methadone, alone and in combination with other drugs, was implicated in 234 cases. Of these, 
156 people (66.7%) may have obtained methadone from illicit sources, compared to 78 (33.3%) 
who were known to be receiving prescribed methadone prior to their death. Methadone alone 
was implicated in 40 cases. Of these, 30 (75.0%) may have obtained the drug from illicit 
sources, compared to 10 (25.0%) who were known to be receiving prescribed methadone. 
 
Hypnotic/sedatives, alone and in combination with other drugs, were implicated in 249 cases. Of 
these, 109 (43.8%) were known to be prescribed these drugs, thus it is now known how 140 
cases (56.2%) obtained them. Of the 24 cases in which hypnotic/sedatives alone were 
implicated, 11 (45.8%) had received the drugs on prescription, compared to 13 (54.2%) who 
may have obtained them illegally. 
 
Anti-depressants, alone and in combination with other drugs, were implicated in 259 cases. Of 
these, 177 (68.3%) were known to be receiving prescribed anti-depressants at the time of their 
death, compared to 82 (31.7%) who may have taken drugs prescribed to others. Anti-
depressants alone were implicated in 48 cases. Of these, 35 (72.9%) were known to be 
prescribed anti-depressants, compared to 13 (27.1%) who may have used drugs that were 
prescribed to others. 
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Other opiates/opioid analgesics (e.g. dextropropoxyphene, or where the exact opiate-type drug 
was unknown) alone and in combination with other drugs, were implicated in 276 cases. Of 
these, 159 (57.6%) may have obtained the drug by illicit means, compared to the 117 (42.4%) 
who were known to be prescribed other opiates/opioid analgesics. Other opiates/opioid 
analgesics alone were implicated in 47 cases. In 25 (53.2%) of these cases the drugs were 
listed as prescribed to the individual in whose death the drugs were implicated, however for the 
remaining 22 (46.8%) cases, the drugs appear to have been obtained by other means. 
 
Heroin/morphine, alone and in combination with other drugs, was implicated in 364 deaths. 331 
(90.9%) of these cases were not prescribed heroin/morphine, and as such may have obtained 
the drug illegally. Only 33 (9.1%) of the cases with heroin/morphine implicated were receiving 
the drug on prescription. Where heroin/morphine was implicated alone, out of 88 cases, only 9 
(10.2%) were known to be prescribed the drug, meaning 79 individuals (89.8%) may have 
obtained heroin/morphine illegally. 
 
Drug abuse/dependence 
Information was available for 839/1,147 individuals on their past or current history of drug 
abuse/dependence. Those with such a history (DAs) accounted for 65.9% (n = 553/839). Those 
without such a history - non drug abusers (NDAs) - accounted for 34.1% (286/839). Out of the 
total number of NPSAD cases reported for 2012, 26.9% (308/1147) were reported as “not 
known” with respect to known history of drug abuse/dependence. These cases were excluded 
from further analysis.  
 
1.13 Demography  
A greater proportion of those with a history of drug abuse (DA) were male than those without 
such a history (NDA) (79.6% vs. 55.6%); and 44 years and younger (74.7% compared to 
50.7%). The median age at death for DAs was 39 years (interquartile range = 12), while that for 
NDAs was 44 years (interquartile range = 22). 
 
1.14 Location of death 
When location of death was known, there was little difference between the two groups with 
respect to dying at home or at a private residential address, with 71.2% of DAs and 74.1% NDAs 
dying at such a location. Indeed, hospital deaths also accounted for a similar proportion of 
deaths in both DA (14.3%) and NDA (13.6%) groups. A relatively similar proportion of DAs 
(5.4%) and NDAs (4.2%) died in public places (e.g. park, street, public toilets etc.).  
 
1.15 Underlying cause(s) of death  
A greater percentage of DAs than NDAs died from accidental poisoning (77.2% vs. 43.0%) – see 
Figure 1.15. Conversely, a greater proportion of NDAs died as a result of intentional self-
poisoning compared to DAs (30.1% vs. 4.3%), and also poisoning of undetermined intent (21.0% 
vs. 6.7%). 
 
1.16 Manner of death  
A similar pattern is exhibited with regard to manner of death. A greater percentage of DAs than 
NDAs died an accidental death (79.4% vs. 44.2%). In contrast, deaths of NDAs were more 
commonly attributed to suicide than those of DAs (31.5% vs. 7.1%), or to a death where the 
manner was undetermined (22.7% vs. 8.3%). Natural deaths were slightly more common 
amongst DAs (4.9%) than NDAs (3.1%). 
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Figure 1.15: Principal underlying cause(s) of death by drug abuse/dependence history, 
NPSAD cases, England, 2012 
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Changes between 2011 and 2012 
 
The following section compares deaths in 2012 with those that occurred in 2011. Deaths in 2012 
are reported as 1,147 whereas in 2011, 1,424 cases were reported. This is a decrease in 
reported NPSAD deaths of 19.5% for 2012, however this does not mean there was an actual 
drop of this magnitude between the years. This reduction in reported cases is likely due to a 
combination of a reduced catchment period for drug-related death notifications compared with 
the previous report and a lower coverage rate of Coroners voluntarily reporting to the 
Programme. Furthermore, due to the nature of the Coronial reporting system and lengthy 
inquest procedures, the figures for 2012 (and 2011 to a lesser extent) can be expected to 
increase as further inquests on drug-related deaths of those who died in these calendar years 
are finally completed (some inquests do happen in the same calendar year); indeed reports of 
more than 100 other drug-related deaths in 2012 have been notified to the Programme since the 
analysis for this report began. However, the key information presented in this report is still highly 
valuable, as it is the percentage changes rather than absolute figures which are most 
informative, as they will be largely unaffected by fluctuations in overall reported deaths. 
 
1.17 Demography 
There were small changes between 2011 and 2012 in the demographic profile of cases. There 
was a slight increase in the proportion of male deaths, from 70.4% to 71.4%, with a 2.2% drop in 
the percentage of deaths amongst White cases. The proportion of deaths amongst those aged 
44 years and under rose by 2.1% (62.2% in 2011 to 64.3%). Those listed as living with others 
fell by 2.2%, and those with no fixed abode increased by 0.9%. Increases were observed in the 
proportion of deaths occurring at a defined residential address (from 68.9% to 70.8%), and those 
occurring in hospital (from 12.6% to 15.5%). A 1.5% rise was seen in the number of people listed 
as drug addicts/abusers when history was known. 
 
1.18 Underlying cause(s) of death 
The proportion of deaths attributed to accidental drug poisoning rose slightly from 62.6% in 2011 
to 63.1% in 2012, with intentional self-poisoning deaths decreasing from 15.5% to 13.7% in 
2012. Poisonings of undetermined intent accounted for 10.6% in 2011, whilst in 2012 this rose to 
12.1%. 
 
1.19 Manner of death 
The percentage of deaths attributed to accidents in 2012 decreased by 1.7%, and the 
percentage attributed to suicide also decreased, by 1.8%. Small rises were seen in the 
proportion of natural deaths (+1.0%); homicides (+0.3%); and deaths of undetermined intent 
(+2.4%). 
  
1.20 Psychoactive substances implicated in death 
In 2012 there were 1,033/1,147 deaths that involved psychoactive substances; 114 cases from 
2012 were therefore excluded from the following analyses as they did not involve psychoactive 
substances. In 2011, 1,308/1,424 cases involved psychoactive substances, thus 116 cases from 
2011 were excluded from the calculations below. 
 
1.21 Psychoactive substances, both alone and in combination 
There were both absolute and proportional increases in deaths involving ecstasy-type drugs and 
GHB/GBL, either alone or in combination with other drugs. There were proportional increases in 
the following substances both alone and in combination: alcohol in combination; anti-
depressants; anti-psychotics; cannabis; cocaine; and heroin/morphine (Table 1.21). The 5.1% 
increase in the proportion of heroin/morphine-related deaths between 2011-12 is of interest 
when compared with the 6.9% decrease seen between 2010-11. 
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Moderate proportional decreases were seen in the following substances either alone or in 
combination: anti-epileptics; anti-Parkinson’s; hypnotics/sedatives; other opiates/opioid 
analgesics; and methadone. The 4.7% decrease in the proportion of deaths involving 
methadone between 2011-12 contrasts with the 2.7% increase seen in 2010-2011. 
  
1.22 Single substance deaths 
There were very slight changes between 2011 and 2012 in terms of the proportions accounted 
for by deaths involving a single psychoactive substance. For substances implicated alone, there 
were absolute and proportional increases in deaths attributed to cocaine; ecstasy-type drugs; 
and GHB/GBL. A proportional increase was seen in deaths in which anti-epileptics were 
implicated alone. 
Proportional decreases were seen in deaths in which the following drugs were implicated alone: 
amphetamines; anti-depressants; anti-Parkinson’s; anti-psychotics; cannabis; methadone; and 
other opiates/opioid analgesics (Table 1.22). There was no change in the proportion of deaths in 
2011-12 involving either heroin/morphine or hypnotics/sedatives when implicated alone.
                 International Centre for Drug Policy 
 
16 
Table 1.21: Changes in percentages of psychoactive substances, alone and in combination, 
implicated in psychoactive substance deaths, NPSAD cases, England, 2011 and 
2012 
 
Substance 
2011 
(n=1172) 
% 
2011 
(n=1308) 
% 
2012 
(n=1033) 
% 
Change 
(percentage 
points) 
Alcohol in 
combination 
27.7 30.7 33.7 +3.0 
Amphetamines 3.7 3.8 4.0 +0.2 
Anti-depressants 24.5 24.5 25.1 +0.6 
Anti-epileptics 2.9 3.0 2.4 -0.6 
Anti-Parkinson’s 0.4 0.4 0.2 -0.2 
Anti-psychotics 5.6 5.7 5.8 +0.1 
Cannabis 2.0 2.1 2.3 +0.2 
Cocaine 10.4 9.9 11.1 +1.2 
Ecstasy-type drugs 1.7 1.6 3.7 +2.1 
GHB/GBL 0.9 0.8 1.1 +0.3 
Heroin/morphine 30.3 30.1 35.2 +5.1 
Hypnotics/sedatives 24.4 24.2 24.1 -0.1 
Methadone 27.9 27.4 22.7 -4.7 
Other opiates/ 
opioid analgesics 
28.0 27.8 26.7 -1.1 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year.  
Column highlighted in:        does not include deaths in 2011 reported since the last report and is therefore not used in the 
change in percentage point calculations 
 
Table 1.22: Changes in percentages of single psychoactive substances implicated alone in 
psychoactive substance deaths, NPSAD cases, England, 2011 and 2012 
 
Substance 
2011 
(n=1172) 
% 
2011 
(n=1308) 
% 
2012 
(n=1033) 
% 
Change 
(percentage 
points) 
Amphetamines 1.6 1.6 1.5 -0.1 
Anti-depressants 5.5 5.8 4.6 -1.2 
Anti-epileptics 0.5 0.5 0.6 +0.1 
Anti-Parkinson’s 0.1 0.1 0.0 -0.1 
Anti-psychotics 1.3 1.2 0.5 -0.7 
Cannabis 0.5 0.5 0.2 -0.3 
Cocaine 1.5 1.5 2.3 +0.8 
Ecstasy-type drugs 0.5 0.5 1.8 +1.3 
GHB/GBL 0.3 0.4 0.6 +0.2 
Heroin/morphine 8.8 8.5 8.5 0.0 
Hypnotics/sedatives 2.4 2.3 2.3 0.0 
Methadone 7.0 7.0 3.9 -3.1 
Other opiates/ 
opioid analgesics 
6.9 6.9 4.5 -2.4 
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year.  
Column highlighted in:        does not include deaths in 2011 reported since the last report and is therefore not used in the 
change in percentage point calculations 
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Deaths per 100,000 population by area  
 
This section provides a break-down of information by different geographical units for NPSAD 
deaths of those aged 16 years and older. Table 1A gives breakdowns for number of reported 
NPSAD deaths and death rate per 100,000 population for the Drug and Alcohol Action Team 
(DAAT) area for cases’ usual area of residence and place of death. Table 1B gives detailed 
breakdowns by place of death DAAT area for key aspects, such as key demographic details and 
primary drugs implicated, for cases of all ages. 
 
Drug and Alcohol Action Team areas with highest and lowest rates in 2012 
The following five DAAT areas in England had the highest reported NPSAD drug-related death 
rates per 100,000 population in 2012 for individuals who were recorded as resident within their 
coverage area (but did not necessarily die there): Blackpool (18.90 = +4.37 compared to 2011); 
Liverpool (11.80 = +3.27); Hammersmith and Fulham (10.67 = +3.48); Blackburn with Darwen 
(10.57 = -3.47); and Brighton and Hove (9.55 = -0.1). 
 
The highest rates of drug-related deaths reported for 2012 for individuals that died within 
specified DAAT areas (but were not necessarily resident there) were found in: Liverpool (12.57 = 
+3.78); Blackburn with Darwen (11.45 = +0.05); Hammersmith and Fulham (11.34 = +1.54); 
Sunderland (10.55 = +1.30); and Manchester (8.79 = -3.62). The death rates per 100,000 
population for all DAAT areas can be found in Table 1A. 
 
It is important to note that due to the geographic coverage of DAAT areas and Coroners’ 
jurisdictions not always being equivalent, it is not possible to give clear statements with regards 
how the figures presented here for DAAT areas have been affected by those Coroners’ 
jurisdictions that did not submit drug-related death notifications to the Programme.    
 
Table 1B provides detailed breakdowns for NPSAD deaths reported by DAAT area, including 
details on information such as ethnicity and selected drug-types implicated in those deaths. 
Comparing these figures for English regions shows that certain drugs were implicated more 
often in certain places than others. For example, in the South of England heroin/morphine was 
implicated in 37.2% of cases, whilst in London this figure dropped to 22.2%. Methadone was 
implicated most often in the Midlands and East of England (28.8% of deaths); whilst in the South 
of England it was only implicated in 12.8% of cases. Hypnotics/sedatives were involved in the 
deaths of a nationwide low of 15.2% of deaths in London, whilst these same substances 
accounted for 26.5% of deaths in the South of England. Ecstasy-type drugs were implicated in 
5.3% of deaths in DAAT areas in the Midlands and East of England, whilst only 0.9% of cases in 
the South of England had such substances implicated. As in 2011, London exhibited the highest 
proportion of cocaine-related deaths (15.2%), whilst it was implicated in just 3.4% of deaths in 
the Midlands and East of England. However, it is important to note that when taking into account 
absolute figures, Liverpool alone had more deaths involving cocaine (20) than the whole of the 
following regions: Midlands and East of England; London; and more than the South of England 
(Table 1B). This is of particular interest when taking into account the population of Liverpool 
compared with these entire regions of the country. 
 
Commentary  
 
The demographic profile of drug-related deaths in England meeting the NPSAD case criteria for 
2011 remains generally consistent with previous reports: a higher proportion of males to 
females, with the majority of White ethnicity and aged less than 45 years. The proportion of 
deaths reported to the Programme amongst those younger than 25 years has fallen by 1.1% 
since 2010; and 4.4% over the past decade.  Conversely, the proportion of NPSAD deaths of 
those aged 35-44 years has risen by 2.2% since 2010; and 4.8% over the past decade.  
 
Consistent with previous years, the majority of deaths reported to the Programme for 2012 were 
as a direct result of accidental poisoning. However, when compared with females and males of 
younger age groups, older females exhibit higher rates of deaths attributed to suicide by self-
poisoning. 
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In 2012 as in 2011, heroin/morphine was the drug most frequently implicated in the deaths of 
males, closely followed by alcohol in combination with other drugs. In contrast, anti-depressants 
and other opiates/opioid analgesics were most frequently implicated in the deaths of females. 
 
The cases reported to the Programme which occurred in England for 2012 show increases in the 
proportions of deaths involving amphetamines; anti-depressants; anti-psychotics; cannabis; 
cocaine; ecstasy-type drugs; GHB/GBL; heroin/morphine; and alcohol in combination with other 
substances. Meanwhile, deaths involving anti-epileptics; anti-Parkinson’s; hypnotics/sedatives; 
methadone; and other opiates/opioid analgesics decreased.  
 
The rise in monovalent deaths noted in last year’s report between 2010-11 appears to have 
reversed, with a substantial decrease from around 37% to below 32%. With regards 
polysubstance deaths, heroin/morphine combined with alcohol still remains the most frequent 
polysubstance combination – a pattern that has remained consistent over the past ten years. 
 
The most commonly prescribed medications implicated in death were anti-depressants, followed 
by hypnotics/sedatives and other opiates/opioid analgesics. Using available information on 
individuals’ prescribed medication status, it would appear that over 56% of hypnotics/sedatives-; 
other opiates/opioid analgesics-; and methadone-related deaths were sourced either illegally, or 
through other means. 
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Table 1A: NPSAD cases in 2012 by Public Health England Regions, Centres and 
Drug and Alcohol Action Teams (16 years and over) – number and rate per 
100,000 population  
 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
ENGLAND No Rate No Rate 
NORTH OF ENGLAND 
1. North East     
County Durham 24 5.64 5 1.18 
Darlington 3 3.52 3 3.52 
Gateshead - - - - 
Hartlepool - - - - 
Middlesbrough 7 6.33 5 4.52 
Newcastle upon Tyne 1 0.43 - - 
North Tyneside 12 7.24 13 7.84 
Northumberland 6 2.28 6 2.28 
Redcar & Cleveland 5 1.90 6 2.28 
South Tyneside - - - - 
Stockton-on-Tees 7 4.52 4 2.58 
Sunderland 21 9.23 24 10.55 
2. Cumbria & Lancashire     
Blackburn with Darwen 12 10.57 13 11.45 
Blackpool 22 18.90 9 7.73 
Cumbria 23 5.53 21 5.05 
Lancashire 66 6.87 59 6.14 
3. Yorkshire & Humber     
Barnsley 1 0.53 - - 
Bradford 16 3.98 15 3.73 
Calderdale 1 0.61 1 0.61 
Doncaster 13 5.30 6 2.45 
East Riding of Yorkshire 5 1.79 6 2.14 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
NORTH OF ENGLAND No Rate No Rate 
Kingston upon Hull 15 7.21 15 7.21 
Kirklees 12 3.54 9 2.66 
Leeds 34 5.52 33 5.36 
North East Lincolnshire - - - - 
North Lincolnshire 2 1.46 1 0.73 
North Yorkshire 4 0.80 4 0.80 
Rotherham 5 2.39 3 1.44 
Sheffield 3 0.66 1 0.22 
Wakefield 13 4.86 13 4.86 
York - - 2 1.20 
4. Greater Manchester     
Bolton 11 4.97 7 3.16 
Bury - - 1 4.52 
Manchester 29 7.08 36 8.79 
Oldham 1 0.57 - - 
Rochdale - - - - 
Salford 6 3.14 6 3.14 
Stockport 9 3.91 9 3.91 
Tameside 13 7.33 12 6.77 
Trafford 4 2.20 3 1.65 
Wigan 4 1.54 3 1.16 
5. Cheshire & Merseyside     
Cheshire 18 3.11 20 3.46 
Halton 2 1.98 1 0.99 
Knowsley 2 1.70 - - 
Liverpool 46 11.80 49 12.57 
Sefton 
 
 
3 1.32 2 0.88 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
NORTH OF ENGLAND No Rate No Rate 
St Helens - - - - 
Warrington 7 4.25 6 3.64 
Wirral 13 4.98 11 4.22 
MIDLANDS & EAST OF ENGLAND 
6. East Midlands 
 
    
Derby 5 2.51 4 2.01 
Derbyshire 17 2.67 15 2.35 
Leicester 5 1.92 3 1.15 
Leicestershire 5 0.93 2 0.37 
Lincolnshire 2 0.34 1 0.17 
Nottingham - - - - 
Nottinghamshire 1 0.15 2 0.31 
Rutland - - - - 
7. West Midlands 
 
    
Birmingham 28 3.35 33 3.94 
Coventry - - - - 
Dudley 1 0.39 1 0.39 
Herefordshire - - - - 
Sandwell 2 0.82 - - 
Shropshire 9 3.52 8 3.13 
Solihull 1 0.60 1 0.60 
Staffordshire 24 3.42 16 2.28 
Stoke-on-Trent 13 6.47 13 6.47 
Telford & Wrekin 1 0.75 1 0.75 
Walsall 3 1.40 2 0.93 
Warwickshire 1 0.22 - - 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
MIDLANDS & EAST OF ENGLAND No Rate No Rate 
Wolverhampton - - - - 
Worcestershire 3 0.64 - - 
8. Anglia & Essex     
Cambridgeshire 1 0.19 1 0.19 
Essex 2 0.17 4 0.35 
Norfolk 35 4.86 36 5.00 
Peterborough 1 0.68 1 0.68 
Southend-on-Sea - - - - 
Suffolk 11 1.84 5 0.83 
Thurrock - - - - 
9. South Midlands & Hertfordshire     
Bedfordshire 14 4.16 14 4.16 
Hertfordshire 25 2.77 21 2.33 
Luton 9 5.69 8 5.05 
Milton Keynes - - - - 
Northamptonshire 18 3.21 15 2.68 
LONDON 
10. London boroughs     
Barking & Dagenham 1 0.71 1 0.71 
Barnet 1 0.35 - - 
Bexley 
 
1 0.54 1 0.54 
Brent 1 0.40 - - 
Bromley 3 1.19 3 1.19 
Camden 2 1.07 1 0.53 
City of London - - - - 
Croydon 3 1.04 5 1.73 
Ealing 6 2.22 9 3.33 
Enfield - - - - 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
LONDON No Rate No Rate 
Greenwich 2 0.98 2 0.98 
Hackney 4 2.00 2 1.00 
Hammersmith & Fulham 16 10.67 17 11.34 
Haringey - - - - 
Harrow 1 0.52 - - 
Havering 2 1.03 1 0.51 
Hillingdon 10 4.50 10 4.50 
Hounslow 15 7.29 16 7.78 
Islington 5 2.82 1 0.56 
Kensington & Chelsea 2 1.52 1 0.76 
Kingston-upon-Thames 8 6.04 7 5.29 
Lambeth 1 0.39 2 0.79 
Lewisham 1 0.45 1 0.45 
Merton 2 1.23 1 0.62 
Newham - - - - 
Redbridge 1 0.45 - - 
Richmond upon Thames 5 3.31 6 3.97 
Southwark 2 0.84 - - 
Sutton 2 1.29 3 1.94 
Tower Hamlets 5 2.38 3 1.43 
Waltham Forest - - - - 
Wandsworth 1 0.39 1 0.39 
Westminster 3 1.59 5 2.64 
 
                 International Centre for Drug Policy 
 
24 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
No Rate No Rate 
SOUTH OF ENGLAND 
11. Surrey, Sussex & Kent 
 
    
Brighton & Hove 22 9.55 16 6.94 
East Sussex 10 2.28 6 1.37 
Kent 25 2.09 26 2.18 
Medway towns 1 0.47 - - 
Surrey 19 2.06 21 2.28 
West Sussex 17 2.54 15 2.24 
12. Thames Valley 
 
    
Bracknell Forest 1 1.09 1 1.09 
Buckinghamshire 8 1.96 8 1.96 
Oxfordshire 4 0.75 4 0.75 
Reading - - - - 
Slough 2 1.86 2 1.86 
West Berkshire - - - - 
Windsor & Maidenhead 4 3.42 5 4.28 
Wokingham 
 
1 0.80 - - 
13. Wessex 
 
    
Bournemouth 13 8.27 11 7.00 
Dorset 8 2.30 7 2.01 
Hampshire 17 1.57 13 1.20 
Isle of Wight 0 0.00 1 0.86 
Poole 4 3.26 4 3.26 
Portsmouth 3 1.78 2 1.19 
Southampton 14 7.13 7 3.57 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
SOUTH OF ENGLAND No Rate No Rate 
14. Devon, Cornwall & Somerset     
Cornwall & Isles of Scilly 11 2.45 8 1.78 
Devon 25 4.04 25 4.04 
Plymouth 1 0.47 - - 
Somerset 10 2.27 11 2.50 
Torbay 1 0.91 - - 
15. Avon, Gloucestershire & 
Wiltshire 
    
Bath & North East Somerset - - - - 
Bristol 1 0.28 - - 
Gloucestershire 22 4.45 18 3.64 
North Somerset 1 0.60 1 0.60 
South Gloucestershire - - - - 
Swindon 10 5.89 9 5.30 
Wiltshire 5 1.30 5 1.30 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were 
usually resident outside the UK. 
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Table 1B: NPSAD cases in 2012 by Drug and Alcohol Action Team according to 
Public Health England Regions and centres demographics and drugs implicated 
 
Drug and Alcohol 
Action Team 
No Gender  Age group Ethnicity Main Drug Strategy drug implicated 
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ENGLAND                      
NORTH OF ENGLAND 
1. North East 
County Durham 5 4 1 0 1 1 0 3 0 0 2 0 0 0 3 1 0 0 0 0 0 
Darlington 3 2 1 0 1 1 1 0 0 0 1 0 0 0 2 1 1 1 0 0 1 
Gateshead - - - - - - - - - - - - - - - - - - - - - 
Hartlepool - - - - - - - - - - - - - - - - - - - - - 
Middlesbrough 5 2 3 0 0 3 2 0 0 0 5 0 0 0 0 2 2 0 0 0 0 
Newcastle upon 
Tyne 
- - - - - - - - - - - - - - - - - - - - - 
North Tyneside 13 4 9 0 0 3 6 3 1 0 12 0 0 0 1 0 4 4 0 2 0 
Northumberland 6 5 1 0 1 2 2 1 0 0 2 0 0 0 4 1 1 2 1 0 0 
Redcar & Cleveland 6 4 2 0 1 2 3 0 0 0 6 0 0 0 0 0 0 0 0 0 0 
South Tyneside - - - - - - - - - - - - - - - - - - - - - 
Stockton-on-Tees 4 4 0 0 0 0 3 1 0 0 4 0 0 0 0 0 0 0 0 0 0 
Sunderland 24 15 9 0 4 7 10 3 0 0 23 0 0 0 1 7 3 4 1 1 0 
2. Cumbria & Lancashire 
 
Blackburn with 
Darwen 
13 9 4 0 0 4 5 2 2 0 11 0 0 0 2 3 3 4 0 2 0 
Blackpool 9 9 0 0 1 2 3 2 1 0 8 0 0 0 1 6 0 2 3 1 1 
Cumbria 21 15 6 0 5 2 6 2 3 3 21 0 0 0 0 4 5 12 1 1 1 
Lancashire 59 44 15 0 3 9 19 17 7 4 17 0 0 1 41 14 10 9 2 2 1 
3. Yorkshire & Humber 
 
Barnsley - - - - - - - - - - - - - - - - - - - - - 
Bradford 15 12 3 0 0 5 4 6 0 0 12 0 0 2 1 8 2 0 7 1 0 
Calderdale 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
Doncaster 6 5 1 0 1 1 2 1 1 0 5 0 0 0 1 0 3 1 1 0 1 
East Riding of 
Yorkshire 
6 2 4 0 0 3 2 0 0 1 6 0 0 0 0 3 1 2 2 0 0 
Kingston upon Hull 15 8 7 0 1 6 7 1 0 0 1 0 0 0 14 8 5 2 1 2 0 
Kirklees 9 8 1 0 1 4 4 0 0 0 8 0 0 0 1 4 0 1 0 0 0 
Leeds 33 22 11 0 6 6 15 3 2 1 27 0 0 0 6 11 9 10 2 0 1 
North East 
Lincolnshire 
- - - - - - - - - - - - - - - - - - - - - 
North Lincolnshire 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 
North Yorkshire 4 4 0 0 0 0 1 3 0 0 0 0 0 0 4 1 0 0 0 0 0 
Rotherham 3 3 0 0 0 1 2 0 0 0 0 0 0 0 3 1 1 1 0 1 0 
Sheffield 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 
Wakefield 13 10 3 0 1 6 3 2 1 0 12 0 0 0 1 4 8 6 1 1 0 
York 2 1 1 0 1 0 1 0 0 0 1 0 0 0 1 1 0 1 0 1 0 
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Drug and Alcohol 
Action Team 
No Gender  Age group 
Ethnicity Main Drug Strategy drug implicated 
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4. Greater Manchester 
Bolton 7 6 1 0 0 1 4 1 0 1 1 0 0 0 6 4 1 2 0 1 0 
Bury 1 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
Manchester 36 24 12 0 2 7 6 7 11 3 23 0 0 1 12 12 3 6 4 0 2 
Oldham - - - - - - - - - - - - - - - - - - - - - 
Rochdale - - - - - - - - - - - - - - - - - - - - - 
Salford 6 5 1 0 0 1 3 2 0 0 0 0 0 0 6 0 3 0 2 0 0 
Stockport 10 5 5 0 1 0 7 2 0 0 6 1 0 0 3 3 3 2 1 1 1 
Tameside 12 10 2 0 1 2 4 2 2 1 7 0 0 1 4 4 2 3 1 1 0 
Trafford 3 2 1 0 0 1 1 0 0 1 2 0 0 0 1 0 0 1 2 1 0 
Wigan 3 2 1 0 1 0 1 1 0 0 0 0 0 0 3 2 1 1 0 0 0 
5. Cheshire & Merseyside 
Cheshire 20 14 6 0 0 8 4 6 0 2 18 0 0 0 2 7 5 9 2 1 0 
Halton 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Knowsley - - - - - - - - - - - - - - - - - - - - - 
Liverpool 49 39 10 0 0 7 18 17 4 3 46 2 0 1 0 13 13 7 20 0 2 
Sefton 2 1 1 0 0 0 1 1 0 0 2 0 0 0 0 1 0 1 1 0 0 
St Helens - - - - - - - - - - - - - - - - - - - - - 
Warrington 6 5 1 0 1 2 2 0 0 1 5 0 0 0 1 5 0 1 1 0 2 
Wirral 12 8 4 1 1 1 3 5 0 1 11 0 0 0 1 3 6 2 2 1 1 
MIDLANDS & EAST OF ENGLAND 
6. East Midlands 
Derby 4 4 0 0 1 0 1 1 1 0 2 0 1 1 0 1 0 1 0 0 0 
Derbyshire 15 7 8 0 0 5 5 1 2 2 8 0 0 0 7 4 2 1 0 2 2 
Leicester 3 2 1 0 0 0 1 2 0 0 2 0 0 0 1 1 2 2 1 0 0 
Leicestershire 2 1 1 0 0 1 1 0 0 0 2 0 0 0 0 0 0 1 0 0 0 
Lincolnshire 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 1 0 0 0 0 
Nottingham City - - - - - - - - - - - - - - - - - - - - - 
Nottinghamshire 2 2 0 0 0 0 1 1 0 0 1 0 0 0 1 0 0 0 0 1 1 
Rutland - - - - - - - - - - - - - - - - - - - - - 
7. West Midlands  
Birmingham 33 23 10 0 2 7 7 5 6 6 0 1 0 0 32 10 6 5 0 1 1 
Coventry - - - - - - - - - - - - - - - - - - - - - 
Dudley 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Herefordshire - - - - - - - - - - - - - - - - - - - - - 
Sandwell - - - - - - - - - - - - - - - - - - - - - 
Shropshire 8 5 3 0 1 0 4 2 1 0 0 0 0 0 8 2 3 1 0 0 0 
Solihull 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 
Staffordshire 16 10 6 0 2 1 8 2 3 0 12 0 0 0 4 8 3 2 0 0 1 
Stoke-on-Trent 13 10 3 0 1 1 9 0 2 0 2 0 0 0 11 4 5 2 0 0 0 
Telford & Wrekin 1 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0 
Walsall 2 1 1 0 0 1 0 0 1 0 2 0 0 0 0 0 1 0 0 0 0 
Warwickshire - - - - - - - - - - - - - - - - - - - - - 
Wolverhampton 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
Worcestershire - - - - - - - - - - - - - - - - - - - - - 
8. Anglia & Essex 
Cambridgeshire 1 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
Essex 4 3 1 0 3 0 0 0 0 1 0 0 0 0 4 0 0 0 0 0 2 
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Drug and Alcohol 
Action Team 
No Gender Age group Ethnicity Main Drug Strategy drug implicated 
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Norfolk 36 24 12 0 1 10 14 6 5 0 0 0 0 0 36 10 14 8 1 0 0 
Peterborough 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
Southend-on-Sea - - - - - - - - - - - - - - - - - - - - - 
Suffolk 5 5 0 0 1 2 1 1 0 0 0 1 0 0 4 1 1 0 1 0 0 
Thurrock - - - - - - - - - - - - - - - - - - - - - 
9. South Midlands & Hertfordshire 
Bedfordshire 14 12 2 0 0 5 3 4 1 1 13 0 1 0 0 2 5 4 3 2 1 
Hertfordshire 21 18 3 0 4 4 6 4 3 0 5 0 0 0 16 4 6 10 1 1 3 
Luton 8 6 2 0 0 3 4 1 0 0 8 0 0 0 0 4 3 0 0 0 0 
Milton Keynes - - - - - - - - - - - - - - - - - - - - - 
Northamptonshire 15 10 5 0 1 2 8 0 2 2 13 0 0 0 2 3 7 5 0 0 0 
LONDON 
10. London boroughs 
Barking & 
Dagenham 
1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 1 0 0 
Barnet - - - - - - - - - - - - - - - - - - - - - 
Bexley 1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 
Brent - - - - - - - - - - - - - - - - - - - - - 
Bromley 3 0 3 0 0 0 2 1 0 0 1 0 0 0 2 0 0 0 1 1 1 
Camden 1 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 
City of London - - - - - - - - - - - - - - - - - - - - - 
Croydon 5 4 1 0 0 3 2 0 0 0 2 0 0 0 3 1 0 0 0 0 0 
Ealing 9 5 4 0 0 1 4 4 0 0 5 1 0 2 1 1 0 1 0 1 0 
Enfield - - - - - - - - - - - - - - - - - - - - - 
Greenwich 2 2 0 0 1 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 
Hackney 2 0 2 0 0 0 0 2 0 0 1 0 0 0 1 1 2 1 1 0 0 
Hammersmith & 
Fulham 
17 12 5 0 1 3 4 3 6 0 13 0 1 1 2 2 5 3 3 0 0 
Haringey - - - - - - - - - - - - - - - - - - - - - 
Harrow - - - - - - - - - - - - - - - - - - - - - 
Havering 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 
Hillingdon 10 7 3 0 0 4 1 2 2 1 9 1 0 0 0 1 0 1 0 0 0 
Hounslow 16 11 5 0 0 8 3 3 2 0 13 1 1 0 1 4 3 3 1 2 0 
Islington 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
Kensington & 
Chelsea 
1 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 
Kingston 
uponThames 
7 6 1 0 0 1 2 1 2 1 7 0 0 0 0 4 2 2 2 0 0 
Lambeth 2 0 2 0 1 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 
Lewisham 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 
Merton 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 
Newham - - - - - - - - - - - - - - - - - - - - - 
Redbridge - - - - - - - - - - - - - - - - - - - - - 
Richmond upon 
Thames 
6 4 2 0 0 1 2 2 1 0 5 0 0 0 1 2 0 1 1 0 0 
Southwark - - - - - - - - - - - - - - - - - - - - - 
Sutton 3 2 1 0 0 1 1 1 0 0 2 0 0 0 1 2 3 1 0 0 0 
Tower Hamlets 3 1 2 0 0 0 1 0 1 1 1 0 0 0 2 0 2 2 1 0 0 
Waltham Forest - - - - - - - - - - - - - - - - - - - - - 
Wandsworth 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 1 
                 International Centre for Drug Policy 
 
29 
Drug and Alcohol 
Action Team 
No Gender Age group Ethnicity Main Drug Strategy drug implicated 
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Westminster 5 5 0 0 1 3 0 0 1 0 3 0 0 0 2 1 0 0 1 0 0 
SOUTH OF ENGLAND 
11.  Kent, Surrey & Sussex  
Brighton & Hove 16 12 4 0 0 2 5 5 2 2 16 0 0 0 0 5 5 5 2 0 0 
East Sussex 6 3 3 0 0 1 2 2 1 0 6 0 0 0 0 2 3 3 1 0 0 
Kent 26 22 4 0 1 2 8 7 5 3 5 0 0 0 21 7 0 4 1 0 0 
Medway towns - - - - - - - - - - - - - - - - - - - - - 
Surrey 21 17 4 0 3 2 9 4 3 0 3 0 0 0 18 9 5 6 3 0 0 
West Sussex 15 7 8 0 0 3 6 2 3 1 14 0 0 0 1 7 0 5 2 0 0 
12. Thames Valley 
Bracknell Forest 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
Buckinghamshire 8 7 1 0 1 1 2 3 0 1 5 1 0 0 2 4 0 4 1 0 1 
Oxfordshire 4 4 0 0 0 3 0 1 0 0 0 0 0 0 4 3 1 1 1 0 0 
Reading - - - - - - - - - - - - - - - - - - - - - 
Slough 2 2 0 0 0 1 1 0 0 0 0 0 0 0 2 2 0 0 2 0 0 
West Berkshire - - - - - - - - - - - - - - - - - - - - - 
Windsor & 
Maidenhead 
5 3 2 0 1 2 2 0 0 0 0 0 0 0 5 1 1 3 1 1 0 
Wokingham - - - - - - - - - - - - - - - - - - - - - 
13. Wessex 
Bournemouth 11 6 5 0 0 2 4 1 4 0 11 0 0 0 0 3 5 2 0 0 0 
Dorset 7 4 3 0 1 0 2 1 2 1 7 0 0 0 0 3 0 4 1 0 0 
Hampshire 13 12 1 0 1 5 4 1 1 1 11 0 0 0 2 6 0 1 0 0 0 
Isle of Wight 1 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
Poole 4 2 2 0 0 1 1 2 0 0 4 0 0 0 0 2 0 1 0 0 0 
Portsmouth 2 2 0 0 0 0 1 0 1 0 2 0 0 0 0 1 1 1 1 0 0 
Southampton 7 6 1 0 1 2 2 1 0 1 6 0 1 0 0 1 0 0 0 0 0 
14. Devon, Cornwall & Somerset 
Cornwall & Isles of 
Scilly 
8 5 3 0 1 0 5 1 1 0 5 0 0 0 3 2 3 2 1 1 0 
Devon 25 17 8 0 3 2 7 4 7 2 1 0 0 0 24 6 1 2 0 0 1 
Plymouth - - - - - - - - - - - - - - - - - - - - - 
Somerset 11 8 3 0 0 2 8 0 1 0 11 0 0 0 0 7 2 3 0 0 0 
Torbay - - - - - - - - - - - - - - - - - - - - - 
15. Avon, Gloucestershire & Wiltshire 
Bath and North East 
Somerset 
- - - - - - - - - - - - - - - - - - - - - 
Bristol - - - - - - - - - - - - - - - - - - - - - 
Gloucestershire 18 10 8 0 2 5 6 3 2 0 14 0 0 0 4 7 0 5 1 1 0 
North Somerset 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 
South 
Gloucestershire 
- - - - - - - - - - - - - - - - - - - - - 
Swindon 9 6 3 0 0 2 3 1 0 3 9 0 0 0 0 3 2 4 1 0 0 
Wiltshire 5 2 3 0 1 2 1 0 0 1 4 0 0 0 1 2 0 3 0 0 0 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were 
usually resident outside the UK. Where no reported deaths could be assigned to a DAAT area, they are marked thus: - 
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Chapter 2: “Drug misuse” deaths in England using the Drug 
Strategy definition 
 
  
72.4% 27.6% 
Gender distributon of 
reported 2012 Drug 
Strategy cases in England 
Male
Female
2 
63 
198 
314 
166 
87 
35 
Age group distribution of 
reported 2012 Drug Strategy 
deaths in England 
14 & under
15-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65 & over
2008 2009 2010 2011 2012
Methadone 24.1 24.1 31.1 34.6 27.9
Heroin/morphine 54.2 59.7 45.8 37.9 42.8
Anti-depressants 11.9 11.2 14.7 19.0 19.7
Hypnotics/sedatives 16.9 20.9 24.1 26.9 26.6
Other opiates 19.1 21.3 25.7 27.9 28.8
10
20
30
40
50
60
P
e
rc
e
n
ta
ge
 
Year of death 
Percentage of psychoactive substance-related Drug 
Strategy deaths attributed to selected drugs reported in 
England, 2008-12  
2008 2009 2010 2011 2012
Number of deaths 1199 1337 987 1026 865
800
900
1000
1100
1200
1300
1400
N
u
m
b
e
r 
o
f 
d
e
at
h
s 
Year of death 
Number of reported Drug Strategy deaths 2008-2012 in 
England 
                 International Centre for Drug Policy 
 
31 
This chapter considers cases meeting the definition used to monitor the Government’s Drug 
Strategy, i.e. “drug misuse”.  
 
The definition comprises two types of deaths. Firstly, deaths where the underlying cause of 
death is mental and/or behavioural disorders due to psychoactive substance use (excluding 
alcohol, tobacco and volatile solvents). Secondly, deaths coded to the following categories and 
where a drug controlled under the Misuse of Drugs Act 1971 was mentioned on the death 
record: (i) Accidental poisoning by drugs, medicaments and biological substances; (ii) Intentional 
self-poisoning by drugs, medicaments and biological substances; (iii) Poisoning by drugs, 
medicaments and biological substances, undetermined intent; (iv) Assault by drugs, 
medicaments and biological substances; and (v) Mental and behavioural disorders due to use of 
volatile solvents. For full details see Appendix 2. 
 
To derive these cases, the following two categories of cases are excluded from the NPSAD 
cases: (a) deaths of non-drug abusers where no Controlled Drugs were found at post mortem or 
where specific compound analgesics were found at post mortem; and (b) deaths of drug abusers 
where no Controlled Drugs were found at post mortem or where specific compound analgesics 
were found at post mortem and the mechanism of death was traumatic, such as hanging, 
drowning, car accident, etc. 
 
Profile of Drug Strategy cases  
2.1 Demography 
Similar patterns were found to those seen in previous years. Of the 865 Drug Strategy (DS) 
cases reported to the Programme, 72.4% of cases were male and 27.6% female (Figure 2.1 and 
Table 2.1). Almost half (49.2%) were unemployed, whilst 26.9% were employed. Those aged 
less than 45 years accounted for 66.7% of deaths. Deaths amongst those who lived alone 
represented 43.1% of cases, with 40.8% living with others, and 3.0% of no fixed abode. Where 
ethnicity was known (n = 568), the vast majority were White (96.8%); the rest were Black (1.1%); 
Asian (1.1%); and Other ethnicities (1.1%). 
 
Figure 2.1: “Drug misuse” deaths reported to NPSAD by age group and gender, England, 
2012
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Table 2.1: Demographic characteristics of “drug misuse” deaths reported to NPSAD, 
England, 2012 
 
Variable Category Number (%) 
TOTAL  865 (100.0) 
Gender Male 626 (72.4) 
Female 239 (27.6) 
Employment status Employed 233 (26.9) 
Unemployed 426 (49.2) 
Childcare/house person 22 (2.5) 
Student  12 (1.4) 
Retired/invalidity/sickness 70 (8.1) 
Not known 102 (11.8) 
Living arrangements Alone 373 (43.1) 
With others 353 (40.8) 
Other 43 (5.0) 
No fixed abode 26 (3.0) 
Not known 70 (8.1) 
Ethnicity Black 6 (0.7) 
Asian 6 (0.7) 
White 550 (63.6) 
Other 6 (0.7) 
Not known 297 (34.3) 
 
2.2 Age  
       
Most DS deaths in England during 2012 occurred amongst those aged 35 years and over 
(69.6%); 22.9% were aged 25-34; and those aged 24 years and under accounted for just 7.5% 
of DS cases (Figure 2.1). The median age at death was 40 years (interquartile range = 15). 
Older male, White drug users are at most risk of drug-related deaths (Bird et al., 2003; Ghodse 
et al., 2009). 
  
2.3 Location of death 
 
In 2012, 73.5% of DS cases died either at the deceased’s home address or at another private 
residential address; whilst 14.6% died in hospital; 5.3% died elsewhere (e.g. public park, railway 
station, place of work etc.); and the remaining 6.6% were listed with an unknown location of 
death. 
 
2.4 Underlying cause(s) of death 
 
The categories of underlying cause of death (based on ICD-10 codes) were as follows: 
 
 Accidental poisoning (X40-X47): 75.5% 
 Intentional self-poisoning (X60-X67): 9.9%  
 Poisonings of undetermined intent (Y10-Y14): 9.9% 
 Other (e.g. natural causes, drowning, hanging, unascertained): 4.6% 
 
A greater proportion of males compared to females died from accidental poisoning (79.2% vs. 
65.7%). Females, by contrast, had a slightly greater proportion of deaths attributed to intentional 
self-poisoning compared to males (12.1% vs. 9.1%), and also to poisoning of undetermined 
intent (16.3% vs. 7.5%). 
 
There were proportionately more deaths resulting from accidental poisoning amongst those 
aged less than 45 years than older cases (81.3% vs. 63.9%). Conversely, those aged 45 years 
and over had a greater percentage of deaths attributed to intentional self-poisoning than 
younger cases (16.3% vs. 6.8%), and also to poisoning of undetermined intent (14.6% vs. 
7.6%). 
 33 
 
2.5 Manner of death  
 
The manner of death in DS cases was as follows:  
 Accidental: 74.6% 
 Undetermined: 10.5% 
 Suicidal: 9.9% 
 Natural: 4.7% 
 Homicidal: 0.2% 
 
Proportionately more males than females died as the result of an accident (77.8% vs. 66.1%). 
Conversely, female deaths were more often attributed to suicide than male deaths (12.1% vs. 
9.1%); and to a manner that was undetermined (16.7% vs. 8.1%). 
 
Deaths of those aged less than 45 years were more often accidental in nature compared to older 
cases (81.6% vs. 60.4%). Those aged 45 years or over had proportionately more suicides than 
younger cases (16.3% vs. 6.8%), and deaths of undetermined intent (15.3% vs. 8.1%). 
 
Psychoactive substances implicated in death  
2.6 Psychoactive substances 
 
Of the 865 Drug Strategy (DS) cases reported, 827 (95.6%) were directly attributed to 
psychoactive drugs. Those cases in which no psychoactive drugs were implicated (n = 38) were 
excluded from further analysis. 
 
The principal substances implicated in psychoactive drug-related deaths alone and in 
combination were: heroin/morphine (42.8%) and alcohol in combination with other drugs 
(35.1%). Other psychoactive substances implicated alone and in combination that made a 
sizeable contribution (10% or over) to deaths were: other opiates/opioid analgesics (28.8%); 
methadone (27.9%); hypnotics/sedatives (26.6%); anti-depressants (19.7%); and cocaine 
(12.9%). Deaths attributed only to heroin/morphine accounted for 9.9% of cases (Table 2.6). 
 
Table 2.6: Psychoactive substances implicated in “drug misuse” deaths reported to 
NPSAD, England, 2012  
 
Drug category 
Number (%) of psychoactive 
drug cases where no other 
substance was implicated 
 
Number  (%) of 
psychoactive drug cases 
where drug was implicated 
 
TOTAL 827 (100.0) 
Alcohol in combination - 290 (35.1) 
Amphetamines 13 (1.6) 38 (4.6) 
Anti-depressants 14 (1.7) 163 (19.7) 
Anti-epileptics 2 (0.2) 17 (2.1) 
Anti-Parkinson’s 0 (0.0) 2 (0.2) 
Anti-psychotics 0 (0.0) 40 (4.8) 
Cannabis 1 (0.1) 20 (2.4) 
Cocaine 21 (2.5) 107 (12.9) 
Ecstasy-type drugs 19 (2.3) 34 (4.1) 
GHB/GBL 6 (0.7) 11 (1.3) 
Heroin/morphine 82 (9.9) 354 (42.8) 
Hypnotics/sedatives 18 (2.2) 220 (26.6) 
Mephedrone 0 (0.0) 12 (1.5) 
Methadone 39 (4.7) 231 (27.9) 
Other opiates/opioid 
analgesics 
32 (3.9) 238 (28.8) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in death. Not all 
cases had psychoactive substances directly implicated in death: these are excluded from this table. 
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2.7 Psychoactive substances most frequently implicated by age group 
 
As Table 2.7 below shows, for those aged 14 and under, ecstasy-type drugs; heroin/morphine; 
and mephedrone were each implicated in an equal number of deaths. For the 15-24 year age 
group, ecstasy-type drugs; heroin/morphine; and alcohol in combination were implicated most 
often, whilst heroin/morphine was found to be most commonly implicated in the deaths of those 
aged between 25-44 years, accounting for 68.4% of all DS deaths implicated to the drug in 
England in 2012 reported to NPSAD. Alcohol in combination with other drugs was the 
psychoactive substance most frequently implicated for those aged between 45-54 years, and 
other opiates/opioid analgesics were implicated in the greatest proportion of deaths amongst 
those aged 55 years and older. 
 
2.8 Highest frequency of each psychoactive substance implicated 
 
As shown in Table 2.7 below, alcohol in combination; amphetamines; anti-depressants; anti-
Parkinson’s; cannabis; cocaine; GHB/GBL; heroin/morphine; hypnotics/sedatives; methadone; 
and other opiates/opioid analgesics were most commonly implicated in the deaths of those aged 
between 35-44 years. Ecstasy-type drugs were most frequently implicated amongst those aged 
15-24 years, whilst anti-epileptics; anti-psychotics; and mephedrone were most commonly 
involved in the deaths of the 25-34 years age group. 
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Table 2.7: Age group and psychoactive substance implicated in Drug Strategy deaths reported to 
NPSAD, England, 2012  
 
 
 
2.9 Gender and implicated psychoactive substance 
 
The pattern of psychoactive substances with regards their implication in the deaths of the 
different genders reveals some interesting differences. 
 
Amongst males, the five most frequently implicated psychoactive substances (alone or in 
combination), presented in numerical order, were: 
 
1. Heroin/morphine (45.3%) 
2. Alcohol in combination (42.6%) 
3. Methadone (29.2%) 
4. Other opiates/opioid analgesics (26.5%) 
5. Hypnotics/sedatives (26.2%) 
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Alcohol in 
combination 
0 
(0.0) 
17 
(5.9) 
69 
(23.8) 
114 
(39.3) 
58 
(20.0) 
26 
(9.0) 
6 
(2.1) 
290 35.1% 
Amphetamines 0 
(0.0) 
1 
(2.6) 
7 
(18.4) 
15 
(39.5) 
12 
(31.6) 
3 
(7.9) 
0 
(0.0) 
38 4.6% 
Anti-depressants 0 
(0.0) 
11 
(6.7) 
32 
(19.6) 
43 
(26.4) 
37 
(22.7) 
32 
(19.6) 
8 
(4.9) 
163 19.7% 
Anti-epileptics 0 
(0.0) 
2 
(11.8) 
7 
(41.2) 
5 
(29.4) 
2 
(11.8) 
1 
(5.9) 
0 
(0.0) 
17 2.1% 
Anti-Parkinson’s 0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
2 
(100) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
2 0.2% 
Anti-psychotics 0 
(0.0) 
2 
(5.0) 
11 
(27.5) 
10 
(25.0) 
7 
(17.5) 
8 
(20.0) 
2 
(5.0) 
40 4.8% 
Cannabis 0 
(0.0) 
5 
(25.0) 
3 
(15.0) 
9 
(45.0) 
2 
(10.0) 
0 
(0.0) 
1 
(5.0) 
20 2.4% 
Cocaine 0 
(0.0) 
5 
(4.7) 
30 
(28.0) 
38 
(35.5) 
21 
(19.6) 
10 
(9.3) 
3 
(2.8) 
107 12.9% 
Ecstasy-type 1 
(2.9) 
17 
(50.0) 
6 
(17.6) 
7 
(20.6) 
3 
(8.8) 
0 
(0.0) 
0 
(0.0) 
34 4.1% 
GHB/GBL 0 
(0.0) 
1 
(9.1) 
4 
(36.4) 
6 
(54.5) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
11 1.3% 
Heroin/morphine 1 
(0.3) 
17 
(4.8) 
90 
(25.4) 
152 
(42.9) 
57 
(16.1) 
27 
(7.6) 
10 
(2.8) 
354 42.8% 
Hypnotics/ 
sedatives 
0 
(0.0) 
12 
(5.5) 
53 
(24.1) 
87 
(39.5) 
35 
(15.9) 
20 
(9.1) 
13 
(5.9) 
220 26.6% 
Mephedrone 1 
(8.3) 
1 
(8.3) 
5 
(41.7) 
2 
(16.7) 
3 
(25.0) 
0 
(0.0) 
0 
(0.0) 
12 1.5% 
Methadone 0 
(0.0) 
13 
(5.6) 
 
62 
(26.8) 
 
96 
(41.6) 
37 
(16.0) 
 
20 
(8.7) 
3 
(1.3) 
231 
 
27.9% 
Other 
opiates/opioid 
analgesics 
0 
(0.0) 
9 
(3.8) 
43 
(18.1) 
78 
(32.8) 
 
 
55 
(23.1) 
 
39 
(16.4) 
14 
(5.9) 
238 
 
 
28.8% 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not all cases had 
drugs directly implicated in death; these are excluded from this table. 
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Among female cases, the most frequently implicated psychoactive substances, alone or in 
combination were: 
 
1. Heroin/morphine (36.2%) 
2. Other opiates/opioid analgesics (34.8%) 
3. Anti-depressants (33.5%) 
4. Alcohol in combination (28.1%) 
5. Hypnotics/sedatives (27.7%) 
 
Comparing the type of psychoactive substances implicated in the deaths of males and females 
reveals that there is a higher proportion of male compared to female deaths in which the 
following drugs were implicated: heroin/morphine; alcohol in combination; methadone; cannabis; 
cocaine; amphetamines; Ecstasy-type drugs; GHB/GBL; anti-epileptics; anti-Parkinson’s; and 
mephedrone. 
 
Meanwhile, females showed a greater proportion of deaths attributed to anti-depressants; other 
opiates/opioid analgesics; hypnotics/sedatives; and anti-psychotics. 
 
2.10 Polysubstances 
 
In 2012, heroin/morphine in combination with alcohol was implicated in 17.0% of the 827 
psychoactive drug-related Drug Strategy deaths reported to NPSAD. Where other 
hypnotics/sedatives combined with heroin/morphine were implicated, these cases made up 
10.3% of reported deaths, whilst 9.8% involved heroin/morphine implicated in combination with 
other opiates/opioid analgesics. Methadone was implicated in combination with heroin/morphine 
in 9.7% of cases. 
 
When implicated in combination, several different substance types often featured with alcohol. 
Alcohol was implicated in 50.0% of all deaths involving cannabis; 40.5% involving 
hypnotics/sedatives; 39.8% involving heroin/morphine; and 38.5% of deaths in which methadone 
was implicated.  
 
Over the past decade, around one-fifth (19.5%) of drug-related deaths has involved 
heroin/morphine in combination with alcohol, and in 2012 8.5% of deaths involved other 
opiates/opioid analgesics combined with alcohol, and in 9.3% of deaths, heroin/morphine and 
other opiates/opioid analgesics were combined. The combination of heroin/morphine and other 
opiates/opioid analgesics fluctuated between 4.3% and 10.3% over the past ten years.  
 
The most prevalent substance combinations implicated during 2003-12 in deaths were: heroin/ 
morphine with alcohol (19.5%); heroin/morphine with hypnotics/sedatives (11.8%); and 
hypnotics/sedatives with alcohol (9.7%). Combinations of drugs, with or without alcohol, pose 
greater risks for mortality (Ghodse et al., 2010).   
 
2.11 Single substances 
 
In 2012, there were 247 (29.9%) Drug Strategy deaths involving psychoactive substances 
reported to NPSAD in which only one of the following substances was implicated. Of these 
single substance deaths, heroin/morphine accounted for 33.2%; methadone for 15.8%; other 
opiates/opioid analgesics – 13.0%; cocaine – 8.5%; ecstasy-type drugs – 7.7%; 
hypnotics/sedatives – 7.3%; anti-depressants – 5.7%; amphetamines – 5.3%; GHB/GBL – 2.4%; 
anti-epileptics – 0.8%; and cannabis – 0.4%. 
 
2.12 Prescribed psychoactive drugs  
 
Of the 865 Drug Strategy cases reported to NPSAD for 2012, 56.1% (n = 485) were reported as 
being prescribed psychoactive drugs at the time of their death (Table 2.12). Of those being 
prescribed such drugs, the most common prescribed medications were anti-depressants 
(54.8%); hypnotics/sedatives (40.8%); other opiates/opioid analgesics (35.2%); methadone 
(21.0%); anti-psychotics (18.7%); anti-epileptics (18.3%); heroin/morphine (8.2%); and anti-
Parkinson’s drugs (1.9%). 
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‘Polypharmacy’, i.e. multiple prescriptions of psychoactive drugs, occurred in 66.4% (322/485) of 
cases. 
 
As with NPSAD cases, age appeared to be related in some way to whether cases were being 
prescribed psychoactive medication when prescribing history was known (n = 685). Those aged 
14 and under were not prescribed any psychoactive medication; amongst 15-24 year olds, 
33.3% were prescribed psychoactive medication; 25-34 – 61.7%; 35-44 – 75.1%; 45-54 – 
76.7%; 55-64 – 88.5%; and 65 & over – 73.3%. 
 
The following paragraphs further examine the Drug Strategy deaths and the involvement of 
prescribed medication.  
 
Of those being prescribed psychoactive medication (n = 485), prescribed hypnotics/sedatives in 
combination with anti-depressants accounted for 19.6% of cases in 2003 and 26.0% in 2012. 
Hypnotics/sedatives in combination with other opiates/opioid analgesics accounted for 11.4% of 
cases in 2003 compared to 19.4% in 2012. Anti-depressants were prescribed together with other 
opiates/opioid analgesics in 8.4% of cases in 2003 and 21.5% of cases in 2012. 
 
In 2012, methadone alone and in combination with other drugs, was implicated in 231 cases. Of 
these, 66.7% may have obtained methadone from illicit sources, compared to 33.3% who were 
known to be receiving prescribed methadone prior to their death. Methadone alone was 
implicated in 39 cases. Of these, 74.4% may have obtained the drug from illicit sources, 
compared to 25.6% who were known to be receiving prescribed methadone.  
Table 2.12: Prescribed psychoactive medication, “drug misuse” deaths reported to 
NPSAD, England, 2012 
 
Drug category 
Number (%) of cases on 
prescribed 
psychoactive medication 
by drug 
Number (%) of these 
cases where same 
prescribed drug was 
implicated in death 
TOTAL 485 (100.0) - 
Anti-depressants 266 (54.8) 102 (38.3) 
Anti-epileptics 89 (18.4) 10 (11.2) 
Anti-Parkinson’s 9 (1.9) 2 (22.2) 
Anti-psychotics 91 (18.8) 31 (34.1) 
Heroin/morphine 40 (8.2) 32 (80.0) 
Hypnotic/sedatives 218 (44.9) 95 (43.6) 
Methadone 102 (21.0) 77 (75.5) 
Other opiates/opioid 
analgesics 
171 (35.3) 96 (56.1) 
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual 
and more than one substance may be implicated in a death. 
 
Hypnotics/sedatives, alone and in combination with other drugs, were implicated in 220 cases. 
Of these, 56.8% may have obtained them illicitly, compared to the 43.2% who were known to be 
receiving a prescription for this drug. Eighteen cases had hypnotics/sedatives alone implicated in 
their death, of whom eight (44.4%) had received the drug on prescription, compared to 10 
(55.6%) who may have obtained it illicitly.  
 
Anti-depressants, alone and in combination with other drugs, were implicated in 163 cases. Of 
these, 62.6% were known to be receiving prescribed anti-depressants at the time of their death, 
compared to 37.4% who may have used drugs prescribed for others. Anti-depressants alone 
were implicated in 14 cases. Of these, nine (64.3%) were known to be receiving prescribed anti-
depressants, compared to five (35.7%) who may have used drugs prescribed for others. 
 
Other opiates/opioid analgesics (e.g. dihydrocodeine, dextropropoxyphene) alone and in 
combination with other drugs, were implicated in 238 cases. Of these, 59.7% may have obtained 
the drug by other means, compared to the 40.3% who were known to be receiving prescribed 
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opiate/opioid analgesics prior to their death. Other opiates/opioid analgesics alone were 
implicated in 32 cases. Of these, only half were prescribed the drugs, meaning 16 individuals 
obtained the drugs by other means. 
 
Heroin/morphine, alone and in combination with other drugs, was implicated in 354 deaths. The 
majority (91.0%) of these cases were not prescribed heroin/morphine, and as such may have 
obtained the drug illegally. Only 9.0% of the cases with heroin/morphine implicated were 
receiving the drug on prescription. Where heroin/morphine was implicated alone, out of 82 
cases, only 9.8% of these were they known to be prescribed the drug, meaning 90.2% may have 
obtained heroin/morphine illegally. 
 
Drug abuse/dependence 
 
Drug abuse/dependence status was known in 655/865 cases. Such status was not known in 210 
individuals, and as such these cases have been removed from the below analysis. 
 
Where such information was known, those with drug abuse/dependence history (DA) accounted 
for 71.9% of cases (n = 471/655). Individuals listed as non-drug abusers (NDA) accounted for 
28.1% (n = 184/655). 
 
2.13 Demography  
 
A greater proportion of those with a history of drug abuse/dependence (DA) were male than 
those without such a history (NDA) (80.3% vs. 57.1%); and also a greater proportion of DAs than 
NDAs were younger than 45 years of age (75.6% compared to 51.6%). The median age at death 
for DAs was 39 years (interquartile range = 11), while that for NDAs was 44 years (interquartile 
range = 22). 
 
Where ethnicity was known, there was a very similar proportion of cases recorded as belonging 
to a White ethnic group for both DA and NDA cases (97.1% vs. 97.0%). 
 
A slightly greater proportion of DAs than NDAs lived alone (44.6% vs. 40.2%) and were of no 
fixed abode (4.5% vs. 0.5%). NDAs however, more commonly lived with others (53.3% vs. 
36.3%). 
 
Proportionately more DA cases were unemployed (56.5% vs. 31.5%); whilst NDA cases were 
more commonly employed (29.9% vs. 25.1%); or retired/receiving invalidity benefits (23.4% vs. 
2.5%); or carrying-out childcare (3.8% vs. 1.5%). 
 
2.14 Location of death 
 
With respect to the location of death for DAs and NDAs, in both groups the majority died at 
home or at a defined residential address (73.7% of DAs and 77.7% of NDAs). Hospital deaths 
accounted for very similar proportions of NDA (13.0%) and DA (12.7%) deaths. 
 
2.15 Underlying cause(s) of death  
 
The deaths of DAs were more commonly attributed to accidental poisoning than NDAs (86.2% 
vs. 54.9%) (see Figure 2.15). NDAs, by contrast, had a greater proportion of deaths than DAs 
resulting from intentional self-poisoning (26.6% vs. 3.0%) and poisoning of undetermined intent 
(15.8% vs. 5.7%). 
 
2.16 Manner of death  
 
A similar pattern is exhibited with regard to manner of death. DAs more commonly had deaths 
resulting from an accident than NDAs (86.4% vs. 52.7%). Conversely, the deaths of NDAs when 
compared to DAs, were attributed more often to suicide (26.6% vs. 3.0%), or to an undetermined 
manner (15.8% vs. 6.2%) 
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Figure 2.15: Principal underlying causes(s) of death by drug abuse/dependence history, 
“drug misuse” (DS) deaths, England 2012 
 
 
Changes between 2011 and 2012  
 
The following section compares deaths in 2012 with those that occurred in 2011. Drug Strategy 
(DS) deaths in 2012 are reported as 865, whereas in 2011, 1,026 cases were reported. This is a 
decrease in reported DS deaths of 15.7% in 2012; however this does not mean there was an 
actual drop of this magnitude between the years. This reduction in reported cases is likely due to 
a combination of a reduced catchment period for drug-related death notifications compared with 
the previous report and a lower coverage rate of Coroners voluntarily reporting to the 
Programme. Furthermore, due to the nature of the Coronial reporting system and lengthy 
inquest procedures, the figures for 2012 (and 2011, to a lesser extent) can be expected to 
increase as further inquests on drug-related deaths are completed and reported to the 
Programme.  
 
2.17 Demography 
There were minor changes between 2011 and 2012 in terms of the demographic profile of 
cases. Whilst median age at death; ethnicity; gender; and living arrangements remained stable, 
there were slight changes in other aspects. The proportion of cases listed as unemployed fell by 
4.1% (from 53.3% to 49.2%), and the number of individuals listed as having a history of drug 
abuse/addiction when such information was known rose marginally by 1.2%, from 70.7% to 
71.9%. A rise of 1.1% was also observed in the number of deaths occurring at the deceased’s 
home or other private residential address (from 72.4% to 73.5%). A 3.8% rise was seen in 
hospital deaths (from 10.8% to 14.6%). 
                   
2.18 Underlying cause(s) of death 
The number of deaths due to accidental poisoning remained stable, at 75.7% in 2011 to 75.5% 
in 2012, whilst deaths attributed to intentional self-poisoning decreased by 3.5%, from 13.4% to 
9.9%. Meanwhile, there was a negligible increase in poisonings of undetermined intent, from 
9.3% to 9.9%, and deaths from other causes rose from 1.7% to 4.6%.  
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2.19 Manner of death 
There was a very minor decrease in accidental deaths between 2011 and 2012 from 75.1% to 
74.6% and a decrease in suicides from 13.5% to 9.9%. Cases in which the manner of death was 
undetermined showed a small decrease, from 9.6% in 2011 to 10.5% in 2012. 
 
 
2.20 Psychoactive substances implicated in death 
In 2012 there were 827/865 Drug Strategy deaths that involved psychoactive substances; 16 
cases were therefore excluded from the following analyses due to their not involving 
psychoactive substances. In 2011, 994 of the 1,026 DS cases reported involved psychoactive 
drugs. 
 
2.21 Psychoactive substances, both alone and in combination 
There was a marked increase in the proportion of deaths attributed to heroin/morphine in 2011 
compared to 2012 (37.9% vs. 42.8% of deaths). As such, heroin/morphine still remains the most 
frequently implicated substance in deaths of DS cases. A further marked rise was seen in the 
proportion of cases in which alcohol was implicated in combination with other psychoactive 
substances (from 29.9% to 35.1%). A large drop was seen in the number of deaths involving 
methadone, alone or in combination (from 34.6% to 27.9%). 
 
Minor increases were seen in the proportion of cases in which amphetamines; anti-depressants; 
anti-Parkinson’s; anti-psychotics; cannabis; ecstasy-type drugs; GHB/GBL; and other 
opiates/opioid analgesics were implicated. Minor decreases were found in the number of cases 
in which anti-epileptics and hypnotics/sedatives were implicated (Table 2.21). 
 
2.22 Single substance 
Small increases were seen in single-substance deaths in which anti-depressants; cocaine; 
ecstasy-type drugs; GHB/GBL; and hypnotic/sedatives were implicated. 
A 4.4% reduction between 2011 and 2012 was seen in the percentage of cases in which 
methadone alone was implicated (9.1% to 4.7%). Deaths involving only other opiates/opioid 
analgesics fell (6.0% to 3.9%), as did deaths involving heroin/morphine alone (10.9% to 9.9%). 
Other minor falls were seen in deaths involving anti-epileptics and anti-psychotics (Table 2.22).  
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Table 2.21: Changes in percentages of psychoactive substances, alone and in 
combination, implicated in psychoactive substance “drug misuse” deaths, 
England, 2011 and 2012 
 
Substance 
2011 
(n=888) 
% 
2011 
(n=994) 
% 
2012 
(n=827) 
% 
Change 
(percentage 
points) 
Alcohol in 
combination 
28.0 29.9 35.1 +5.2 
Amphetamines 4.4 4.5 4.6 +0.1 
Anti-depressants 19.1 19.0 19.7 +0.7 
Anti-epileptics 2.6 2.8 2.1 -0.7 
Anti-Parkinson’s 0.1 0.1 0.2 +0.1 
Anti-psychotics 3.8 4.1 4.8 +0.7 
Cannabis 1.6 1.7 2.4 +0.7 
Cocaine 12.0 11.5 12.9 +1.4 
Ecstasy-type drugs 2.1 2.0 4.1 +2.1 
GHB/GBL 1.1 0.9 1.3 +0.4 
Heroin/morphine 38.2 37.9 42.8 +4.9 
Hypnotics/sedatives 26.8 26.9 26.6 -0.3 
Methadone 35.2 34.6 27.9 -6.7 
Other opiates/ 
opioid analgesics 
27.9 27.9 28.8 +0.9 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
Column highlighted in:        does not include deaths in 2011 reported since the last report and is therefore not used in the 
change in percentage point calculations 
 
 
 
Table 2.22: Changes in percentages of psychoactive substances implicated alone in 
psychoactive substance “drug misuse” deaths, England, 2011 and 2012 
 
Substance 
2011 
(n=888) 
% 
2011 
(n=994) 
% 
2012 
(n=827) 
% 
Change 
(percentage 
points) 
Amphetamines 1.7 1.6 1.6 0.0 
Anti-depressants 1.4 1.3 1.7 +0.4 
Anti-epileptics 0.3 0.4 0.2 -0.2 
Anti-Parkinson’s 0.0 0.0 0.0 0.0 
Anti-psychotics 0.5 0.4 0.0 -0.4 
Cannabis 0.1 0.1 0.1 0.0 
Cocaine 1.8 1.8 2.5 +0.7 
Ecstasy-type drugs 0.7 0.7 2.3 +1.6 
GHB/GBL 0.5 0.4 0.7 +0.3 
Heroin/morphine 11.3 10.9 9.9 -1.0 
Hypnotics/sedatives 1.9 1.9 2.2 +0.3 
Methadone 9.3 9.1 4.7 -4.4 
Other opiates/ 
opioid analgesics 
6.2 6.0 3.9 -2.1 
Column highlighted in:        does not include deaths in 2011 reported since the last report and is therefore not used in the 
change in percentage point calculations 
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Deaths per 100,000 population by area 
 
This section provides a break-down of information by different geographical units for deaths 
meeting the Drug Strategy definition of those aged 16 years and older. Table 2A gives 
breakdowns for number of reported NPSAD deaths and death rate per 100,000 population for 
the Drug and Alcohol Action Team (DAAT) area for cases’ usual area of residence and place 
of death. Table 2B gives detailed breakdowns by place of death DAAT area for key aspects, 
such as key demographic details and primary drugs implicated, for cases of all ages. 
 
Drug and Alcohol Action Team areas with highest and lowest rates in 2012 
The following five DAAT areas in England had the highest reported Drug Strategy death rates 
per 100,000 population in 2012 for individuals resident within their coverage area (but did not 
necessarily die there): Blackpool (17.18 = +3.88 compared to 2011); Blackburn with Darwen 
(8.81 = -1.55); Liverpool (8.72 = +2.07); Brighton and Hove (8.25 = +0.1); and Sunderland 
(7.03 = +1.36). 
 
The highest rates of Drug Strategy deaths reported for 2012 for individuals that died within 
specified DAAT areas (but were not necessarily resident there) were found in: Liverpool (9.49 
= +2.04); Blackburn with Darwen (8.81 = -1.91); Sunderland (6.87 = +1.2); Brighton and Hove 
(6.94 = +0.60); and Blackpool (6.87 = -6.43). The death rates per 100,000 population for all 
DAAT areas can be found in Table 2A. 
 
It is important to note that due to the geographic coverage of DAAT areas and Coroners’ 
jurisdictions not always being equivalent, it is not possible to give clear statements with 
regards how the figures presented here for DAAT areas have been affected by those 
Coroners’ jurisdictions that did not submit drug-related death notifications to the Programme.    
 
Table 2B provides detailed breakdowns for Drug Strategy deaths by DAAT area reported to 
the Programme, with specific details of information such as age group and primary drug 
groups implicated. Comparing the drug types implicated for different English regions shows 
that certain drugs were implicated more often in certain regions than others, and the overall 
patterns seen are broadly similar to those for reported NPSAD cases. For example, in the 
South of England heroin/morphine was implicated in 49.7% of DS cases, whilst in the 
Midlands and East of England this figure dropped to 35.7%. Methadone was implicated most 
frequently in the Midlands and East of England (34.4% of deaths), whilst in the South of 
England it was implicated in just 16.8% of deaths. London showed the lowest proportion of 
deaths attributed to hypnotics/sedatives (19.4%), which contrasts with the South of England in 
which these drug types were implicated in 31.2% of cases. As in 2011, London showed the 
highest proportion of cocaine-related deaths (21.0%), whilst it was only implicated in 4.5% of 
deaths in the Midlands and East of England. Ecstasy-type drugs were implicated in 6.4% of 
deaths in DAAT areas in the North of England, whilst only 1.2% of cases in the South of 
England had drugs such as ecstasy implicated. 
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Commentary  
The demographic profile of “drug misuse” deaths in England remains generally consistent with 
previous reports: a higher proportion of males to females; predominantly White; with the majority 
under 45 years of age. The proportion of “drug misuse” deaths reported to the Programme amongst 
those aged under 25 years has dropped between 2010-12 by 1.7%; and 6.2% over the past decade. 
Meanwhile, the proportion of those aged 35-44 years has increased by 6.6% since 2003. 
 
Accidental poisoning still remains the most frequent underlying cause of death across all age groups. 
In comparison with females and males of younger age groups, older females again show a greater 
proportion of deaths attributed to intentional self-poisoning. 
 
Amongst males, heroin/morphine followed by alcohol in combination were the most frequently 
implicated drugs in their deaths, whilst in females it was heroin/morphine, closely followed by other 
opiates/ opioid analgesics. In 2011, anti-depressants contributed to the greatest proportion of female 
deaths. 
 
“Drug misuse” deaths reported to the Programme for 2012 suggest an increase in the involvement in 
death of amphetamines; anti-depressants; anti-Parkinson’s; anti-psychotics; cannabis; cocaine, 
ecstasy-type drugs; GHB/GBL; heroin/morphine; other opiates/opioid analgesics; and alcohol in 
combination. Deaths involving anti-epileptics; hypnotics/sedatives; and methadone have decreased. 
The plateau in monovalent deaths noted in last year’s report appears to have ended, with a 
substantial drop from 36% in 2011 to around 30% in 2012. Heroin/morphine combined with alcohol 
remains the most frequently implicated polysubstance combination over the past decade, followed by 
heroin/morphine combined with hypnotics/sedatives, and then hypnotics/sedatives with alcohol.  
 
The most commonly prescribed medications implicated in death were anti-depressants; other 
opiates/opioid analgesics; hypnotics/sedatives; followed by methadone. Taking into account known 
prescription status of individuals in which hypnotics/sedatives; other opiates/opioid analgesics; and 
heroin/morphine were implicated, upwards of 56.8% of these individuals with these drugs implicated 
in their deaths may have obtained the drugs illegally. Over 66.7% of those cases in which methadone 
was implicated may have obtained the drug illegally. 
 
It has to be acknowledged that there are some distinct differences between the definition of drug-
related death used by NPSAD and that of “drug misuse” employed by Government departments to 
monitor trends in the effectiveness of the Government’s Drug strategy. 
 
Whilst the main source of information for the Office for National Statistics is the medical certificate of 
death, supplemented by part V of the Coroner’s Inquisition form, NPSAD receives detailed information 
from inquests with reports from various sources (including toxicology) to the Coroner to determine the 
cause of death and thus the verdict. Both sets of data are of value and complementary. The detailed 
data from Coroners allows for the Programme to contribute to early warning monitoring systems, 
providing information on the epidemiology of Novel Psychoactive Substances (including “legal highs”), 
as well as on prescribing history, risk factors, etc. Both sources of data are needed to obtain a fuller 
understanding of the nature of drug-related mortality in England, and the UK as a whole.  
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Table 2A: Drug Strategy cases in 2012 by Public Health England Regions, Centres and 
Drug and Alcohol Action Teams (16 years and over) – number and rate per 100,000 
population  
 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual death 
rate per 100,000 
population – place of death 
ENGLAND No Rate No Rate 
NORTH OF ENGLAND 
1. North East     
County Durham 14 3.29 2 0.47 
Darlington 3 3.52 3 3.52 
Gateshead - - - - 
Hartlepool - - - - 
Middlesbrough 3 2.71 3 2.71 
Newcastle upon Tyne - - - - 
North Tyneside 8 4.82 9 5.43 
Northumberland 6 2.28 4 1.52 
Redcar & Cleveland 3 2.71 2 1.80 
South Tyneside - - - - 
Stockton-on-Tees 2 1.29 2 1.29 
Sunderland 16 7.03 18 7.91 
2. Cumbria & Lancashire     
Blackburn with Darwen 10 8.81 10 8.81 
Blackpool 20 17.18 8 6.87 
Cumbria 19 4.57 17 4.09 
Lancashire 48 4.99 44 4.58 
3. Yorkshire & Humber     
Barnsley 1 0.53 - - 
Bradford 13 3.24 12 2.99 
Calderdale 1 0.61 1 0.61 
Doncaster 11 4.48 5 2.04 
East Riding of Yorkshire 5 1.79 6 2.14 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual death 
rate per 100,000 
population – place of death 
NORTH OF ENGLAND No Rate No Rate 
Kingston upon Hull 14 6.72 14 6.72 
Kirklees 8 2.36 6 1.77 
Leeds 27 4.38 27 4.38 
North East Lincolnshire - - - - 
North Lincolnshire 2 1.46 1 0.73 
North Yorkshire 3 0.60 4 0.80 
Rotherham 5 2.39 3 1.44 
Sheffield 3 0.66 1 0.22 
Wakefield 12 4.49 12 4.49 
York - - 1 0.60 
4. Greater Manchester     
Bolton 10 4.52 7 3.16 
Bury - - 1 0.67 
Manchester 23 5.62 28 6.84 
Oldham 1 0.57 - - 
Rochdale - - - - 
Salford 4 2.09 4 2.09 
Stockport 6 2.60 7 3.04 
Tameside 12 6.77 11 6.20 
Trafford 3 1.65 2 1.10 
Wigan 2 0.77 2 0.77 
5. Cheshire & Merseyside     
Cheshire 13 2.25 15 2.59 
Halton 2 1.98 1 0.99 
Knowsley 2 1.70 - - 
Liverpool 34 8.72 37 9.49 
Sefton 3 1.32 2 0.88 
St Helens - - - - 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual death 
rate per 100,000 
population – place of death 
NORTH OF ENGLAND No Rate No Rate 
Warrington 6 3.64 5 3.03 
Wirral 12 4.60 10 3.83 
MIDLANDS & EAST OF ENGLAND 
6. East Midlands     
Derby 4 2.01 3 1.51 
Derbyshire 15 2.35 13 2.04 
Leicester 4 1.53 2 0.77 
Leicestershire 4 0.74 2 0.37 
Lincolnshire 2 0.34 1 0.17 
Nottingham - - - - 
Nottinghamshire 1 0.15 2 0.31 
Rutland - - - - 
7. West Midlands     
Birmingham 15 1.79 18 2.15 
Coventry - - - - 
Dudley 1 0.39 1 0.39 
Herefordshire - - - - 
Sandwell 1 0.41 - - 
Shropshire 7 2.74 6 2.35 
Solihull 1 0.60 1 0.60 
Staffordshire 18 2.56 13 1.85 
Stoke-on-Trent 9 4.48 9 4.48 
Telford & Wrekin - - - - 
Walsall 3 1.40 2 0.93 
Warwickshire 1 0.22 - - 
Wolverhampton - - - - 
Worcestershire 2 0.43 - - 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
MIDLANDS & EAST OF ENGLAND No Rate No Rate 
8. Anglia & Essex     
Cambridgeshire 1 0.19 1 0.19 
Essex 1 0.09 2 0.17 
Norfolk 28 3.89 29 4.03 
Peterborough 1 0.68 1 0.68 
Southend-on-Sea - - - - 
Suffolk 7 1.17 3 0.50 
Thurrock - - - - 
9. South Midlands & Hertfordshire 
 
    
Bedfordshire 9 2.67 9 2.67 
Hertfordshire 22 2.44 19 2.11 
Luton 8 5.05 7 4.42 
Milton Keynes - - - - 
Northamptonshire 14 2.50 12 2.14 
LONDON 
10. London boroughs     
Barking & Dagenham - - 1 0.71 
Barnet - - - - 
Bexley 1 0.54 1 0.54 
Brent - - - - 
Bromley 2 0.79 3 1.19 
Camden 2 1.07 1 0.53 
City of London - - - - 
Croydon 2 0.69 3 1.04 
Ealing 5 1.85 5 1.85 
Enfield - - - - 
Greenwich 2 0.98 2 0.98 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
LONDON No Rate No Rate 
Hackney 4 2.00 2 1.00 
Hammersmith & Fulham 8 5.34 9 6.00 
Haringey - - - - 
Harrow - - - - 
Havering 1 0.51 - - 
Hillingdon 4 1.80 4 1.80 
Hounslow 10 4.86 10 4.86 
Islington 3 1.69 1 0.56 
Kensington & Chelsea 2 1.52 1 0.76 
Kingston upon Thames 6 4.53 5 3.78 
Lambeth 1 0.39 1 0.39 
Lewisham 1 0.45 1 0.45 
Merton 2 1.23 - - 
Newham - - - - 
Redbridge 1 0.45 - - 
Richmond upon Thames 2 1.32 3 1.99 
Southwark 2 0.84 - - 
Sutton 2 1.29 3 1.94 
Tower Hamlets 5 2.38 3 1.43 
Waltham Forest - 0.97 - - 
Wandsworth 1 0.39 1 0.39 
Westminster 1 0.53 2 1.06 
SOUTH OF ENGLAND 
11. Surrey, Sussex & Kent     
Brighton & Hove 19 8.25 16 6.94 
East Sussex 9 2.05 5 1.14 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
SOUTH OF ENGLAND No Rate No Rate 
Kent 11 0.92 11 0.92 
Medway towns 0 0.00 0 0.00 
Surrey 17 1.84 20 2.17 
West Sussex 15 2.24 14 2.09 
12. Thames Valley     
Bracknell Forest 1 1.09 1 1.09 
Buckinghamshire 8 1.96 7 1.71 
Oxfordshire 4 0.75 4 0.75 
Reading - - - - 
Slough 2 1.86 2 1.86 
West Berkshire - - - - 
Windsor & Maidenhead 4 3.42 5 4.28 
Wokingham - - - - 
13. Wessex 
 
    
Bournemouth 10 6.36 9 5.73 
Dorset 6 1.72 6 1.72 
Hampshire 12 1.11 8 0.74 
Isle of Wight 0 0.00 0 0.00 
Poole 4 3.26 4 3.26 
Portsmouth 3 1.78 2 1.19 
Southampton 6 3.06 2 1.02 
14. Devon, Cornwall & Somerset 
 
    
Cornwall & Isles of Scilly 8 1.78 6 1.34 
Devon 15 2.42 15 2.42 
Plymouth - - - - 
Somerset 9 2.04 10 2.27 
Torbay 1 0.91 - - 
 50 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
SOUTH OF ENGLAND No Rate No Rate 
15. Avon, Gloucestershire & 
Wiltshire 
    
Bath & North East Somerset - - - - 
Bristol - - - - 
Gloucestershire 1 0.60 1 0.60 
North Somerset 19 3.84 15 3.03 
South Gloucestershire - - - - 
Swindon 7 4.12 7 4.12 
Wiltshire 3 0.78 3 0.78 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of no 
fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were usually 
resident outside the UK. Where no reported deaths could be assigned to a DAAT area, they are marked thus: - 
 
 
  
 51 
Table 2B: “Drug misuse” cases in 2012 by Drug and Alcohol Action Team according 
to Public Health England Regions and centres demographics and drugs implicated 
 
Drug and 
Alcohol Action 
Team 
No Gender Age group Ethnicity Main Drug Strategy drug 
implicated 
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ENGLAND                      
NORTH OF ENGLAND 
1. North East 
County Durham 2 2 0 0 0 0 0 2 0 0 1 0 0 0 1 1 0 0 0 0 0 
Darlington 3 2 1 0 1 1 1 0 0 0 1 0 0 0 2 1 1 1 0 0 1 
Gateshead - - - - - - - - - - - - - - - - - - - - - 
Hartlepool - - - - - - - - - - - - - - - - - - - - - 
Middlesbrough 3 1 2 0 0 2 1 0 0 0 3 0 0 0 0 2 2 0 0 0 0 
Newcastle upon 
Tyne 
- - - - - - - - - - - - - - - - - - - - - 
North Tyneside 9 3 6 0 0 3 3 3 0 0 8 0 0 0 1 0 4 4 0 2 0 
Northumberland 4 3 1 0 1 1 1 1 0 0 2 0 0 0 2 1 1 2 0 0 0 
Redcar & 
Cleveland 
2 2 0 0 0 2 0 0 0 0 2 0 0 0 0 1 0 0 0 0 0 
South Tyneside - - - - - - - - - - - - - - - - - - - - - 
Stockton-on-Tees 2 2 0 0 0 0 1 1 0 0 2 0 0 0 0 0 0 0 0 0 0 
Sunderland 18 9 9 0 2 6 8 2 0 0 17 0 0 0 1 7 3 4 1 1 0 
2. Cumbria & Lancashire 
Blackburn with 
Darwen 
10 7 3 0 0 2 4 2 2 0 9 0 0 0 1 3 3 4 0 2 0 
Blackpool 8 8 0 0 1 2 3 1 1 0 8 0 0 0 0 6 0 2 3 1 1 
Cumbria 17 13 4 0 4 2 5 1 2 3 17 0 0 0 0 4 5 12 1 1 1 
Lancashire 44 33 11 0 2 8 20 11 2 1 14 0 0 1 29 14 10 8 2 3 1 
3. Yorkshire & Humber 
Barnsley - - - - - - - - - - - - - - - - - - - - - 
Bradford 12 9 3 0 0 2 4 6 0 0 9 0 0 2 1 8 2 0 7 1 0 
Calderdale 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
Doncaster 5 4 1 0 1 1 1 1 1 0 4 0 0 0 1 0 3 1 1 0 1 
East Riding of 
Yorkshire 
6 2 4 0 0 3 2 0 0 1 6 0 0 0 0 3 1 2 2 0 0 
Kingston upon 
Hull 
14 8 6 0 1 6 6 1 0 0 13 0 0 0 1 8 5 2 1 2 0 
Kirklees 6 5 1 0 0 3 3 0 0 0 5 0 0 0 1 4 0 1 0 0 0 
Leeds 27 18 9 0 3 5 13 3 2 1 21 0 0 0 6 11 9 10 2 0 0 
North East 
Lincolnshire 
- - - - - - - - - - - - - - - - - - - - - 
North 
Lincolnshire 
1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 
North Yorkshire 4 4 0 0 0 0 1 3 0 0 0 0 0 0 4 1 0 0 0 0 0 
Rotherham 3 3 0 0 0 1 2 0 0 0 0 0 0 0 3 1 1 1 0 1 0 
Sheffield 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 
Wakefield 12 9 3 0 1 6 2 2 1 0 11 0 0 0 1 4 8 5 1 1 0 
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Drug and 
Alcohol Action 
Team 
No Gender Age group Ethnicity 
Main Drug Strategy drug 
implicated 
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York 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 1 0 0 0 
4. Greater Manchester 
Bolton 7 6 1 0 0 1 4 1 0 1 1 0 0 0 6 4 1 2 0 1 0 
Bury 1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Manchester 28 18 10 0 2 5 4 5 10 2 18 0 0 0 10 12 3 5 3 0 2 
Oldham - - - - - - - - - - - - - - - - - - - - - 
Rochdale - - - - - - - - - - - - - - - - - - - - - 
Salford 4 3 1 0 0 0 2 2 0 0 0 0 0 0 4 0 3 0 2 0 0 
Stockport 8 4 4 0 1 0 5 2 0 0 4 1 0 0 3 4 3 2 1 1 1 
Tameside 11 9 2 0 1 2 4 2 1 1 6 0 0 1 4 4 2 3 1 1 0 
Trafford 2 2 0 0 0 0 1 0 0 1 1 0 0 0 1 0 0 1 1 1 0 
Wigan 2 1 1 0 0 0 1 1 0 0 0 0 0 0 2 1 1 0 0 0 0 
5. Cheshire & Merseyside 
 
Cheshire 15 11 4 0 0 7 2 5 0 1 14 0 0 0 1 6 5 7 2 1 0 
Halton 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Knowsley - - - - - - - - - - - - - - - - - - - - - 
Liverpool 37 30 7 0 0 5 15 14 1 2 34 2 0 1 0 13 12 6 18 0 2 
Sefton 2 1 1 0 0 0 1 1 0 0 2 0 0 0 0 1 0 0 1 0 0 
St Helens - - - - - - - - - - - - - - - - - - - - - 
Warrington 5 5 0 0 1 1 2 0 0 1 5 0 0 0 0 4 0 1 1 0 2 
Wirral 11 7 4 1 0 1 3 5 0 1 10 0 0 0 1 3 6 2 2 1 1 
MIDLANDS & EAST OF ENGLAND 
6. East Midlands 
Derby 3 3 0 0 1 0 1 0 1 0 1 0 0 0 2 1 0 0 0 0 0 
Derbyshire 13 5 8 0 0 4 5 1 2 1 6 0 0 0 7 4 2 1 0 2 2 
Leicester 2 2 0 0 0 0 1 1 0 0 2 0 0 0 0 1 2 1 1 0 0 
Leicestershire 2 1 1 0 0 1 1 0 0 0 2 0 0 0 0 0 0 1 0 0 0 
Lincolnshire 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0   
Nottingham - - - - - - - - - - - - - - - - - - - - - 
Nottinghamshire 2 2 0 0 0 0 1 1 0 0 1 0 0 0 1 0 0 0 0 1 1 
Rutland - - - - - - - - - - - - - - - - - - - - - 
7. West Midlands 
Birmingham 18 12 6 0 2 3 3 2 6 2 0 0 0 0 18 9 6 3 0 1 1 
Coventry - - - - - - - - - - - - - - - - - - - - - 
Dudley 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Herefordshire - - - - - - - - - - - - - - - - - - - - - 
Sandwell - - - - - - - - - - - - - - - - - - - - - 
Shropshire 6 5 1 0 1 0 4 1 0 0 0 0 0 0 6 2 3 1 0 0 0 
Solihull 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 
Staffordshire 13 9 4 0 2 1 7 1 2 0 9 0 0 0 4 8 3 2 0 0 1 
Stoke-on-Trent 9 7 2 0 1 1 6 0 1 0 1 0 0 0 8 4 5 2 0 0 0 
Telford & Wrekin - - - - - - - - - - - - - - - - - - - - - 
Walsall 2 1 1 0 0 1 0 0 1 0 2 0 0 0 0 0 1 0 0 0 0 
Warwickshire - - - - - - - - - - - - - - - - - - - - - 
Wolverhampton 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
Worcestershire - - - - - - - - - - - - - - - - - - - - - 
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8. Anglia & Essex 
Cambridgeshire 1 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
Essex 2 2 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 
Norfolk 29 21 8 0 1 8 11 6 3 0 0 0 0 0 29 10 14 7 1 0 0 
Peterborough 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
Southend-on-Sea - - - - - - - - - - - - - - - - - - - - - 
Suffolk 3 3 0 0 0 1 1 1 0 0 0 0 0 0 3 1 1 0 1 0 0 
Thurrock - - - - - - - - - - - - - - - - - - - - - 
9. South Midlands & Hertfordshire 
Bedfordshire 9 7 2 0 0 2 3 2 1 1 8 0 1 0 0 2 0 4 3 0 0 
Hertfordshire 19 16 3 0 4 3 6 3 3 0 4 0 0 0 15 4 6 10 1 1 3 
Luton 7 5 2 0 0 3 3 1 0 0 7 0 0 0 0 4 3 0 0 0 0 
Milton Keynes - - - - - - - - - - - - - - - - - - - - - 
Northamptonshire 12 8 4 0 1 2 7 0 1 1 10 0 0 0 2 3 7 5 0 0 0 
LONDON 
10. London boroughs 
Barking and 
Dagenham 
1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 1 0 0 
Barnet - - - - - - - - - - - - - - - - - - - - - 
Bexley 1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 
Brent - - - - - - - - - - - - - - - - - - - - - 
Bromley 3 0 3 0 0 0 2 1 0 0 1 0 0 0 2 0 0 0 1 1 1 
Camden 1 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 
City of London - - - - - - - - - - - - - - - - - - - - - 
Croydon 3 3 0 0 0 2 1 0 0 0 1 0 0 0 2 1 0 0 0 0 0 
Ealing 5 4 1 0 0 0 3 2 0 0 2 1 0 1 1 1 0 0 0 1 0 
Enfield - - - - - - - - - - - - - - - - - - - - - 
Greenwich 2 2 0 0 1 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 
Hackney 2 0 2 0 0 0 0 2 0 0 1 0 0 0 1 1 2 1 1 0 0 
Hammersmith 
and Fulham 
9 8 1 0 0 2 0 2 5 0 7 0 1 0 1 2 5 2 2 0 0 
Haringey - - - - - - - - - - - - - - - - - - - - - 
Harrow - - - - - - - - - - - - - - - - - - - - - 
Havering - - - - - - - - - - - - - - - - - - - - - 
Hillingdon 4 2 2 0 0 2 0 0 1 1 4 0 0 0 0 1 0 1 0 0 0 
Hounslow 10 6 4 0 0 5 2 2 1 0 9 0 1 0 0 4 3 3 1 1 0 
Islington 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Kensington & 
Chelsea 
1 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 
Kingston upon 
Thames 
5 5 0 0 0 1 2 0 2 0 5 0 0 0 0 4 2 1 2 0 0 
Lambeth 1 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
Lewisham 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 
Merton - - - - - - - - - - - - - - - - - - - - - 
Newham - - - - - - - - - - - - - - - - - - - - - 
Redbridge - - - - - - - - - - - - - - - - - - - - - 
Richmond upon 
Thames 
3 3 0 0 0 0 0 2 1 0 3 0 0 0 0 2 0 1 1 0 0 
Southwark - - - - - - - - - - - - - - - - - - - - - 
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Sutton 3 2 1 0 0 1 1 1 0 0 2 0 0 0 1 2 3 1 0 0 0 
Tower Hamlets 3 1 2 0 0 0 1 0 1 1 1 0 0 0 2 0 2 2 1 0 0 
Waltham Forest - - - - - - - - - - - - - - - - - - - - - 
Wandsworth 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
Westminster 2 2 0 0 0 2 0 0 0 0 1 0 0 0 1 1 0 0 1 0 0 
SOUTH OF ENGLAND 
11. Kent, Surrey & Sussex  
Brighton & Hove 16 12 4 0 0 2 5 5 2 2 16 0 0 0 0 5 5 5 2 0 0 
East Sussex 5 2 3 0 0 1 1 2 1 0 5 0 0 0 0 2 3 3 1 0 0 
Kent 11 9 2 0 0 0 7 2 2 0 2 0 0 0 9 7 0 1 1 0 0 
Medway towns - - - - - - - - - - - - - - - - - - - - - 
Surrey 20 16 4 0 3 2 9 3 3 0 3 0 0 0 17 9 5 6 3 0 0 
West Sussex 14 6 8 0 0 3 6 2 2 1 1 0 0 0 13 7 0 5 2 0 0 
12. Thames Valley 
Bracknell Forest 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 
Buckinghamshire 7 6 1 0 1 1 1 3 0 1 4 1 0 0 2 4 0 3 1 0 1 
Oxfordshire 4 4 0 0 0 3 0 1 0 0 0 0 0 0 4 3 1 1 1 0 0 
Reading - - - - - - - - - - - - - - - - - - - - - 
Slough 2 2 0 0 0 1 1 0 0 0 0 0 0 0 2 2 0 0 2 0 0 
West Berkshire - - - - - - - - - - - - - - - - - - - - - 
Windsor & 
Maidenhead 
5 3 2 0 1 2 2 0 0 0 0 0 0 0 5 1 1 3 1 1 0 
Wokingham - - - - - - - - - - - - - - - - - - - - - 
13. Wessex 
Bournemouth 9 6 3 0 0 2 3 1 3 0 9 0 0 0 0 3 5 2 0 0 0 
Dorset 6 4 2 0 1 0 2 0 2 1 6 0 0 0 0 3 0 4 1 0 0 
Hampshire 8 8 0 0 1 4 3 0 0 0 8 0 0 0 0 6 0 1 0 0 0 
Isle of Wight - - - - - - - - - - - - - - - - - - - - - 
Poole 4 2 2 0 0 1 1 2 0 0 4 0 0 0 0 2 0 1 0 0 0 
Portsmouth 2 2 0 0 0 0 1 0 1 0 2 0 0 0 0 1 1 1 1 0 0 
Southampton 2 2 0 0 0 1 1 0 0 0 1 0 1 0 0 1 0 0 0 0 0 
14. Devon, Cornwall & Somerset 
Cornwall & Isles 
of Scilly 
6 4 2 0 0 0 4 1 1 0 4 0 0 0 2 1 3 2 1 1 0 
Devon 15 11 4 0 2 2 3 2 4 2 1 0 0 0 14 6 1 2 0 0 1 
Plymouth - - - - - - - - - - - - - - - - - - - - - 
Somerset 10 8 2 0 0 2 8 0 0 0 10 0 0 0 0 7 2 3 0 0 0 
Torbay - - - - - - - - - - - - - - - - - - - - - 
15. Avon, Gloucestershire & Wiltshire 
Bath & North 
East Somerset 
- - - - - - - - - - - - - - - - - - - - - 
Bristol - - - - - - - - - - - - - - - - - - - - - 
North Somerset 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 
Gloucestershire 15 7 8 0 1 3 6 3 2 0 13 0 0 0 2 7 0 5 1 1 0 
South 
Gloucestershire 
- - - - - - - - - - - - - - - - - - - - - 
Swindon 7 6 1 0 0 2 3 1 0 1 7 0 0 0 0 3 2 3 1 0 0 
Wiltshire 3 2 1 0 1 1 1 0 0 0 2 0 0 0 1 2 0 2 0 0 0 
 Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of no fixed abode and/or 
the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were usually resident outside the UK. Where no 
reported deaths could be assigned to a DAAT area, they are marked thus: - 
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This chapter describes the pattern of drug-related deaths in Wales reported by Coroners to 
NPSAD that meet the Programme’s case criteria.  
 
Profile of NPSAD cases 
3.1 Demography 
Notifications of 58 drug-related deaths occurring in 2012 which met the NPSAD case criteria 
were received from Coroners in Wales – a fall of 28.4% compared to 2011, when the number of 
such deaths was 81; whilst in 2010, 84 deaths were reported. However, this does not mean 
there was an actual drop of this magnitude between the years. This reduction in reported cases 
is likely due to a combination of a reduced catchment period for drug-related death notifications 
compared with the previous report and a lower coverage rate of Coroners voluntarily reporting to 
the Programme. Furthermore, due to the nature of the Coronial reporting system and lengthy 
inquest procedures, the figures for 2012 (and 2011 to a lesser extent) can be expected to 
increase as further inquests on drug-related deaths of those who died in these calendar years 
are finally completed (some inquests do happen in the same calendar year). However, the key 
information presented in this report is still highly valuable, as it is the percentage changes rather 
than absolute figures which are most informative, as they will be largely unaffected by 
fluctuations in overall reported deaths. 
 
The majority (75.9%) of the cases in 2012 were male (Table 3.1). The median age at death was 
36.0 years (interquartile range = 12.3) (Figure 3.1) and 86.2% of all cases were aged under 45 
years. Those who were unemployed accounted for 58.6% of cases, and the living arrangements 
showed 43.1% living with others. Addict status was known in 47 cases, 80.1% of which had a 
history of dependence or drug use. Ethnicity was known in 38 cases, and 97.4% of these were 
White; whilst 2.6% were Black. In 20 cases, ethnicity information was not provided. 
 
Table 3.1: Demographic variables for drug-related deaths reported by Coroners meeting 
NPSAD criteria, Wales, 2012  
Variable Category Number (%) 
TOTAL  58 (100.0) 
Gender Male 44 (75.9) 
Female 14 (24.1) 
Employment status Employed 20 (34.5) 
Unemployed 34 (58.6) 
Retired/sickness/invalidity 2 (3.4) 
Not known 2 (3.4) 
Living arrangements Alone 22 (37.9) 
With others 25 (43.1) 
No fixed abode 4 (6.9) 
Other 2 (3.4) 
Not known 5 (8.6) 
Ethnicity Black 1 (1.7) 
White 37 (63.8) 
Not known 20 (34.5) 
 
3.2 Location of death 
Most fatalities (74.1%) occurred at a defined residential address (i.e. the deceased’s home 
address or other private residential address). Deaths in hospital accounted for 10.3% of cases; a 
further 10.3% died in a public place such as a park; and 5.2% occurred at unspecified locations. 
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3.3 Cause(s) of death 
Accidental poisoning accounted for 89.7% of deaths, with 1.7% of deaths from intentional self-
poisoning, and a further 1.7% from poisonings of undetermined intent. The remaining 6.9% died 
from other causes. 
Figure 3.1: Drug-related deaths reported by Coroners meeting NPSAD criteria, by age 
group and gender, Wales, 2012 
 
 
Psychoactive substances implicated in death  
3.4 All substances 
Psychoactive drugs were directly implicated in 53/58 (91.4%) cases. The principal substances 
implicated alone or in combination were: heroin/morphine (54.7%); methadone (41.5%); 
hypnotics/sedatives (37.7%); other opiates/ opioid analgesics (15.1%); anti-depressants 
(15.1%); and alcohol in combination (13.2%) (Table 3.4). 
 
Figure 3.7 takes into account data where one of the following drugs was known to be implicated: 
alcohol in combination; amphetamines; anti-depressants; anti-psychotics; cannabis; cocaine; 
ecstasy-type drugs; heroin/morphine; hypnotics/sedatives; methadone; and other opiates/opioid 
analgesics. 
 
3.5 Single substances 
Single substance deaths accounted for 43.4% (23/53) of all fatalities where psychoactive 
substances were implicated. Heroin/morphine and methadone accounted for 73.9% (17/23) of 
these deaths when implicated alone (Table 3.4). 
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Table 3.4: Psychoactive substances implicated in deaths reported by Coroners meeting 
NPSAD criteria, Wales, 2012  
Drug category 
Number (%) of psychoactive 
drug cases where no other 
substance was implicated 
Number  (%) of 
psychoactive drug cases 
where drug was implicated 
TOTAL 53 (100.0) 
Alcohol in combination - 7 (13.2) 
Amphetamines 2 (3.8) 2 (3.8) 
Anti-depressants 1 (1.9) 8 (15.1) 
Anti-psychotics 0 (0.0) 1 (1.9) 
Cannabis 0 (0.0) 1 (1.9) 
Cocaine 0 (0.0) 2 (3.8) 
Ecstasy-type drugs 0 (0.0) 1 (1.9) 
Heroin/morphine 11 (20.8) 29 (54.7) 
Hypnotics/sedatives 0 (0.0) 20 (37.7) 
Methadone 6 (11.3) 22 (41.5) 
Other opiates/opioid 
analgesics 
3 (5.7) 8 (15.1) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in death. Not all 
cases had psychoactive substances directly implicated in death: these are excluded from this table. 
 
3.6 Age and drug implicated in death  
Of the 53 drug related deaths where a psychoactive drug was implicated, heroin/morphine 
accounted for the most deaths in all age groups below 55 years old; whilst hypnotics/sedatives 
accounted for the most deaths amongst those aged 55 years and above when compared to any 
other drug type. Table 3.6 shows where any particular drug was implicated across the whole 
range of age groups. 
 
Table 3.6: Age and drug implicated in deaths meeting NPSAD criteria reported by 
Coroners, Wales, 2012 
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Drug category most frequently implicated (alone or in combination) in each age 
group 
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15-24 
 
3 1 1 0 0 0 2 0 0 0 0 
25-34 
 
9 6 5 0 4 1 0 1 0 1 1 
35-44 
 
14 14 11 6 2 4 0 1 1 0 0 
45-54 
 
2 1 1 1 1 1 0 0 0 0 0 
55-64 
 
1 0 2 1 1 1 0 0 0 0 0 
TOTAL 29 22 20 8 8 7 2 2 1 1 1 
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3.7 Gender and drug implicated in death 
The pattern of drugs implicated in mortality was somewhat different in male and female cases 
(Figure 3.2). 
 
Among male cases in which psychoactive drugs were implicated (n = 44), the three most frequently 
mentioned drugs were: 
 
1. Heroin/morphine (52.3%) 
2. Methadone (40.9%) 
3. Hypnotics/sedatives (40.9%) 
 
In female cases in which psychoactive drugs were implicated (n = 14), the top three drugs 
mentioned were: 
 
1. Heroin/morphine (42.9%) 
2. Methadone (28.6%) 
3. Other opiates/opioid analgesics (14.3%) 
 
Examining the principal differences between male and female deaths for implicated drugs reveals a 
higher proportion of male deaths involving: heroin/morphine; methadone; hypnotics/sedatives; and 
alcohol in combination with other drugs. A greater proportion of female deaths were attributed to 
other opiates/opioid analgesics than amongst males.  
 
Regional data 
This section contains information based on Welsh Drug and Alcohol Action Team (DAAT) areas. 
 
Data for Drug and Alcohol Action Team (DAAT) areas are given in Tables 3.8 and 3.9. Table 3.4 
shows the number of deaths by population (rate per 100,000 population aged 16 years and over), 
and show the age group; gender; ethnicity; and principal psychoactive drugs implicated in death.  
 
Heroin/morphine was implicated in the greatest proportion of deaths in Iechyd Morgannwg (54.5%) 
and Bro Taf (52.3%), whilst Bro Taf also had the greatest proportion of deaths attributed to 
hypnotics/sedatives (38.1%) when compared with other DAAT areas. The two deaths located in 
Powys also both involved hypnotics/sedatives.  
 
Figure 3.7: Drug-related deaths meeting NPSAD criteria reported by Coroners, by selected 
psychoactive drug implicated, Wales, 2012 
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Table 3.8: Deaths by Drug and Alcohol Action Team (DAAT) area (16 years and over) – 
number and rate per 100,000 population, Wales, 2012  
 
Drug and Alcohol 
Action Team Area 
National and annual death rate per 
100,000 population – usual area of 
residence 
National and annual death rate 
per 100,000 population – place 
of death 
 Number Rate Number Rate 
Bro Taf 28 4.48 21 3.36 
Dyfed Powys 5 1.17 5 1.17 
Gwent* - - 1* - 
Iechyd Morgannwg 15 3.51 11 2.57 
North Wales 6 1.06 4 0.71 
Note: There were two cases that were resident outside of Wales and two of unknown usual address. There were 16 deaths 
that could not be allocated to a specific DAAT.  
* Case details obtained through media sources thus incomplete coverage. 
 
 
 
Table 3.9: Deaths by Drug and Alcohol Action Team area – demographics and drugs 
implicated, Wales, 2012  
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Bro Taf 21 17 4 2 6 11 0 2 14 1 6 11 7 8 1 1 0 
Dyfed 
Powys 
5 3 2 1 2 1 0 1 5 0 0 1 2 3 0 1 0 
Gwent* 1* - 1* - 1* - - - - - 1* - - - - - 1* 
Iechyd 
Morgannwg 
11 7 4 0 5 4 2 0 8 0 3 6 4 3 0 0 0 
North Wales 4 4 0 0 1 2 1 0 1 0 3 1 3 0 1 0 0 
Note: There were 16 deaths that could not be allocated to a specific DAAT.  
* Case details obtained through media sources thus incomplete coverage. 
 
Commentary 
There was a higher ratio of male to female (4.25:1) drug-related deaths in Bro Taf compared to 
other areas in Wales in 2011. The majority of deaths in Wales were amongst those aged 25 to 44 
years, which is a pattern seen across the UK. Deaths of those aged 15-24 occurred in Bro Taf and 
Dyfed Powys. 
 
The proportion of deaths attributed to heroin/morphine was higher in Wales than in any other part 
of the UK, having been implicated in 54.7% of cases. The proportion of cases in which methadone 
was implicated was second only to Scotland, being involved in 41.5% of deaths, which is almost 
double that of England. Meanwhile, the role other opiates/opioid analgesics played in Welsh deaths 
was substantially lower than other countries in the UK (15.1% in Wales vs. 60.8% in Northern 
Ireland). 
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Chapter 4: Drug-related deaths in Northern Ireland 
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This chapter describes the pattern of drug-related deaths in Northern Ireland reported by Coroners 
and from registrations data supplied by The Northern Ireland Statistics and Research Agency 
(NISRA) recorded by the General Register Office for Northern Ireland.  
 
Profile of NPSAD cases 
4.1 Demography 
Notifications of 78 drug-related deaths occurring in 2012 which met the NPSAD case criteria were 
received from NISRA and Coroners. In 2011 the number of such deaths was 82; whilst in 2010, 80 
deaths were reported (these figures include deaths in these years reported in 2012-13). This 
represents a fall of 4.9% in reported deaths in Northern Ireland from 2011-12.  
 
In 2012, 64.1% of cases were male (Table 4.1), and 35.9% were female. Unemployed individuals 
made up 53.8% of the cases, and 50.0% of cases lived with others. Ethnicity was known in 62 
cases with all decedents being White, and in the remaining 16 cases ethnicity was not known. 
Addict status was known in 20/78 cases, 12 (60.0%) of which had a history of drug use or 
dependence. 
 
The median age at death was 40.5 years (interquartile range = 17.3). Over half of the decedents 
(53.8%) were under the age of 45 years. 
  
 
Table 4.1: Demographic variables for drug-related deaths reported by NISRA and 
Coroners meeting NPSAD criteria, Northern Ireland, 2012  
 
Variable Category Number (%) 
TOTAL  78 (100.0) 
Gender Male 50 (64.1) 
Female 28 (35.9) 
Employment status Employed 19 (24.4) 
Unemployed 42 (53.8) 
Childcare/house person 3 (3.8) 
Retired 10 (12.8) 
Not known 4 (5.1) 
Living arrangements Alone 33 (42.3) 
With others 39 (50.0) 
Other 2 (2.6) 
Not known 4 (5.1) 
Ethnicity White 62 (79.5) 
Not known 16 (20.5) 
 
 
4.2 Location of death 
Most fatalities (93.6%) occurred at a defined residential address (i.e. the deceased’s home 
address or another private residential address); with 5.1% deaths occurring in hospital and 1.3% 
in a public place, such as a bus shelter. 
 
4.3 Cause(s) of death 
Based on the information available from Coroners, 33.3% of cases died from accidental 
poisoning, 23.1% from intentional self-poisoning, and in 42.3% of cases the intent was 
undetermined. The cause of death of the remaining case was unascertained. 
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Figure 4.1: Drug-related deaths reported by NISRA and Coroners meeting NPSAD criteria, 
by age group and gender, Northern Ireland, 2012 
 
 
 
Psychoactive substances implicated in death 
4.4 All substances 
Psychoactive drugs were directly implicated in 74/78 (94.9%) cases. The principal substances 
implicated were: other opiates/opioid analgesics (60.8%); hypnotics/sedatives (55.4%); anti-
depressants (41.9%); alcohol in combination (39.2%); heroin/morphine (16.2%); and anti-
psychotics (13.5%) (Table 4.4). 
 
4.5 Single substances 
Single substance deaths accounted for 18.9% (14/74) of deaths where psychoactive substances 
were implicated. These substances were: other opiates/opioid analgesics; anti-depressants; and 
heroin/morphine (Table 4.4). 
 
Table 4.4: Psychoactive substances implicated in deaths reported by NISRA and 
Coroners meeting NPSAD criteria, Northern Ireland, 2012 
Drug category 
Number (%) of psychoactive 
drug cases where no other 
substance was implicated 
Number  (%) of 
psychoactive drug cases 
where drug was implicated 
TOTAL 74 (100.0) 
Alcohol in combination - 29 (39.2) 
Anti-depressants 5 (6.8) 31 (41.9) 
Anti-epileptics 0 (0.0) 4 (5.4) 
Anti-psychotics 0 (0.0) 10 (13.5) 
Cannabis 0 (0.0) 1 (1.4) 
Cocaine 0 (0.0) 1 (1.4) 
Ecstasy-type drugs 0 (0.0) 2 (2.7) 
Heroin/morphine 2 (2.7) 12 (16.2) 
Hypnotics/sedatives 0 (0.0) 41 (55.4) 
Methadone 0 (0.0) 3 (4.1) 
Other opiates/opioid 
analgesics 
7 (9.5) 45 (60.8) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in death. Not all 
cases had psychoactive substances directly implicated in death: these are excluded from this table. 
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Figure 4.6 takes into account data where one of the following drugs was known to be implicated: 
alcohol in combination; amphetamines; anti-depressants; anti-epileptics; anti-psychotics; 
cannabis; cocaine; heroin/ morphine; hypnotics/sedatives; methadone; and other opiates/opioid 
analgesics. 
 
4.6 Gender and drug implicated in death 
The pattern of other drug-specific mortality was somewhat different in male and female cases. 
Of the total 50 male deaths, the most frequently mentioned drugs were: hypnotics/sedatives 
(56.0%); other opiates/opioid analgesics (54.0%); alcohol in combination (44.0%); anti-
depressants (40.0%); heroin/morphine (18.0%); anti-psychotics (14.0%); methadone (4.0%); 
anti-epileptics (4.0%); ecstasy-type drugs (4.0%); cocaine (2.0%); and cannabis (2.0%). 
 
Of the total 28 female deaths, the drugs mentioned most commonly were: other opiates/opioid 
analgesics (64.3%); hypnotics/sedatives (46.4%); anti-depressants (39.3%); alcohol in 
combination (25.0%); heroin/morphine (10.7%); anti-psychotics (10.7%); anti-epileptics (7.1%); 
and methadone (3.6%). There were no female deaths involving ecstasy-type drugs; cocaine; or 
cannabis. 
 
Compared to female cases, males had a higher proportion of fatality associated with all drugs, 
except other opiates/opioid analgesics (female 64.3% vs. male 54.0%) and anti-epileptics 
(female 7.1% vs. male 4.0%). 
 
There were no male or female deaths involving amphetamines; anti-Parkinson’s drugs; or 
GHB/GBL. 
 
Figure 4.6: Number and gender of drug-related deaths reported by NISRA and Coroners 
meeting NPSAD criteria, by psychoactive drug implicated, Northern Ireland, 
2012 
 
 
4.7 Age and drug implicated in death  
 
Overall, of the 74 drug-related deaths where a psychoactive drug was implicated, other 
opiates/opioid analgesics were the leading substances implicated (60.8%). Such drugs also 
accounted for the greatest proportion of cases in most age groups, apart from in the 45-54 and 
65+ age groups.  
Alcoho
l in
combi
nation
Anti-
depres
sants
Anti-
epilep
tics
Anti-
psych
otics
Canna
bis
Cocain
e
Ecstas
y-type
Heroin
/morp
hine
Hypno
tics/se
dative
s
Metha
done
Other
opiate
s/opioi
d
analge
sics
Females 7 11 2 3 0 0 0 3 13 1 18
Males 22 20 2 7 1 1 2 9 28 2 27
0
5
10
15
20
25
30
35
40
45
N
u
m
b
e
r 
o
f 
d
e
at
h
s 
Implicated drug 
 65 
 
Hypnotic/sedatives and anti-depressants drugs were implicated in the greatest proportion of 
deaths amongst 45-54 year olds. Table 4.7 shows where any particular drug-type was implicated 
across the whole range of age groups.  
 
Table 4.7: Age and psychoactive drug implicated in deaths reported to NISRA meeting 
NPSAD criteria, Northern Ireland, 2012 
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group 
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15-24 5 5 4 5 2 1 0 0 0 0 0 
25-34 9 8 4 2 1 0 0 0 2 1 1 
35-44 11 11 4 6 4 4 0 1 0 0 0 
45-54 11 12 12 10 2 3 2 2 0 0 0 
55-64 8 4 6 5 3 2 2 0 0 0 0 
65+ 1 1 1 1 0 0 0 0 0 0 0 
TOTAL 45 41 31 29 12 10 4 3 2 1 1 
 
Commentary 
The number of deaths notified to the Programme from sources in Northern Ireland showed a 
small decrease from 2011 to 2012 (however, it is important to note that due to the nature of the 
reporting system there are likely to be proportionately more 2012 deaths reported in 2013-14 
than 2011 deaths, meaning these results may change). The demographic profile of those dying 
in 2012 showed a very slight increase in the proportion of male compared to female deaths. 
 
The general profile of the psychoactive substances implicated in the Northern Ireland NPSAD 
cases is relatively similar to previous years. Northern Ireland contrasts with the rest of the UK 
with higher proportions of deaths attributed to the following substance types: 
hypnotics/sedatives; other opiates/opioid analgesics; anti-depressants; alcohol in combination 
with other drugs; and anti-psychotics. As in previous years, Northern Ireland displayed a 
substantially lower proportion of deaths attributed to heroin/morphine and methadone than other 
regions.  
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Chapter 5: Drug-related deaths in Scotland  
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This section describes the pattern of drug-related deaths in Scotland. The Scottish Crime and 
Drug Enforcement Agency (SCDEA) collate data on drug-related deaths obtained from Scottish 
police forces. These data are used to populate a police/SCDEA national database maintained by 
the SCDEA. As such the data supplied to the SCDEA remain the property of the submitting force 
that is also responsible for its accuracy and submission to the database.  
 
Drug-related death cases are those that meet the definition used by the Association of Chief 
Police Officers (Scotland) – “where there is prima facie evidence of a fatal overdose of controlled 
drugs. Such evidence would be recent drug misuse, for example controlled drugs and/or a 
hypodermic syringe found in close proximity to the body and/or the person is known to the police 
as a drug misuser although not necessarily a notified addict.” Thus, most suicides in Scotland 
are excluded. Figures for “drug misuse” deaths registered in 2012 have been published by the 
National Records of Scotland (NRS, 2013). 
 
Profile of NPSAD cases 
 
5.1 Demography 
Notifications of 326 drug-related deaths occurring in 2012 were received by the SCDEA, 
covering the following police force areas: Central Scotland (3.1%); Dumfries & Galloway (1.2%); 
Fife (6.1%); Grampian (3.7%); Lothian & Borders (28.2%); Northern (5.5%); Strathclyde (35.0%); 
and Tayside (17.2%). This represents a fall of 3.8% compared to 2011 (339 cases). 
 
The majority (76.4%) of cases were male (Table 5.1). The median age at death was 37.1 years 
(interquartile range = 13.8) (Figure 5.1). Most cases (78.2%) were under 45 years. Where 
ethnicity was known, 98.2% were White. 
 
5.2 Location of death 
In line with data protection, the SCDEA database structure does not record information on living 
arrangements and place of death. Where such information was available (from external sources 
– five cases), three died at a defined residential address, and two in hospital. 
 
5.3 Cause(s) of death 
Most of the fatalities (92.3%) were considered to be accidental (i.e. clearly non-deliberate) 
poisoning; this reflects the definition being used by Scottish police. Possible intentional 
poisonings accounted for 2.1% and deaths caused by mental disorders due to psychoactive 
substances (3.7%) accounted for most of the remaining cases. 
 
Psychoactive substances implicated in death  
 
5.4 All substances 
Psychoactive drugs were not directly implicated in 4.6% of cases (n = 15). Of the remaining 311 
cases, the principal substances implicated were: methadone (47.6%); hypnotics/sedatives 
(43.7%); heroin/morphine (42.1%); other opiates/ opioid analgesics (20.9%); alcohol in 
combination with other substances (19.9%); and cocaine (5.5%) (Table 5.4). 
 
Figure 5.2 takes into account data where one of the following drugs was known to be implicated: 
alcohol in combination; amphetamines, anti-depressants; cocaine; ecstasy-type drugs; 
heroin/morphine; methadone; hypnotics/ sedatives; or other opiates/opioid analgesics. 
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5.5 Single substances 
The following substances, as the sole implicated drug, accounted for 77 (24.8%) deaths: 
heroin/morphine (10.6%); methadone (7.4%); other opiates/opioid analgesics (2.6%); cocaine 
(1.3%); amphetamines (1.0%); GHB/GBL (1.0%); anti-depressants (0.3%); ecstasy-type (0.3%); 
and hypnotics/sedatives (0.3%) (Table 5.4). 
Table 5.1: Demographic variables for drug-related deaths as reported by Scottish police 
forces to the SCDEA, 2012 
 
Variable Category Number (%) 
TOTAL  326 (100.0) 
Gender Male 249 (76.4) 
Female 77 (23.6) 
Age group (years) 15-24 29 (8.9) 
25-34 100 (30.7) 
35-44 126 (38.7) 
45-54 54 (16.6) 
55-64 16 (4.9) 
65 & over 1 (0.3) 
 
 
 
Table 5.4: Psychoactive substances implicated in drug-related deaths as reported by 
Scottish police forces to the SCDEA, 2012  
 
Drug category 
Number (%) of psychoactive 
drug cases where no other 
substance was implicated 
 
Number  (%) of 
psychoactive drug cases 
where drug was implicated 
 
TOTAL 311 (100.0) 
Alcohol in combination - 62 (19.9) 
Amphetamines 3 (1.0) 15 (4.8) 
Anti-depressants 1 (0.3) 39 (12.5) 
Anti-epileptics 0 (0.0) 19 (6.1) 
Anti-psychotics 0 (0.0) 4 (1.3) 
Cocaine 4 (1.3) 17 (5.5) 
Ecstasy-type drugs 1 (0.3) 6 (1.9) 
GHB/GBL 3 (1.0) 5 (1.6) 
Heroin/morphine 33 (10.6) 131 (42.1) 
Hypnotics/sedatives 1 (0.3) 136 (43.7) 
Methadone 23 (7.4) 148 (47.6) 
Other opiates/opioid 
analgesics 
8 (2.6) 65 (20.9) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in death. Not all 
cases had psychoactive substances directly implicated in death: these are excluded from this table. 
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Figure 5.1: Drug-related deaths as reported by Scottish police forces to the SCDEA, by 
age and gender, 2012 
 
 
 
 
 
 
 
 
Figure 5.4: Drug-related deaths as reported by Scottish police forces to the SCDEA, by 
selected psychoactive substance implicated, 2012 
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5.5 Age and drug implicated in death  
Methadone was the most frequently mentioned drug contributing to fatality for all (jointly for 25-34 
year-olds) of the individual age groups from 25-34 to 45-54 years (Table 5.5), occurring in 
between 47-54% of cases in these groups. 
 
 
Table 5.5: Age and psychoactive substance implicated in drug-related deaths as reported by 
Scottish police forces to the SCDEA, 2012  
 
Age group (years) Number (%) 
Drug category most frequently implicated (alone 
or in combination) in each age group (%) 
All ages combined 311 (100.0) Methadone (47.4) 
15-24 28 (9.0) Hypnotics/sedatives (46.4) 
25-34 100 (32.2) 
Heroin/morphine (47.0) 
Methadone (47.0) 
35-44 114 (36.7) Methadone (50.0) 
45-54 52 (16.7) Methadone (53.8) 
55-64 16 (5.1) Other opiates/opioid analgesics (56.3) 
65 & over 1 (0.3) 
Heroin/morphine (100.0) 
Alcohol in combination (100.0) 
 
 
5.6 Gender and drug implicated in death 
In males (n = 236) and females (n = 75), the pattern of drug-specific fatality was somewhat 
different.  
 
Among males, the most frequently mentioned drugs were: methadone (47.0%); heroin/morphine 
(44.5%); hypnotics/sedatives (43.2%); alcohol in combination (20.3%); other opiates/ opioid 
analgesics (18.2%); anti-depressants (9.3%); cocaine (6.4%); and amphetamines (5.9%). 
Furthermore, there appears to be a higher proportion of cases of drug-specific fatality among 
males compared to females in respect of heroin/morphine (44.5% vs. 34.7%); cocaine (6.4% vs. 
2.7%); and amphetamines (5.9% vs. 1.3%) 
 
Among female cases, the most frequently mentioned drugs were: methadone (49.3%); 
hypnotics/sedatives (45.3%); heroin/morphine (34.7%); other opiates/opioid analgesics (29.3%); 
anti-depressants (22.7%); alcohol in combination (18.7%); and anti-epileptics (14.7%). Compared 
to male cases, it appears that female cases had a higher proportion of fatality associated with 
other opiates/opioid analgesics (29.3% vs. 18.2%); anti-depressants (22.7% vs. 9.3%); and anti-
epileptics (14.7% vs. 3.4%). 
 
Regional data  
 
The number of drug-related deaths reported by police to the SCDEA and meeting the NPSAD 
case criteria fell from 312 in 2004 to 254 in 2005 and then rose to 374 in 2006. The figure for 
2007 was 357, but rose to a new peak of 478 in 2008, remaining stable in 2009.  This figure fell in 
2010 to 364, 339 in 2011 and to 326 in 2012 - a decrease of 3.8% (Table 5.7). The rates in the 
Lothian & Borders and Tayside police force areas are on a par with some of the higher rates 
reported in England and Wales. 
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Table 5.7: Deaths meeting NPSAD criteria as reported by Scottish police forces to the 
SCDEA, per 100,000 population by police force area, 2010-12  
 
Police force 
area 
Number 
of deaths 
2010 
Annual 
death rate 
per 
100,000 
population 
2010 
*
 
Number 
of deaths 
2011 
Annual 
death rate 
per 
100,000 
population 
2011 
*
 
Number 
of deaths 
2012 
Annual 
death rate 
per 
100,000 
population 
2012 
*
 
Central 
Scotland 
Police 
11 5.80 12 4.96 10 4.07 
Dumfries & 
Galloway 
Constabulary 
2 2.19 8 6.46 4 3.17 
Fife 
Constabulary 
31 13.17 17 5.62 20 6.63 
Grampian 
Police 
38 10.52 48 10.47 12 2.52 
Lothian & 
Borders 
Police 
79 12.49 98 12.26 92 11.58 
Northern 
Constabulary 
7 3.83 22 9.16 18 7.15 
Strathclyde 
Police 
164 11.23 103 5.60 114 6.13 
Tayside 
Police 
32 12.55 31 9.49 56 16.33 
Scotland 364 10.66 339 7.81 326 7.41 
* The rate per 100,000 population is based on published mid-year population estimates for local government 
administrative areas for the years in question. 
 
Commentary 
 
Data received by NPSAD from Coroners suggests that the number of drug-related deaths 
decreased in the rest of the UK during 2012, and information from the Scottish police also 
indicates a fall in SCDEA cases. Figures released by the National Records of Scotland (NRS) 
also show a decrease in deaths registered in 2012, using a number of different definitions (NRS, 
2013). The fall in notifications to the SCDEA may be due, in part, to reduced compliance. 
 
Where recorded by the SCDEA, the demographic profile of those who died from drug-related 
causes is similar to those in other parts of the UK e.g. a higher proportion of males to females, 
aged typically 25-44 years, and White. The overwhelming majority of deaths were accidental 
drug overdoses. The level in Scotland was much higher than in other regions reflecting the 
different case definition used by Scottish police forces.  
 
Opiates such as heroin and methadone are implicated in the majority of cases, and play a larger 
role than in other regions. These drugs in combination with other substances and 
hypnotics/sedatives (which are mostly diazepam and temazepam) also feature prominently in 
Scottish deaths. 
 
The most important changes emerging from these data are that for the second year running 
methadone accounts for more deaths than heroin/morphine as the principal drug involved in 
deaths. This echoes the pattern described in deaths registered in Scotland during 2011 (NRS, 
2012). The fall in 2011 was followed by a stabilisation in the proportions for both substances. 
The proportion of cases in which hypnotics/sedatives (35% vs. 42%) and anti-depressants (7% 
vs. 13%) also increased between 2011 and 2012, as did those for cocaine and ecstasy-type 
drugs.
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Chapter 6: Drug-related deaths in the Islands (Guernsey, 
Jersey, and the Isle of Man) 
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This chapter reports on deaths in 2012 and examines the pattern of drug-related deaths in the 
Islands between 2008 and 2012. Coroners and their equivalents in Guernsey, Jersey and the 
Isle of Man routinely submit returns on drug-related deaths to NPSAD that meet the 
Programme’s case criteria. As there are comparatively few cases in a single year when 
compared with the UK, even when combining data for the Islands together, data for 2008-12 
have been aggregated together so that the findings are more statistically robust. 
 
Profile of NPSAD cases 
 
6.1 Demography 
The Programme has been notified of a total of four drug-related deaths that occurred during 
2012: two deaths on Jersey, two on the Isle of Man, and none on Guernsey. Between 2008 and 
2012 a total of 42 cases were notified, respectively: nine in 2008; 14 in 2009; eight in 2010; 
seven in 2011 and four in 2012. Considering the number of deaths in each island in the five year 
period (2008-2012), it was: five on Guernsey; 21 on Jersey; and 16 on the Isle of Man. 
 
In 2012 the number of deaths per 100,000 population aged 16 years and over was 2.42 for 
Jersey and 2.88 for Isle of Man (Tables 6.1.1 and 6.1.2). 
 
 
Table 6.1.1: Changes in annual death rate per 100,000 population for NPSAD cases (16 
years old and over), and annual percentage of all inquests held, by Island, 2010 and 2012 
 
 
Island 
Annual death rate 
per 100,000 
population 
2010¹ 
Annual death rate 
per 100,000 
population 
2011¹ 
Annual death rate 
per 100,000 
population 
2012 
Guernsey 1.91 3.80 0.00 
Jersey 4.45 2.44 2.42 
Isle of Man 2.91 4.31 2.88 
¹ Including deaths notified after the publication of the NPSAD Annual Report for 2011 deaths 
 
 
Table 6.1.2: Number per 100,000 population (16 years and over) for NPSAD cases, by 
place of residence and death, by Island, 2012 
 
 
Island 
National and annual death rate per 
100,000 population-usual area of 
residence 
National and annual death rate per 
100,000 population-place of death 
 No. Rate No. Rate 
Guernsey 0 0.00 0 0.00 
Jersey 2 2.42 2 2.42 
Isle of Man 2 2.88 2 2.88 
 
 
Among the 42 drug-related deaths that occurred during the five year period, 30 were male and 
12 were female. The median age at death was 36.6 years (interquartile range = 15.03), with the 
majority (85.8%) of cases under 45 years old (Figure 6.1.4). Where ethnicity was known, the 
overwhelming majority of decedents were White (97.6%). Those that were employed accounted 
for 50.0% of cases, whilst 35.7% were unemployed. In terms of living arrangements, 40.5% were 
living alone and 47.6% lived with others (Table 6.1.3). Previous drug use history was known in 
34/42 cases, and of these, 18 (52.9%) had a history of drug use or dependence. 
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Table 6.1.3 Demographics of drug-related deaths in the Islands, 2008-2012 
Variable Category Number (%) 
TOTAL  42 (100.0) 
Gender 
Male 30 (71.4) 
Female 12 (28.6) 
Employment status 
Employed 21 (50.0) 
Unemployed 15 (35.7) 
Retired/sickness/invalidity 5 (11.9) 
Not known 1 (2.4) 
Living arrangements 
With others 20 (47.6) 
Alone 17 (40.5) 
Not known 2 (4.8) 
Other 2 (4.8) 
No fixed abode 1 (2.4) 
 
 
 
Figure 6.1.4 Drug-related deaths meeting NPSAD criteria, by age group and gender, the 
Islands, 2008-2012 
 
 
 
 
Key demographics and the principal drugs implicated in death during 2012 are given for the 
individual Islands in Table 6.4. 
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Table 6.4: Key demographics and principal drugs implicated in deaths for NPSAD 
cases, by Island, 2012 
 
Island No Gender Age group Ethnicity Drug implicated 
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Jersey 2 1 1 2 0 0 2 0 1 1 0 1 1 
Isle of 
Man 
2 2 0 0 1 1 2 0 0 1 1 0 0 
Notes: The number of cases for principal drugs implicated, may sum to more than the total case 
number since more than one substance may be implicated in a death 
 
 
6.2 Location of death 
Most fatalities (76.2%) occurred at a defined residential address (i.e. the deceased’s home 
address or another private residential address); 16.7% of the deaths occurred in hospital; and 
7.1% elsewhere. 
 
6.3 Manner of death 
Based on the information available from Coroners, the manner of death of cases reported was 
accidental in 26 cases (61.9%), intentional in 13 (31.0%) and undetermined in three cases 
(7.1%). 
 
Psychoactive substances implicated in death 
 
6.4 All substances 
Psychoactive drugs were directly implicated in all 42 cases. The main substances implicated 
alone or in combination were: heroin/morphine (40.5%); other opiates/opioid analgesics (28.6%); 
alcohol in combination (28.6%); hypnotics/sedatives (26.2%); and anti-depressants (23.8%) 
(Table 6.4). 
 
6.5 Single substances 
The following substances, as the sole implicated drug, accounted for 20/42 (47.6%) deaths: 
heroin/morphine (12 cases); anti-depressants (three cases); other opiates/opioid analgesics 
(three cases); hypnotic/sedatives (one case); and methadone (one case). 
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6.6 Age and drug implicated in death 
Among those aged 15-34 years, heroin/morphine was the leading drug implicated, whilst for 
those aged between 35-44 the substance type most frequently implicated was 
hypnotic/sedatives. Table 6.6 provides a breakdown for each age group. 
 
Table 6.4: Psychoactive substances implicated in deaths meeting NPSAD criteria, the 
Islands, 2008-2012 
Drug category 
Number (%) of cases 
where no other substance 
was implicated 
Number (%) of 
psychoactive drug 
cases where drug was 
implicated 
TOTAL 42 (100.0) 
Alcohol in combination - 12 (28.6) 
Anti-depressants 3 (7.1) 10 (23.8) 
Anti-psychotics 0 (0.0) 1 (2.4) 
Ecstasy-type drugs 0 (0.0) 1 (2.4) 
Heroin/morphine 12 (28.6) 17 (40.5) 
Hypnotic/sedatives 1 (2.4) 11 (26.2) 
Methadone 1 (2.4) 3 (7.1) 
Other opiates/opioid analgesics 3 (7.1) 12 (28.6) 
 
Figure 6.7 Gender and drug implicated in death by gender (2008-2012) 
 
6.7 Gender and drug implicated in death 
The gender distribution by type of psychoactive substances implicated in fatalities reveals some 
interesting differences between male and female cases. Among the 30 male cases in which 
psychoactive drugs were implicated, the top three substances most frequently implicated alone 
or in combination were: 
 
1. Heroin/morphine (50.0%) 
2. Other opiates/opioid analgesics (26.7%) 
3. Hypnotics/sedatives (23.3%) & alcohol in combination with other drugs (23.3%) 
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Among the 12 female cases, the top three substances were: 
 
1. Anti-depressants (66.7%) 
2. Alcohol in combination with other drugs (41.7%) 
3. Other opiates/opioid analgesics (33.3%) & hypnotics/sedatives (33.3%) 
 
Comparing the type of psychoactive substances implicated in the deaths of both genders, 
heroin/morphine contributed to a substantially larger proportion of male deaths than female 
deaths (50.0% vs. 16.7%), whilst anti-depressants accounted for a greater proportion of female 
deaths (66.7% vs. 6.7%). There were no female fatalities due to methadone or anti-psychotics 
reported to the Programme. Conversely, there were no male deaths involving ecstasy-type 
substances, whilst one female death involved such drugs. 
 
Table 6.6: Age and psychoactive drug implicated in deaths reported by Guernsey, Jersey, 
and the Isle of Man 
Age group (years) Number of cases 
Drug category (alone or in 
combination) most frequently 
implicated in each group 
All ages 42 
Alcohol in combination (12) 
Anti-depressants (10) 
Anti-psychotics (1) 
Ecstasy-type drugs (1) 
Heroin/morphine (17) 
Hypnotics/sedatives (11) 
Methadone (3) 
Other opiates/opioid analgesics (12) 
15-24 6 
Alcohol in combination (2) 
Anti-depressants (1) 
Ecstasy-type drugs (1) 
Heroin/morphine (3) 
Hypnotics/sedatives (1) 
Other opiates/opioid analgesics (1) 
25-34 13 
Alcohol in combination (3) 
Anti-depressants (1) 
Heroin/morphine (8) 
Hypnotics/sedatives (2) 
Methadone (1) 
Other opiates/opioid analgesics (3) 
35-44 17 
Alcohol in combination (5) 
Anti-depressants (5) 
Anti-psychotics (1) 
Heroin/morphine (5) 
Hypnotics/sedatives (6) 
Methadone (2) 
Other opiates/opioid analgesics (4) 
45-54 4 
Alcohol in combination (1) 
Heroin/morphine (1) 
Hypnoticssedatives (1) 
Other opiates/opioid analgesics (1) 
 
55-64 
 
2 
Alcohol in combination (1) 
Anti-depressants (1) 
65 & over 2 
Hypnotics/sedatives (1) 
Other opiates/opioid analgesics (1) 
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Commentary 
The number of deaths notified to the Programme for 2012 from the Islands showed a decrease 
in general and for each island in particular. There were no reported drug-related deaths on 
Guernsey. The general demographic profile of cases in the Islands is in line with the pattern in 
the UK as a whole. When data for the three Islands are combined together, the relative 
proportions of deaths attributed to certain psychoactive substances is broadly similar across the 
period 2008-12, with heroin/morphine; other opiates/opioid analgesics; alcohol in combination 
with other drugs; hypnotic/sedatives; and anti-depressants drugs being implicated most 
frequently. The proportion of cases involving only one substance is much lower than in the UK. 
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Chapter 7: Drug-related deaths in the United Kingdom and 
Islands 
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Total reported deaths 
 
The total number of deaths that occurred during 2011 in the UK and Islands reported to the 
National Programme on Substance Abuse Deaths (NPSAD) was 1,613. This number compares 
to 1,933 cases reported by similar sources for 2011. This change represents a decrease of 
16.6% for the UK in the number of notifications to the Programme, but not necessarily in drug-
related mortality during this period. This reduction in reported cases is likely due to a 
combination of a reduced catchment period for drug-related death notifications compared with 
the previous report and a lower coverage rate of Coroners voluntarily reporting to the 
Programme. Furthermore, due to the nature of the Coronial reporting system and lengthy 
inquest procedures, the figures for 2012 (and 2011, to a lesser extent) can be expected to 
increase as further inquests on drug-related deaths are completed and reported to the 
Programme. 
 
Of the 1,613 drug-related deaths reported for 2012, England had 1,147 (71.1%); Scotland 326 
(20.2%); Wales 58 (3.6%); Northern Ireland 78 (4.8%); and the Islands 4 (0.2%). Out of the 
1,933 reported cases for 2011, England had 1,424 (73.7%); Scotland 339 (17.5%); Wales 81 
(4.2%); Northern Ireland 82 (4.2%); and the Islands 7 (0.4%). 
 
The number of cases reported from England represents a decrease of 19.5% between 2011 and 
2012; 28.4% in Wales; 4.9% in Northern Ireland; 3.8% in Scotland; and the number of deaths 
reported for the Islands fell from seven cases to four. These falls are only in relation to the 
number of deaths reported to the Programme, and not necessarily a reflection of actual 
reductions in the number of NPSAD deaths that occurred. 
 
Profile of NPSAD cases 
 
7.1 Demography 
The majority (72.2%) of cases were male (Table 7.1 and Figure 7.1). This proportion varied from 
64.1% in Northern Ireland to 76.4% in Wales. Where ethnicity was known, the majority were 
White (97.3%), and the proportion of cases living with others ranged from 39.6% in England to 
50.0% in Northern Ireland. Those who were unemployed accounted for 37.1% of cases, ranging 
from 45.2% in England to 58.6% in Wales. Where previous drug use was known, 67.1% of 
cases had such a history of drug use or dependence. 
 
The median age at death was 40 years (interquartile range = 15 years) for all regions combined. 
The medians ranged from 36 years in Wales to 41 years in England. There were also 
differences in the median ages broken down by gender: 39 years (interquartile range = 14 years) 
for males compared to 42 years (interquartile range = 18 years) for females. Figure 7.1 gives a 
breakdown by gender and age group. 
 
The above differences reflect distinctions in the nature and purpose of the data sources; the 
types of cases covered including the definitions used; and the volumes of cases dealt with by 
them. These variations also illustrate the limitations on making comparisons between them.  
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Table 7.1: Demographic variables for drug-related deaths, UK and Islands, 2012 
 
Variable Category Number (%) 
TOTAL  1,613 (100.0) 
Gender Male 1165 (72.2) 
Female 448 (27.8) 
Age group (years) 14 & under 2 (0.1) 
15-24 139 (8.6) 
25-34 389 (24.1) 
35-44 558 (34.6) 
45-54 305 (18.9) 
55-64 154 (9.5) 
65 & over 66 (4.1) 
Living arrangements Alone 557 (34.5) 
With others 521 (32.3) 
Other 55 (3.4) 
No fixed abode 37 (2.3) 
Not known 443 (27.5) 
Ethnicity Black 11 (0.7) 
Asian 8 (0.5) 
White 1140 (70.7) 
Other 13 (0.8) 
Not known 441 (27.3) 
Employment status Unemployed 598 (37.1) 
Employed 366 (22.7) 
Childcare/houseperson 32 (2.0) 
Student/pupil 21 (1.3) 
Retired/invalidity/sickness 126 (7.8) 
Other 11 (0.7) 
Not known 459 (28.5) 
History of drug 
use/addiction 
Yes 619 (38.4) 
No 304 (18.8) 
Not known 690 (42.8) 
Location of death Defined residential address 934 (57.9) 
Hospital 191 (11.8) 
Public place  77 (4.8) 
Other 11 (0.7) 
Not known 400 (24.8) 
 
 
Figure 7.1: NPSAD drug-related deaths by age group and gender, UK and Islands, 2012 
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7.2 Location of death 
In 2012, amongst cases whose place of death was known, 77.0% died at a defined residential 
address (i.e. the deceased’s home address or other private residential address), whilst 15.7% 
died in hospital and 7.3% died elsewhere (e.g. in a public place or derelict building). The 
proportion of cases dying at a defined residential address when such information was reported 
ranged from 75.8% in England to 93.6% in Northern Ireland. The corresponding proportions for 
deaths in hospital ranged from 16.6% in England to 5.1% in Northern Ireland. Information for 
Scotland on living arrangements and place of death was not available as the SCDEA does not 
report information on these details for data protection reasons. 
 
7.3 Cause(s) of death 
Over two thirds (67.9%) of the fatalities in 2012 reported to the Programme were considered to 
be as a result of accidental poisoning (i.e. clearly non-deliberate). Deaths attributed to intentional 
self-poisoning accounted for 11.0%, whilst 11.2% were poisonings of undetermined intent. The 
remaining 9.9% of cases were attributed to other or unascertained causes of death. There are 
differences between different parts of the UK and Islands in the proportions of deaths accounted 
for by these main groupings of underlying cause(s) of death (Table 7.3.1). These reflect, in part, 
differences between the SCDEA and NPSAD case definitions. A detailed breakdown for all 
cases covered by this report is given in Table 7.3.2. 
   
 
 
Table 7.3.1: Main underlying causes of death, by country and territory, 2012 
 
 
 
Country or territory 
England Wales Scotland 
Northern 
Ireland 
Jersey 
Isle of 
Man 
UK & 
Islands 
 Number of deaths 1147 58 326 78 2 2 1613 
        
U
n
d
er
ly
in
g
 c
au
se
 o
f 
d
ea
th
 (
%
) 
Accidental poisoning 
724 
(63.1) 
52 
(89.7) 
291 
(89.3) 
26 
(33.3) 
1 
(50.0) 
1 
(50.0) 
1095 
(67.9) 
Intentional poisoning 
157 
(13.7) 
1 
(1.7) 
0 
(0.0) 
18 
(23.1) 
0 
(0.0) 
1 
(50.0) 
177 
(11.0) 
Undetermined 
poisoning 
139 
(12.1) 
1 
(1.7) 
7 
(2.1) 
33 
(42.3) 
1 
(50.0) 
0 
(0.0) 
181 
(11.2) 
Other/unascertained 
causes 
127 
(11.1) 
4 
(6.9) 
28 
(8.6) 
1 
(1.3) 
0 
(0.0) 
0 
(0.0) 
160 
(9.9) 
Note: no NPSAD deaths were reported for Guernsey in 2012 
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Table 7.3.2: Drug-related deaths by underlying cause(s) of death, UK and Islands, 2012  
 
ICD-10 
No. of cases 
(n = 1,613) 
% Description 
 
X40 
 
X41 
 
X42 
 
X43 
 
X44 
 
X45 
X46 
 
X47 
 
6 
 
132 
 
907 
 
1 
 
31 
 
11 
1 
 
6 
 
0.4 
 
8.2 
 
56.2 
 
0.1 
 
1.9 
 
0.7 
0.1 
 
0.4 
Accidental poisoning  
Non-opioid analgesics, antipyretics and anti-
rheumatics  
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism 
and psychotropic drugs, not elsewhere classified 
Narcotics and psychodysleptics (hallucinogens), not 
elsewhere classified  
Other drugs acting on the autonomic nervous 
system 
Other and unspecified drugs, medicaments and 
biological substances 
Alcohol 
Organic solvents and halogenated hydrocarbons 
and their vapours 
Gases 
 
X60 
 
X61 
 
X62 
 
X63 
 
X64 
 
X67 
 
 
5 
 
87 
 
77 
 
4 
 
3 
 
1 
 
0.3 
 
5.4 
 
4.8 
 
0.2 
 
0.2 
 
0.1 
Intentional self-poisoning  
Non-opioid analgesics, antipyretics and anti-
rheumatics 
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism 
and psychotropic drugs, not elsewhere classified 
Narcotics and psychodysleptics (hallucinogens), not 
elsewhere classified 
Other drugs acting on the autonomic nervous 
system 
Other and unspecified drugs, medicaments and 
biological substances 
Other gases and vapours 
 
Y10 
Y11 
 
Y12 
Y13 
Y14 
Y17 
 
3 
55 
 
113 
1 
8 
1 
 
0.2 
3.4 
 
7.0 
0.1 
0.5 
0.1 
Poisoning of undetermined intent  
Non-opioid analgesics  
Antiepileptic, sedative-hypnotic, anti-Parkinsonism 
and psychotropic drugs not elsewhere classified 
Narcotics and psychodysleptics 
Other drugs acting on autonomic nervous system 
Other/unspecified drugs 
Other gases and vapours 
 
 
F10.2 
F12.0 
F15.2 
F18.0 
F19.0 
F19.2 
Z72.2 
 
 
1 
1 
1 
1 
2 
8 
11 
 
 
0.1 
0.1 
0.1 
0.1 
0.1 
0.5 
0.7 
Mental & behavioural disorders due to psychoactive 
substance use 
Chronic alcoholism 
Intoxication – cannabinoids 
Dependence – stimulants 
Intoxication – volatile substances 
Intoxication – unspecified substances 
Multiple drug use 
Drug abuse, personal history 
 
G04.8 
G40.9 
G93.1 
G97.8 
 
1 
1 
2 
1 
 
0.1 
0.1 
0.1 
0.1 
Brain 
Other encephalitis, myelitis and encephalomyelitis 
Epileptic seizures 
Anoxic or hypoxic brain damage 
Cerebral hypoxia unspecified 
 
 
I11 
I20-I25 
I25.1 
I33 
I38 
I40.9 
I46.9 
I49.9 
I61.9 
I70 
 
 
 
1 
1 
4 
1 
1 
1 
1 
1 
2 
1 
 
 
 
0.1 
0.1 
0.2 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
 
Cardiovascular system – diseases, defects or 
conditions affecting 
Hypertensive heart disease 
Ischaemic heart diseases 
Atherosclerotic heart disease 
Acute and subacute endocarditis 
Endocarditis, unspecified valve 
Acute myocarditis 
Cardiac arrest, unspecified 
Cardiac arrhythmia 
Intracerebral haemorrhage 
Atherosclerosis 
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ICD-10 
No. of cases 
(n = 1,613) 
% Description 
 
J18.9 
J20 
J44.9 
J45.9 
J46 
J69.0 
J85.1 
J98.8 
 
1 
1 
3 
1 
2 
1 
1 
1 
 
0.1 
0.1 
0.2 
0.1 
0.1 
0.1 
0.1 
0.1 
Diseases of the respiratory system 
Pneumonia, unspecified 
Acute bronchitis 
Chronic obstructive pulmonary disease 
Asthma, unspecified 
Status asthmaticus 
Aspiration pneumonia 
Abscesses of lung with pneumonia 
Other specified respiratory disorders 
 
B17.1 
K70.3 
K70.9 
 
 
1 
1 
2 
 
 
0.1 
0.1 
0.1 
 
Diseases of the liver 
Acute hepatitis C 
Alcoholic cirrhosis of liver 
Alcoholic liver disease 
 
 
V47.3 
V47.5 
 
 
3 
2 
 
 
0.2 
0.1 
 
Road traffic incidents 
Car occupant injured in collision with fixed object 
Driver injured in collision with fixed/stationary object 
 
 
W76 
X70 
X91 
Y20 
 
2 
22 
1 
11 
 
0.1 
1.4 
0.1 
0.7 
Hanging 
Other accidental hanging and strangulation  
Intentional hanging 
Assault by hanging, strangulation and suffocation 
Hanging, undetermined intent 
 
R09.0 
W78 
 
2 
2 
 
0.1 
0.1 
Asphyxia 
Asphyxia general 
Aspiration of gastric contents 
 
T75.1 
W69 
W70 
W74 
X71 
 
 
1 
1 
1 
4 
3 
 
 
0.1 
0.1 
0.1 
0.2 
0.2 
 
Drowning & submersion 
Immersion in water 
Whilst in natural water 
Following fall into natural water 
Drowning and submersion, unspecified 
Intentional self-harm by drowning 
 
 
A22.7 
E10 
E87.2 
I72.9 
I87.2 
K22.3 
K92.2 
L02.2 
L08.8 
M80.1/6 
S02.9 
S09.9 
S15 
S29.9 
T04 
T07 
W19 
X00 
X73 
 
X81 
X85 
 
X93 
X99 
 
1 
2 
4 
1 
1 
1 
1 
1 
1 
1 
2 
1 
1 
1 
1 
5 
1 
1 
1 
 
2 
1 
 
1 
1 
 
0.1 
0.1 
0.2 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.3 
0.1 
0.1 
0.1 
 
0.1 
0.1 
 
0.1 
0.1 
Other 
Anthrax septicaemia 
Diabetic ketoacidosis 
Metabolic acidosis, exc. diabetic acidosis 
Aneurysm and dissection of unspecified site 
Chronic peripheral venous insufficiency 
Rupture of oesophagus 
Gastrointestinal haemorrhage, unspecified 
Groin abscess 
Other specified local infections of skin and tissue 
Carcinoma, metastatic not elsewhere specified 
Fracture of skull & facial bones, part unspecified 
Head injuries, unspecified 
Injury of blood vessels at neck level 
Injury of thorax, unspecified 
Crushing injuries involving multiple body regions 
Multiple injuries, unspecified 
Fall, unspecified 
Exposure to uncontrolled fire in building or structure 
Intentional self-harm by rifle, shotgun and larger 
firearm discharge 
Jumping or lying before moving object, intentional 
Assault by drugs, medicaments and biological 
substances 
Assault by handgun discharge 
Assault by sharp object 
R99 13 0.8 Unascertained 
 
Where possible, causes of death have been grouped together in terms of the mechanisms of death.  At present, although all 
causes of death on the death certificate (together with other information if available) are taken into consideration in classifying 
underlying cause of death, the principal cause of death is used here by NPSAD to allocate the ICD-10 code. In order to achieve 
a greater level of consistency, a hierarchical system was introduced for classifying the underlying cause of death using ICD-10 
criteria for deaths involving multiple substances. Deaths that involve a combination of narcotics and other psychoactive drugs are 
coded as narcotic deaths. Where possible a code which specifies intentionality is used. 
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Psychoactive substances implicated in death  
Psychoactive substances were directly implicated in the deaths of 91.4% (1,475/1,613) of all 
cases reported to the Programme. The remaining 8.6% (n = 138) did not have any 
psychoactive substances implicated in their deaths, and have therefore been excluded from 
the following analyses. Of the 1,475 cases in which psychoactive substances were implicated, 
the principal substances were: heroin/morphine (36.4%); hypnotics/sedatives (30.3%); alcohol 
in combination (30.3%); methadone (27.6%); other opiates/opioid analgesics (26.8%); and 
anti-depressants (23.0%). 
 
Table 7.4 shows that whilst there are certain similarities across the UK and Islands in terms of 
the various psychoactive substances implicated in death, there are some interesting regional 
differences. For example, hypnotics/sedatives; other opiates/opioid analgesics; anti-
depressants; alcohol in combination; and anti-psychotics play a proportionately greater role in 
Northern Ireland than in other parts of the UK. Meanwhile, methadone; anti-epileptics; 
amphetamines; and GHB/GBL feature in proportionately more deaths in Scotland than in 
other areas. Heroin/morphine accounted for over half of the deaths in Wales in which 
psychoactive substances were implicated, which is higher than any other part of the UK. 
However, England showed the greatest proportion of deaths involving cocaine; cannabis; 
ecstasy-type drugs; and anti-Parkinson’s drugs. 
 
Some of these regional differences can be attributed in part to differences in prescribing 
practice and case qualification standards. For example, the lesser role played by methadone 
in Northern Ireland may be attributable to the fact that methadone is not prescribed as widely 
there as in other areas. Also, a potential explanation why anti-depressants are not implicated 
as often in Scottish cases as in other areas is that the definition used by the SCDEA does not 
cover the general population or suicides, but focuses on accidental overdoses involving 
controlled drugs. 
 
Commentary  
The data received by NPSAD from Coroners suggest that the number of drug-related deaths 
in 2012 fell in England; Wales; Northern Ireland; Jersey; and the Isle of Man. However, as 
discussed previously, with regards England and Wales, the very sharp drop in drug-related 
deaths reported to the Programme may be due in part to lower coverage rates and also 
potentially a reduction in reporting from the responding Coroners. Information from the 
SCDEA police indicates a fall in Scottish police cases, and this is supported by information 
from the National Records of Scotland (NRS, 2013). 
 
As has been found in previous years, the general demographic details of those who died from 
drug-related causes are relatively similar across the UK, with a higher proportion of males to 
females; typically between 25-44 years of age; White; and mostly living with others. 
 
Accidental drug overdoses accounted for the greatest proportion of deaths across the UK, 
and most cases died at home or at another private residential address. The substances 
playing the most prominent roles in deaths have not changed substantially over recent years, 
with opiates – such as heroin, methadone and opioid analgesics – and hypnotics/sedatives 
and alcohol in combination with other substances being involved in the greatest proportions of 
deaths. However, as covered in the individual countries’ chapters, there are regional 
variations in the deaths attributed to these substances. 
 
Deaths reported to the Programme for 2012 in the UK and Islands as a whole show 
proportional increases in cases involving heroin/morphine; alcohol in combination with other 
drugs; hypnotics/sedatives; ecstasy-type drugs; cannabis; GHB/GBL; anti-depressants; anti-
epileptics; and amphetamines.  Slight drops were found in deaths in which anti-Parkinson’s 
drugs; anti-psychotics; methadone; and other opiates/opioid analgesics were implicated. The 
fall in methadone-related deaths is in contrast with the gradual rise in the number of deaths 
involving the drug in recent years. The rise in the number of deaths involving heroin/morphine 
is also an abrupt change considering the reduction in such deaths found over the past few 
years. The patterns observed in different parts of the UK, and possible reasons for the 
continuing changes in recreational drug use, are examined in the following chapter. 
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Table 7.4: Psychoactive substances (%) implicated in drug-related deaths, by country 
and territory, 2012  
 
 Country or territory 
England Wales Scotland 
Northern 
Ireland 
Jersey 
Isle 
of 
Man 
UK & 
Islands 
 Total deaths 1033 53 311 74 2 2 1475 
 Number of deaths (%) 
D
ru
g
 c
a
te
g
o
ry
 
Alcohol in 
combination 
348 
(33.7) 
7 
(13.2) 
62 
(19.9) 
29 
(39.2) 
1 
(50.0) 
0 
(0.0) 
447 
(30.3) 
Amphetamines 
41 
(4.0) 
2 
(3.8) 
15 
(4.8) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
58 
(3.9) 
Anti-depressants 
259 
(25.1) 
8 
(15.1) 
39 
(12.5) 
31 
(41.9) 
1 
(50.0) 
1 
(50.0) 
339 
(23.0) 
Anti-epileptics 
25 
(2.4) 
0 
(0.0) 
19 
(6.1) 
4 
(5.4) 
0 
(0.0) 
0 
(0.0) 
48 
(3.3) 
Anti-Parkinson’s 
2 
(0.2) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
2 
(0.1) 
Anti-psychotics 
60 
(5.8) 
1 
(1.9) 
4 
(1.3) 
10 
(13.5) 
0 
(0.0) 
0 
(0.0) 
75 
(5.1) 
Cannabis 
24 
(2.3) 
1 
(1.9) 
0 
(0.0) 
1 
(1.4) 
0 
(0.0) 
0 
(0.0) 
26 
(1.8) 
Cocaine 
115 
(11.1) 
2 
(3.8) 
17 
(5.5) 
1 
(1.4) 
0 
(0.0) 
0 
(0.0) 
135 
(9.2) 
Ecstasy-type drugs 
38 
(3.7) 
1 
(1.9) 
6 
(1.9) 
2 
(2.7) 
0 
(0.0) 
0 
(0.0) 
47 
(3.2) 
GHB/GBL 
11 
(1.1) 
0 
(0.0) 
5 
(1.6) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
16 
(1.1) 
Heroin/morphine 
364 
(35.2) 
29 
(54.7) 
131 
(42.1) 
12 
(16.2) 
0 
(0.0) 
1 
(50.0) 
537 
(36.4) 
Hypnotics/sedatives 
249 
(24.1) 
20 
(37.7) 
136 
(43.7) 
41 
(55.4) 
1 
(50.0) 
0 
(0.0) 
447 
(30.3) 
Methadone 
234 
(22.7) 
22 
(41.5) 
148 
(47.6) 
3 
(4.1) 
0 
(0.0) 
0 
(0.0) 
407 
(27.6) 
Other opiates/ 
opioid analgesics 
276 
(26.7) 
8 
(15.1) 
65 
(20.9) 
45 
(60.8) 
1 
(50.0) 
0 
(0.0) 
395 
(26.8) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
No NPSAD deaths were reported for Guernsey in 2012. 
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Chapter 8: Commentary and emerging themes  
Introduction 
 
This chapter provides up-to-date information on emerging trends and issues for those who 
investigate drug-related deaths (DRDs) and those who are trying to prevent such fatalities. 
The main trends and issues highlighted here emerge from the submitted forms, 
communications from Coroners, and other relevant sources. This section also draws on 
published sources and intelligence from forensic toxicological agencies. 
 
General patterns 
The total number of deaths that occurred during 2012 in the UK reported to the National 
Programme on Substance Abuse Deaths (NPSAD) was 1,613. This number compares to 
1,757 cases reported by the same sources during the equivalent period in 2011. This change 
represents a decrease in the number of notifications to the Programme, but not necessarily in 
drug-related mortality during this period. Similarly, the decreased number of cases reported 
by Coroners in England and by the SCDEA for Scotland, does not necessarily mean a 
decrease in deaths related to drug use.  
 
The demographic profile of fatalities reported to the NPSAD remains broadly consistent with 
previous reports. Compared to 2011, the proportion under 45 years of age increased by about 
one percent; the proportion unemployed fell by 5%; and the proportion with a known history of 
drug use or dependence rose by 2%. There was a decrease in the proportion of UK deaths 
where the underlying cause of death was accidental poisoning (down from 70% to 68%) and 
for poisonings of undetermined intent (from 13% to 11%), with corresponding increases in the 
proportions recorded as intentional self-poisoning and other causes.  
 
Opiates/opioids (i.e. heroin/morphine; methadone; other opiates/opioid analgesics), alone or 
in combination with other drugs continue to account for the majority of all cases. 
Heroin/morphine alone or in combination with other drugs, accounted for the highest 
proportion (36%) of ‘drug misuse’ fatalities in 2012, an increase over the 2011 level of 32% 
(53% in 2009). There were modest increases in the proportions of deaths due to alcohol in 
combination (27% to 30%); anti-depressants (21% to 23%); and hypnotics/sedatives (28% to 
30%). There were falls in the proportions accounted for by methadone (31% to 28%) and 
other opiates/opioid analgesics (28% to 27%), whilst the proportion involving anti-psychotics 
remained stable at 5%. For stimulants, there was a stabilisation in the proportion of cases 
involving cocaine (9%) and amphetamines (4%), but there were further slight increases for 
ecstasy-type drugs (from 1.7% to 3.4%) and GHB/GBL (0.6% to 1.1%). These patterns are 
also generally reflected at country level. Over recent years there has been a trend towards 
multiple substances, including alcohol, being implicated in deaths. In 2012, there was a fall in 
the proportion of monovalent deaths, from 34% to 30%. 
 
Prescribed heroin/morphine and methadone are most commonly involved in deaths where 
these substances are directly implicated in death. Other opiates/opioid analgesics, 
hypnotics/sedatives, and anti-depressants prescribed to individuals are less frequently 
involved in their deaths.  
 
The median age at death of individuals notified to NPSAD with a known history of drug use or 
dependence was 38 years (interquartile range = 12 years) in 2012. 
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Emerging issues 
 
Opioid-related deaths 
Over recent years there has been growing concern in North America, Australia, and the 
European Union (Giraudon et al., 2013), about increasing recreational use and abuse of 
prescription drugs and fatalities resulting from such use, especially those involving synthetic 
opioid pain-killers (Darke et al., 2011; Fischer et al., 2013; Häkkinen et al., 2012; Okic et al., 
2013; Rintoul et al., 2011). Interest in these developments has been expressed in the UK 
(National Treatment Agency, 2011). Specific substances of interest are oxycodone and 
fentanyls (Mounteney et al., 2012). At the same time, there has been interest in the evolution 
of deaths involving buprenorphine and tramadol. The Home Office concluded a public 
consultation in late October 2013 on the proposed control of tramadol as a Class C drug, the 
intention being to reduce its misuse whilst ensuring that those who need it as a prescription 
medicine will still have access to it under a process known as scheduling (Home Office, 
2013a). Oxycodone has featured in fatalities in the USA and Australia, and fentanyls (both 
those used therapeutically and those produced illicitly) in deaths in the Baltic States. The 
patterns in UK deaths involving these substances over the period 2000-12 are examined 
below against the background of the noticeable changes involving heroin/morphine and 
methadone noted above. 
 
Figure 8.1 shows that deaths involving buprenorphine, fentanyl and oxycodone have steadily 
increased over the last 13 years, particularly since 2007 but are still at relatively low levels. As 
noted in previous NPSAD reports, there was a steady increase in deaths involving tramadol 
following the tightening up of prescribing of the pain-killer co-proxamol. There was an 
increase in such deaths between 2008 and 2009 followed by stabilisation in 2010; however, 
there was a further increase in 2011 – deaths nearly tripling between 2005 and 2011 (from 53 
to 156). In 2012 there was drop to pre-2009 levels. During the period 2000-12, 
heroin/morphine deaths rose from 767 to peak at 1,219 in 2009 before falling by more than 
50% to 537 in 2012. By contrast methadone-related deaths more than doubled, from 202 in 
2000 to 556 in 2011 before falling to 407 in 2012. 
    
Figure 8.1: Trends in UK deaths involving opiate/opioid analgesics, NPSAD data, 2000-
2012 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Heroin/morphine 767 826 855 661 878 887 981 1041 1012 1219 718 576 537
Methadone 202 211 237 216 249 258 353 438 471 529 474 556 407
Oxycodone 0 2 0 6 3 7 5 16 18 19 25 32 30
Fentanyl 0 1 2 4 2 2 2 4 4 13 10 21 16
Buprenorphine 0 0 1 3 0 5 5 6 5 9 12 13 8
Tramadol 10 32 19 36 46 53 76 83 79 114 113 156 106
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Stimulant use 
As reported in last year’s NPSAD report (Ghodse et al., 2013), previous years saw decreases 
in the number of deaths involving ‘traditional’ stimulants such as cocaine, amphetamines, and 
ecstasy-type substances. Reasons for these decreases, also seen in death registration 
statistics from the General Mortality Registers, may include a decline in cocaine purity and/or 
a shift to using alternative stimulants, including ‘legal highs’. However, 2012 saw rises in the 
proportion of deaths involving cocaine and ecstasy-type drugs, and this reversal of the pattern 
of recent years may in part be due to changes in purity. For example, the mean purity of 
powder cocaine seized by the police in England & Wales fell from 33% in 2007 to 24% in 
2010 but rose to 37% in 2012; the MDMA content of ‘ecstasy’ tablets fell from 52mg in 2007 
to 33mg in 2008, then rose very slightly in 2009-10 to 49mg but by 2012 had risen to 102mg 
(Davies and Murray, 2013). Last year use of powder cocaine amongst 16–59 year-olds in 
England & Wales fell from 3.0% in 2008/9 to 1.9% in 2012/13 (Home Office, 2012b). During 
the same period, last year use of amphetamines fell from 1.2% to 0.6%, and that of ecstasy-
type drugs from 1.8% to 1.3%. It has been suggested that the fall in ecstasy and cocaine-
related deaths in the United Kingdom in 2008-10 may be as a result of users switching to 
‘legal highs’ with the suggestion that this may have had an unintended harm reduction effect 
(Bird, 2010).  
 
Whilst the use of amphetamine, ecstasy-type drugs and cocaine appears to have continued to 
fall between 2009 and 2012 (Home Office, 2013b), the street purity of these substances rose 
in 2011 and 2012 (Davies and Murray, 2013). The proportion of stimulant deaths reported to 
the NPSAD that occurred in 2011 and 2012 increased compared to 2010. This is in line with 
the rises in the average street purity of the stimulants mentioned above, both in the UK, EU 
and elsewhere. UK deaths registered in 2011 involving ecstasy-type substances and 
amphetamine showed increases whereas cocaine-related fatalities fell (Davies and Murray, 
2013). The number of seizures of cocaine and amphetamines has continued to fall in recent 
years, whereas those for ecstasy rose in 2012/3; the amount of amphetamines and cocaine 
seized rose in 2012/3 (Coleman, 2013). These changes in traditional and newer stimulants 
and club drugs are evident in treatment presentations in England (National Treatment 
Agency, 2012), and inquiries to the National Poisons Information Service and Toxbase (NPIS, 
2013).  
 
Misuse of prescribed medications 
In the UK there has been growing concern about the misuse of prescribed medications, 
including tramadol (see above) and the hypnotic/sedative ‘Z’ drugs – zaleplon, zolpidem and 
zopiclone. For further details of cases involving ‘Z’ drugs see the Programme’s evidence to 
the ACMD (Casula et al., 2013). So far during 2013 the EMCDDA has been notified of at least 
six NPS which are or were prescribed medications. We look briefly at these (Table 8.1), 
together with pregabalin, which was first reported as an NPS in 2009. 
 
Atomoxetine is used in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). This 
drug was prescribed in only one case in 2011 and two in 2012, otherwise there have been no 
notifications to the Programme. It has not been recorded in post mortem toxicology or in the 
cause of death in any NPSAD cases. 
 
Diphenhydramine is an antihistamine used to treat allergy symptoms, motion-sickness, and 
induce sleep (e.g. Nytol). This medication has only occasionally been prescribed to 
individuals whose deaths have been notified. The number of cases in which it was found in 
post mortem toxicology and/or implicated in death increased from 2003-4 but has since varied 
from year to year with only a slight apparent upward trend. The majority of cases involving the 
drug do not appear to have been prescribed it. 
 
Gabapentin is a GABA (γ-Amino butyric acid) analogue used to treat epilepsy and 
neuropathic pain. This medication seems to have been increasingly prescribed to individuals 
notified since 2003 but has been stable during 2009-12. Instances of it being found in post 
mortem toxicology and/or cause of death rose sharply in 2012, with most cases (two-thirds in 
2012) not prescribed it. 
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Table 8.1: Profile of deaths involving selected medications notified to NPSAD, 2000-12 
 
Substance Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Atomoxetine 
Prescribed 
Sole              
Any            1 2 
Post Mortem + 
Sole              
Any              
Implicated in 
death 
Sole              
Any              
Diphenhydramine 
Prescribed 
Sole           1   
Any     1 1 3 1 2 1 1   
Post Mortem + 
Sole     1 1     1 4  
Any  3 2 2 11 13 18 24 13 26 24 29 21 
Implicated in 
death 
Sole      1     2 4  
Any  1 2 2 2 10 9 14 6 11 10 20 10 
Gabapentin 
Prescribed 
Sole     1 1   1 2  1 3 
Any  1  6 10 17 12 11 11 34 30 33 32 
Post Mortem + 
Sole            1  
Any     2 2 2 3 5 10 13 18 52 
Implicated in 
death 
Sole            1  
Any      1  2 4 4 6 5 22 
Pregabalin 
Prescribed 
Sole            3 1 
Any       1 9 14 15 27 46 50 
Post Mortem + 
Sole              
Any       1 3 4 5 6 12 17 
Implicated in 
death 
Sole             1 
Any       1 2 5 3 3 7 13 
Venlafaxine 
Prescribed 
Sole  1   6 7 7 9 4 1 5 9 2 
Any 7 19 14 29 65 44 44 53 44 44 36 61 38 
Post Mortem + 
Sole 1   3 6 8 6 6 3 2 1 5  
Any 7 11 5 20 47 40 37 45 45 51 38 78 54 
Implicated in 
death 
Sole 1 1  2 6 9 9 8 8 5 4 9 6 
Any 6 8 4 13 19 34 32 32 33 30 21 44 33 
 
n (all NPSAD 
deaths notified) 
 
1484 1708 1806 1689 2039 1968 2077 2247 2239 2474 1932 1933 1613 
 
 
Pregabalin is used in the treatment of several conditions including neuropathic pain, epilepsy 
and anxiety. It is structurally related to GABA. This medication first emerged in cases reported 
to the Programme in 2006 and has shown an increasing trend in respect of being prescribed, 
positive post mortem toxicology findings and being implicated in death. 
 
Sibutramine is an oral anorexiant used in the treatment of obesity (in conjunction with dieting 
and exercise), but following increased instances of cardiovascular events and strokes was 
withdrawn from the UK in 2010 as well as in other markets. It is a serotonin-norepinephrine 
reuptake inhibitor (SNRI) structurally related to amphetamines, although its mode of action is 
different. There are no cases on the NPSAD database. 
 
Venlafaxine is a SNRI antidepressant. Cases where this medication had been prescribed to 
cases notified rose from 7 in 2000 to a peak of 65 in 2004 before falling moderately, before 
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another peak of 61 in 2011. Positive post mortem findings increased over this period peaking 
in 2011, as did the number of cases where it was implicated in death. Most of such cases 
appear to have been prescribed it. 
 
For all of those substances for which cases have been reported to NPSAD, the majority 
involved multiple prescriptions of psychoactive drugs. Similarly, most post mortem toxicology 
findings and deaths involved multiple substances. The psychoactive properties of these 
(prescription) medications make them liable to potential misuse/abuse. However, so far as the 
information submitted to NPSAD to date will allow, none of the deaths notified to the 
Programme was the result of recreational use of these six specific medications.  
 
Novel Psychoactive Substances (NPS) 
The UK Advisory Council on the Misuse of Drugs (ACMD) uses the following definition: 
 
“psychoactive drugs which are not prohibited by the United Nations Single Convention on 
Narcotic Drugs or by the Misuse of Drugs Act 1971, and which people in the UK are seeking 
for intoxicant use’ (ACMD, 2011:10). 
 
This report considers substances brought under control by legislation after being examined by 
the ACMD; being considered for control/regulation; or still legal. This presentation makes no 
distinctions. However, changes in legal status may affect availability – and thus use.  
 
The number of NPS reported to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) has increased year on year from 24 in 2009 to 73 in 2012 (EMCDDA-
Europol, 2013). It is likely that the number reported during 2013 will be of a similar magnitude; 
more than one a week. 
 
There have been calls at the international level, e.g. EU (EU, 2013; G8, 2013) for increased 
sharing of information via early warning systems (EWS) such as the Reitox networks and the 
Home Office Forensic EWS (Home Office, 2013c). Such information can assist in establishing 
what is known of the characteristics and potential harms of these chemicals, and therefore 
inform prevention, intervention, and treatment options.   
 
As part of its surveillance function, in recent years the NPSAD Annual Report has reported on 
new substances which are appearing on the drug scene and which have either been noted in 
post mortem toxicological reports and/or implicated in deaths reported to the Programme. In 
the main, new substances appear first in the toxicological reports and then sometime later in 
the cause of death. 
 
Against this background, NPSAD has observed an increase in the number and range of NPS 
in the post mortem toxicology results and/or cause of death of cases notified to the 
Programme (see Figure 8.2). Chemical groups represented by these NPS include: 
aminoindanes; amphetamine-type substances; anabolic steroids; benzofurans; 
benzodiazepines; dietary supplements; indoles; ketamine derivatives; piperidines; synthetic 
cannabinoids; tryptamines (AMT, 5-MeO-DALT); natural products (ibogaine, khat (Catha 
edulis), mescaline, salvia divinorum); and, most prominently, the methcathinones.  
 
Methcathinones 
This class of chemical continues to dominate the UK NPS scene in terms of fatalities, being 
implicated in nearly half of such deaths in 2009-12. The Programme’s annual reports for 
2010-12 specifically mentioned mephedrone (Methylmethcathinone); MDPV 
(Methylenedioxypyrovalerone); and NRG-1 (Naphyrone). As can be seen from Table 8.2 
(which also includes cases not recorded on the NPSAD database), the number of cases 
where mephedrone and MDPV were mentioned increased significantly in 2010, falling away 
in 2011. Mephedrone involvement stabilised in 2012. Other methcathinones also emerged 
onto the scene during this period; of note is 4-MEC which was involved in a total of 12 deaths 
in 2011-12. In many instances, several such chemicals were involved in individual cases.  
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Table 8.2: Deaths involving Novel Psychoactive Substances known* to NPSAD, 2009-12  
Substance  PM toxicology Cause of Death 
Year  2009 2010 2011 2012 2009 2010 2011 2012 
Aminoindanes  0 0 2 2 0 0 0 2 
5-IAI 0 0 0 1 0 0 0 1 
MDAI  0 0 2 1 0 0 2 1 
Amphetamine-type 
substances  
1 1 9 24 0 0 9 23 
2,5-Dimethoxy-4-
chloroamphetamine 
0 0 1 0 0 0 1 0 
4-MA 0 0 1 2 0 0 1 2 
Bromo-STP 0 0 0 0 0 0 0 0 
Fluoroamphetamine  1 0 0 1 0 0 0 1 
MPA 0 0 0 6 0 0 0 4 
PMA  0 1 5 19 0 0 5 17 
PMMA  0 0 2 3 0 0 2 3 
Benzofurans  0 0 1 9 0 0 1 7 
APB  0 0 1 4 0 0 1 2 
6-APB 0 0 0 3 0 0 0 3 
Benzofuran, unspecified 0 0 0 2 0 0 0 2 
Benzodiazepines 
(phenazepam) 
0 0 14 14 0 0 9 5 
Ketamine derivatives  
(Methoxetamine) 
0 0 1 6 0 0 1 5 
Natural products  3 1 1 2 4 1 2 0 
Cathinone (khat) 1 1 1 1 1 1 1 0 
Datura products  1 0 0 0 1 0 0 0 
Ibogaine 1 0 0 0 1 0 0 0 
Noribogaine 1 0 0 0 0 0 0 0 
Mescaline 0 0 0 1 0 0 0 0 
Salvia  0 0 0 0 0 0 1 0 
Piperidines  
(Desoxypipradrol) 
0 3 0 0 0 3 0 0 
Methcathinones  8 62 39 37 5 37 26 24 
3-Fluoroephedrine 0 0 0 2 0 0 0 2 
4-MEC  0 0 6 12 0 0 5 7 
Flephedrone  0 2 2 3 0 2 2 2 
MDPBP  0 0 1 0 0 0 1 0 
MDPV⁺  0 9 5 1 0 4 6 0 
Mephedrone  8 53 26 22 5 33 16 14 
Methedrone  0 2 3 0 0 1 2 0 
Methylone  0 2 0 2 0 2 0 2 
N-desakyl-4-
methylmethcathinone  
0 1 0 0 0 0 0 0 
Naphyrone  0 2 0 0 0 2 0 0 
Pentylone  0 0 1 0 0 0 1 0 
Pyrovalerone  0 1 0 0 0 1 0 0 
Tryptamines  1 1 2 4 1 1 2 4 
5-MeO-DALT  0 1 0 1 0 1 0 1 
AMT  0 0 2 4 0 0 2 4 
Tryptamine  1 0 0 0 1 0 0 0 
Dietary supplements 0 0 2 4 0 0 1 3 
DMAA (1,3-
dimethylamylamine) 
0 0 2 2 0 0 1 1 
DNP  0 0 0 2 0 0 0 2 
Indoles 
(5-IT) 
0 0 0 5 0 0 0 5 
Synthetic cannabinoid 
(AM2201) 
0 0 0 1 0 0 0 1 
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Anabolic steroids 1 0 1 0 1 0 1 0 
DHEA 
(Dehydroepiandrosterone) 
1 0 1 0 1 0 1 0 
Trenbolone 0 0 0 0 0 0 0 0 
Metendone 1 0 0 0 1 0 0 0 
Methandienone 0 0 0 0 0 0 0 0 
Stanozolol 1 0 0 0 1 0 0 0 
Total number of cases 12 68 68 97 10 42 51 68 
Column totals may sum to more than 100% since more than one substance may be found in post mortem toxicology 
and/or implicated in a death 
⁺ There is some ambiguity around the classification of MDPV as a methcathinone due to its chemical structure 
* The  additional cases (8) currently not recorded on the database relating to deaths in the period up to the end of 
2012 have been identified  thorough networks with which the Programme is in contact, including the LTG (formerly 
London Toxicology Group) and other forensic providers; the SCDEA; Police forces; Drug and Alcohol Action Teams; 
and medical practitioners. 
 
 
 
Figure 8.2: Trends in UK ‘traditional’ and Novel Psychoactive Substances, NPSAD data, 
2005-12  
 
 
During 2011-3, forensic toxicologists continued to report increased numbers of samples from 
seizures referred to them for analysis by law enforcement agencies positive for ‘legal highs’ 
derived from methcathinone, particularly mephedrone commonly known as “bubbles” and 
“meow-meow”. Many of these cases have now gone to inquest or through similar formal 
investigations by Procurators Fiscal in Scotland, and are being reported to NPSAD. This class 
of chemical remains present in the UK recreational drug scene, and its use is developing into 
one of a problematic nature in respect of injecting and dependence – evidenced by treatment 
presentations, etc. (National Treatment Agency, 2012). It is important, therefore, to be aware 
of this fact in terms of information and service provision, and prevention initiatives. 
 
Other NPS substances 
A number of new chemical classes were represented in deaths occurring in 2012 (see Table 
8.2). New molecules of particular interest are the following: indoles e.g. 5-IT 5-(2-
Aminopropyl)indole), the synthetic cannabinoid AM2201, and the dietary supplement DNP 
(2,4-Dinitrophenol). Amongst existing categories already reported, new substances include: 
aminoindanes (5-IAI or 5-Iodo-2-aminoindane); amphetamine-type substances (MPA or 
methiopropamine); benzofuran 6-APB (6-(2-aminopropyl)benzofuran or 1-benzofuran-6-
2005 2006 2007 2008 2009 2010 2011 2012
Cocaine 221 206 319 260 216 155 162 135
Amphetamines 59 61 74 68 53 52 69 58
Ecstasy-type 57 64 70 41 9 13 30 47
GHB/GBL 5 11 17 18 24 22 9 20
Ketamine 3 6 7 18 23 11 12 8
Piperazines 0 1 5 13 18 10 8 8
Mephedrone 0 0 0 0 5 32 15 14
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ylpropan-2-amine); and the natural product mescaline. The amphetamine-type substances 
PMA (para-Methoxyamphetamine) and PMMA (para-Methoxy-N-methylamphetamine); the 
benzofuran APB; the synthetic ketamine derivative methoxetamine; and AMT (α-
Methyltryptamine) continue to cause fatalities. Of particular concern here is PMA with 17 
deaths in 2012 and further cases already reported for 2013.  Furthermore, deaths involving 
the benzodiazepine phenazepam continue to be reported. This medication is not licensed for 
use in the UK but is used legally in Eastern Europe and the Russian republics (Corkery et al, 
2012). The Government has also announced its intention to control khat (Catha edulis) as a 
Class C drug (Home Office, 2013e). 
 
Other chemical classes that appear to be emerging as substances that require monitoring in 
respect of their potential contribution to causing fatalities include synthetic cannabinoids (e.g. 
AM2201); indoles (e.g. 5-IT); and the NBOMe class (e.g. 25C-NBOMe and 25I-NBOMe). The 
latter two groups were made subject to 12-month Temporary Class Drug Orders in the UK on 
4 June 2013 (Home Office, 2013d), and the Advisory Council on the Misuse of Drugs has 
recommended that benzofurans be made Class B drugs (ACMD, 2013a) and the NBOMe 
compounds be controlled as Class A drugs (ACMD, 2013b).  
 
Blood-borne viruses 
In 2012, 43 cases from England were known to have been suffering from hepatitis: 35 
hepatitis C; five hepatitis B; and three from unspecified hepatitis. In five cases hepatitis C was 
regarded as a contributory factor in death; hepatitis B in one case; and unspecified hepatitis in 
three cases. Eight cases suffering from HIV/AIDS were reported in England in respect of 2012 
deaths. In only one case was this recorded as a contributory factor in the death. 
 
Anthrax outbreak & necrotising fasciitis 
One 2012 death due to anthrax septicaemia was notified to NPSAD. There is an ongoing 
outbreak of anthrax among people who inject drugs in a number of countries in Europe with 
14 cases now identified since early June 2012. The latest case in Scotland brings the total 
number affected in the UK to eight – five in England (Blackpool – two fatalities; Medway – one 
fatality; Oxford – one fatality; unknown – one case); two in Scotland (Lanarkshire – one 
fatality, unknown – one case); and one in Wales (Gwynedd – one case) (Health Protection 
Agency, 2012). The source is presumed to be contaminated heroin. It is unclear whether the 
British cases are linked to the European outbreak, which has affected drug users in Denmark, 
Germany and France. The Health Protection Agency continues to monitor the situation. 
 
In May 2013 Scottish health officials in Lanarkshire issued an alert after the deaths of two 
injecting drug users who had contracted necrotising fasciitis, there was also a possible case 
in a patient with a history of injecting drug use (BBC News Glasgow and West Scotland, 
2013; NHS Lanarkshire Press Release, 2013). 
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Conclusions 
Opiates, mainly heroin/morphine and methadone, still account for the majority of drug-related 
deaths in the UK. There is evidence both from NPSAD data and other authoritative sources that 
the role of heroin/morphine decreased in 2010 and 2011 but increased in 2012. However, 
deaths involving methadone fell back slightly during the past year.  
 
The increase in cases involving stimulants (such as cocaine, amphetamines, and ecstasy-type 
drugs) following a decline in 2009 and stabilisation in 2010 may well be due to the growing use 
in recent years of so-called ‘legal highs’ such as ketamine, the piperazines, GHB/GBL, and more 
recently the methcathinones such as mephedrone. Whilst these are still available their popularity 
has declined slightly, in part as a consequence of them having been brought under the control of 
the Misuse of Drugs Act 1971. However, these substances are still popular on the UK 
recreational drug scene and may be causing problems in terms of dependency. Indeed, there 
appears to have been a slight increase in deaths involving amphetamines and ecstasy-type 
substances. At the same time, other novel substances – principally other methcathinones and 
related molecules as well as those from other chemical classes – have tightened their grip on 
the recreational drug scene in Western Europe but especially the British Isles.  
 
As noted in previous reports, the rate at which these new substances have emerged continues 
to increase. In the past, the market for new psychoactive substances to explore evolved steadily 
over much longer periods of time. It is now difficult to gauge with any certainty what will be the 
next ‘big thing’ that will capture the attention of the experimenter or regular recreational drug 
user. The range of drug classes now on offer, both diverted pharmaceutical products such as 
phenazepam and synthetic opioids, misused prescription drugs (such as gabapentin, pregabalin 
and venlafaxine), and synthetic substances is also growing. Several new classes were present 
in the post mortem toxicology and cause of death in 2011 and 2012 cases. These trends appear 
to have continued into 2013. New classes of chemicals continue to be reported by UK and 
international early warning systems.  
 
It is important, however, not to overlook the fact that opiates/opioids still account for the majority 
of drug-related deaths in England and other parts of the UK. Together with hypnotics/sedatives 
(chiefly benzodiazepines such as diazepam and temazepam) the involvement of methadone in 
deaths has grown in recent years.  
 
As reported in the last two years, the injection of heroin contaminated with anthrax or botulism is 
a continuing and serious risk factor for adverse health consequences and death at present. As 
heroin can be stockpiled for several years before being released onto the market it is important 
that vigilance is maintained by heroin users and those who treat them for any signs of infection, 
thereby preventing premature death. 
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Chapter 9: Other issues 
 
This chapter looks at other Information reported about the decedents such as mental health 
issues; certain infections such as hepatitis or HIV/AIDS; and prison history. This information is 
derived only from those cases where such data has been reported, and as such the figures 
presented in this section should be regarded as the minimum. Section one looks at NPSAD 
cases in England for 2012, and for Wales, Northern Ireland and the Islands over a five year 
period from 2008-2012. Section 2 considers the same issues for England Drug Strategy cases 
for 2012, where such data is available. No such information was available for deaths in Scotland.  
 
Section One: NPSAD cases 
Mental health issues  
 
The abuse of drugs or addiction to them is a problem often linked to mental health issues. The 
terms ‘dual diagnosis’ and ‘comorbidity’ are used commonly and interchangeably to describe the 
co-occurrence in the same individual of a psychoactive substance use disorder and other 
psychiatric disorder or vice versa (World Health Organisation,1994). 
 
9.1 England 2012 
Of the NPSAD cases for England in 2012 reported to the Programme, 285 were noted as having 
some form of mental health problem. The demographic breakdown is: 178 males (62.5%) and 
107 females (37.5%), with the majority (52.6%) aged between 35-54 years. Where drug use 
status was known (n = 186), the majority were confirmed drug addicts or users (102/186, 54.8%) 
(Table 9.1.1).  
 
Of these 285 cases reported with diagnosed mental health issues, 172 suffered from 
depression; 55 had an anxiety disorder; 21 suffered from psychosis (including schizophrenia); 16 
had a personality disorder; 14 had bipolar disorder; five had an eating disorder; whilst 72 were 
listed as suffering from other unspecified mental health issues (Tables 9.1.2 and 9.1.3). 
  
Among the decedents who were suffering from depression, 50 cases (29.1%) were deemed to 
have committed suicide, and amongst those listed with depression, the most commonly 
implicated drugs were anti-depressants (65/172, 37.8%). The principal substances implicated in 
the deaths for each mental health issue are summarised in Table 9.1.3. 
 
Of these cases the drug use status of 201 was given; 82 were known drug addicts and died from 
drug poisoning. As to manner of death the most frequent was accidental (56/82, 68.3%); 
followed by intentional (14/82, 17.1%); and poisoning of undetermined intent (12/82, 14.6%). Of 
the 95 individuals who were confirmed as non-drug users and who died of drug poisoning, 
intentional self-poisoning was the most frequent underlying cause of death (38/95, 40.0%); 
followed by accidental (33/95, 34.7%); and undetermined poisoning (24/95, 25.3%). 
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Table 9.1.1: Demography of cases with mental health issues, England 2012 
Variable Category Number (%) 
TOTAL  285 (100.0) 
Gender Male 178 (62.5) 
Female 107 (37.5) 
Age group 15-24 15 (5.3) 
25-34 53 (18.6) 
35-44 82 (28.8) 
45-54 68 (23.9) 
55-64 49 (17.2) 
65 & older 18 (6.3) 
Drug addict 
status 
Yes 102 (35.8) 
No 99 (34.7) 
Not known 84 (29.5) 
 
 
Table 9.1.2: Epidemiology according to mental issues cases, England 2012 
 
Gender  
(n, %) 
Age group at death 
(n, %) 
Drug use/addiction 
history 
(n, %) 
Specific 
mental 
issue 
(Total) 
M F 15-24 25-34 35-44 45-54 55-64 65+ Yes No 
Not 
known 
Anxiety 
Disorder 
(55) 
31 
(56.4) 
24 
(43.6) 
2 
(3.6) 
10 
(18.2) 
17 
(30.9) 
12 
(21.8) 
11 
(20.0) 
3 
(5.5) 
25 
(45.5) 
15 
(27.3) 
15 
(27.3) 
Bipolar 
Disorder 
(14) 
7 
(50.0) 
7 
(50.0) 
0 
(0.0) 
3 
(21.4) 
3 
(21.4) 
5 
(35.7) 
2 
(14.3) 
1 
(7.1) 
2 
(14.3) 
7 
(50.0) 
5 
(35.7) 
Depression 
(172) 
104 
(60.5) 
68 
(39.5) 
8 
(4.7) 
36 
(20.9) 
48 
(27.9) 
39 
(22.7) 
29 
(16.9) 
12 
(7.0) 
64 
(37.2) 
61 
(35.5) 
47.0 
(27.3) 
Eating 
Disorder 
(5) 
1 
(20.0) 
4 
(80.0) 
1 
(20.0) 
1 
(20.0) 
3 
(60.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
2 
(40.0) 
1 
(20.0) 
2 
(40.0) 
Other 
mental 
issues 
(72) 
48 
(66.7) 
24 
(33.3) 
7 
(9.7) 
9 
(12.5) 
22 
(30.6) 
20 
(27.8) 
9 
(12.5) 
5 
(6.9) 
22 
(30.6) 
25 
(34.7) 
25 
(34.7) 
Personality 
Disorder 
(16) 
7 
(43.8) 
9 
(56.3) 
0 
(0.0) 
2 
(12.5) 
8 
(50.0) 
2 
(12.5) 
4 
(25.0) 
0 
(0.0) 
9 
(56.3) 
3 
(18.8) 
4 
(25.0) 
Psychosis 
(21) 
17 
(81.0) 
4 
(19.0) 
2 
(9.5) 
3 
(14.3) 
6 
(28.6) 
4 
(19.0) 
6 
(28.6) 
0 
(0.0) 
10 
(47.6) 
5 
(23.8) 
6 
(28.6) 
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Table 9.1.3: Psychoactive substances implicated alone and in combination in cases 
diagnosed with specific mental health problems, England 2012 
 Mental health problem (n, %) 
 
Psychoactive 
substance 
implicated alone 
and in combination 
 
Anxiety 
disorder 
n=55 
Bipolar 
Disorder 
n=14 
Depression 
n=172 
Eating 
disorder 
n=5 
Personality 
disorder 
n=16 
Psychosis 
n=21 
Other mental 
health issues 
n=72 
Alcohol in 
combination 
22 
(40.0) 
1 
(7.1) 
44 
(25.6) 
0 
(0.0) 
5 
(31.3) 
1 
(4.8) 
20 
(27.8) 
Amphetamines 
0 
(0.0) 
0 
(0.0) 
1 
(0.6) 
0 
(0.0) 
1 
(6.3) 
1 
(4.8) 
1 
(1.4) 
Anti-depressants 
20 
(36.4) 
0 
(0.0) 
65 
(37.8) 
2 
(40.0) 
4 
(25.0) 
4 
(19.0) 
27 
(37.5) 
Anti-epileptics 
1 
(1.8) 
2 
(14.3) 
2 
(1.2) 
0 
(0.0) 
1 
(6.3) 
0 
(0.0) 
1 
(1.4) 
Anti-Parkinson’s 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(4.8) 
0 
(0.0) 
Anti-psychotics 
4 
(7.3) 
4 
(28.6) 
9 
(5.2) 
0 
(0.0) 
1 
(6.3) 
5 
(23.8) 
6 
(8.3) 
Cannabis 
0 
(0.0) 
0 
(0.0) 
1 
(0.6) 
0 
(0.0) 
1 
(6.3) 
1 
(4.8) 
0 
(0.0) 
Cocaine 
3 
(5.5) 
0 
(0.0) 
6 
(3.5) 
0 
(0.0) 
1 
(6.3) 
1 
(4.8) 
4 
(5.6) 
Ecstasy-type drug 
0 
(0.0) 
0 
(0.0) 
1 
(0.6) 
0 
(0.0) 
0 
(0.0) 
1 
(4.8) 
0 
(0.0) 
GHB/GBL 
0 
(0.0) 
0 
(0.0) 
2 
(1.2) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Heroin/morphine 
19 
(34.5) 
2 
(14.3) 
35 
(20.3) 
1 
(20.0) 
5 
(31.3) 
4 
(19.0) 
11 
(15.3) 
Hypnotics/sedatives 
10 
(18.2) 
4 
(28.6) 
26 
(15.1) 
1 
(20.0) 
1 
(6.3) 
4 
(19.0) 
16 
(22.2) 
Methadone 
6 
(10.9) 
0 
(0.0) 
13 
(7.6) 
0 
(0.0) 
2 
(12.5) 
2 
(9.5) 
7 
(9.7) 
Other 
opiates/opioid 
analgesics 
19 
(34.5) 
4 
(28.6) 
51 
(29.7) 
1 
(20.0) 
7 
(43.8) 
4 
(19.0) 
27 
(37.5) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death. The case total 
sums to greater than the total number of cases since an individual may have more than one disorder. Cells highlighted in:        
   show the drug most frequently implicated for each mental health problem.     
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 9.2 Wales 2008-2012 
Among the deaths that occurred in Wales reported to the Programme for 2008-2012, 52 were 
reported as having some type of mental illness. The majority were male (38/52 = 73.1%); and 
aged between 25-44 years (39/52, 75.0%). Where the ethnicity was reported, all individuals 
were White (30/30, 100%). Where drug use status was known (n = 38), 65.8% (25/38) were 
reported to have either historically used or been addicted to drugs (Table 9.2.1). 
 
Among all individuals reported as diagnosed with some form of mental health issue and who 
were known drug users or addicts, accidental poisoning was the most common underlying cause 
of their deaths (17/20, 85.0%). Conversely in inviduals without past drug use history, the majority 
of their deaths were as a result of intentional self-poisoning (7/10, 70.0%). 
Among individuals reported as suffering from some form of mental health issue, 30 cases were 
listed as suffering from depression; eight from psychosis; two from anxiety disorders; two from 
bipolar disorders; one from a personality disorder; and 15 cases were reported to be diagnosed 
with unspecified mental health issues. The principal substances implicated in deaths for each 
mental health issue are summarised in Table 9.2.2. 
 
In those with a diagnosis of depression the most common implicated drugs were anti-
depressants (11/30, 36.7%), and other opiates/opioid analgesics (11/30, 36.7%). Among those 
diagnosed with depression, 46.7% (14/30) were deemed to have committed suicide. Among 
those diagnosed as suffering from psychosis (schizophrenia or other unspecified psychosis) the 
principal implicated substance was alcohol in combination with other drugs (4/8, 50%). In 
individuals with unspecified mental health issues, the most frequently implicated drugs were 
heroin/morphine (6/15, 40.0%), and alcohol in combination with other drugs (6/15, 40.0%). 
 
 
Table 9.2.1: Demography of those with mental health issues, Wales 2008-2012 
 
 
  
Variable Category Number (%) 
TOTAL  52 (100.0) 
Gender Male 38 (73.1) 
Female 14 (26.9) 
Age group 15-24 1 (1.9) 
25-34 14 (26.9) 
35-44 25 (48.1) 
45-54 4 (7.7) 
55-64 4 (7.7) 
65 & older 4 (7.7) 
Drug addict 
status 
Yes 25 (48.1) 
No 13 (25.0) 
Not known 14 (26.9) 
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Table 9.2.2: Psychoactive substances implicated alone and in combination in percentage 
of cases diagnosed with specific mental health problems, Wales 2008-2012 
Psychoactive 
substance implicated 
alone and in 
combination 
 
Mental health diagnosis (n, %) 
Anxiety 
disorder 
n=2 
Bipolar 
Disorder 
n=2 
Depression 
n=30 
Personality 
disorder 
n=1 
Psychosis 
n=8 
Other 
mental 
issues 
n=15 
Alcohol in combination 
 
0 (0.0) 1 (50.0) 7 (23.3) 0 (0.0) 4 (50.0) 6 (40.0) 
Amphetamines 
 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 
Anti-depressants 
 
0 (0.0) 2 (100.0) 11 (36.7) 0 (0.0) 0 (0.0) 1 (6.7) 
Anti-epileptics 
 
0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 
 
Anti-psychotics 
 
0 (0.0) 1 (50.0) 1 (3.3) 0 (0.0) 1 (12.5) 1 (6.7) 
Cocaine 
 
0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 
Heroin/morphine 
 
0 (0.0) 0 (0.0) 7 (23.3) 1 (100.0) 3 (37.5) 6 (40.0) 
Hypnotics/sedatives 0 (0.0) 1 (50.0) 3 (10.0) 0 (0.0) 2 (25.0) 2 (13.3) 
Methadone 
 
1 (50.0) 0 (0.0) 7 (23.3) 0 (0.0) 1 (12.5) 4 (26.7) 
Other opiates/opioid 
analgesics 
1 (50.0) 0 (0.0) 11 (36.7) 0 (0.0) 0 (0.0) 4 (26.7) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death. The 
case total sums to greater than the total number of cases since an individual may have more than one disorder. 
Cells highlighted in:      indicate the drug most frequently implicated for each mental health problem. 
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9.3 Northern Ireland 2008-2012 
Among the deaths that occurred in Northern Ireland reported to the Programme between 2008 
and 2012, 188 were reported as having a mental illness. The majority of were male (60.1%); 
White (86.7%); and aged 35-54 years (52.1%). When drug use status was known (81/188), 
46.9% were known drug addicts or users (Table 9.3.2). 
 
Among the 188 individuals reported as suffering from some form of mental health issues, 144 
cases were diagnosed with depression; 50 with anxiety disorders; 22 with psychosis (including 
schizophrenia and other unspecified psychosis); eight with personality disorders; four with 
bipolar disorders; and 21 cases were diagnosed with other unspecified mental health issues 
(Table 9.3.1). 
 
The most frequently implicated drugs in the deaths of those diagnosed with depression were 
other opiates/opioid analgesics (72/144, 50.0%); anti-depressants (69/144, 47.9%); and 
hypnotics/sedatives (68/144, 47.2%). In those diagnosed as suffering from an anxiety disorder, 
the principal implicated substances were hypnotics/sedatives (27/50 cases, 54.0%); other 
opiates/opioid analgesics (26/50 cases, 52.0%; and anti-depressants (21/50 cases, 42.0%). Of 
the cases diagnosed with psychosis, the substances most commonly implicated were 
hypnotics/sedatives (16/22, 72.7%); other opiates/opioid analgesics (13/22, 59.1%); and alcohol 
in combination with other substances (13/22, 59.1%). The principal substances implicated in 
deaths for the above and other mental health issues are summarised in Table 9.3.3. 
 
Of the individuals reported to the Programme as diagnosed with some form of mental health 
issue, among those who were known drug users or addicts the most frequent manner of death  
was accidental (14/33, 42.4%); followed by poisoning of undetermined intent (13/33, 39.4%); 
and  intentional self-poisoning (6/33, 18.2%). In contrast, among those who were reported as 
neither being addicted to nor using drugs, the most common manner of poisoning was 
undetermined (20/41, 48.8%); followed by accidental (12/41, 29.3%); and intentional self-
poisoning (9/41, 22.0%). 
 
Table 9.3.1: Epidemiology of mental issues cases, Northern Ireland 2008-2012 
 
Gender  
(n, %) 
Age group at death 
(n, %) 
Drug use/addiction 
history (n, %) 
Specific 
mental issue 
(Total 
cases) 
M F 
15-24 
 
25-34 
 
35-44 
 
45-54 
 
55-64 
 
65+ 
 
Yes 
 
No 
 
Not 
known 
 
Anxiety 
disorder 
 (50) 
26 
(52.0) 
24 
(48.0) 
4  
(8.0) 
10 
(20.0) 
17 
(34.0) 
10 
(20.0) 
5 
(10.0) 
4 
(8.0) 
6 
(12.0) 
10 
(20.0) 
34 
(68.0) 
Bipolar 
disorder 
(4) 
0 
(0.0) 
4 
(100.0) 
0 
(0.0) 
0 
(0.0) 
1 
(25.0) 
2 
(50.0) 
1 
(25.0) 
0 
(0.0) 
1 
(25.0) 
1 
(25.0) 
2 
(50.0) 
Depression  
(144) 
79 
(54.9) 
65 
(45.1) 
9 
(6.3) 
30 
(20.8) 
41 
(28.5) 
35 
(24.3) 
19 
(13.2) 
10 
(6.9) 
26 
(18.1) 
37 
(25.7) 
81 
(56.3) 
Eating 
disorder 
(5) 
0 
(0.0) 
5 
(100.0) 
0 
(0.0) 
1 
(20.0) 
2 
(40.0) 
2 
(40.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(20.0) 
4 
(80.0) 
Personality 
disorder (8) 
5 
(62.5) 
3 
(37.5) 
0 
(0.0) 
1 
(12.5) 
2 
(25.0) 
3 
(37.5) 
2 
(25.0) 
0 
(0.0) 
3 
(37.5) 
1 
(12.5) 
4 
(50.0) 
Psychosis 
(22) 
20 
(90.9) 
2 
(9.1) 
1 
(4.5) 
7 
(31.8) 
7 
(31.8) 
6 
(27.3) 
1 
(4.5) 
0 
(0.0) 
4 
(18.2) 
6 
(27.3) 
12 
(54.5) 
Other 
mental 
issues (21) 
15 
(71.4) 
6 
(28.6) 
2 
(9.5) 
4 
(19.0) 
4 
(19.0) 
4 
(19.0) 
6 
(28.6) 
1 
(4.8) 
7 
(33.3) 
2 
(9.5) 
12 
(57.1) 
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Table 9.3.2: Demography of those with mental health issues, Northern Ireland 2008-2012 
Variable Category Number (%) 
TOTAL  188 (100.0) 
Gender Male 113 (60.1) 
Female 75 (39.9) 
Age group 15-24 13 (6.9) 
25-34 39 (20.7) 
35-44 56 (29.8) 
45-54 42 (22.3) 
55-64 27 (14.4) 
65 & older 11 (5.9) 
Drug addict 
status 
Yes 38 (20.2) 
No 43 (22.9) 
Not known 107 (56.9) 
 
 
Table 9.3.3: Psychoactive substances implicated alone and in combination in percentage 
of cases diagnosed with specific mental health problems, Northern Ireland 2008-2012 
 Mental health problems (n, %) 
Psychoactive 
substance 
implicated alone and 
in combination 
 
Anxiety 
disorder 
n=50 
 
Bipolar 
Disorder 
n=4 
 
Depression 
n=144 
 
Eating 
disorder 
n=5 
 
Personality 
disorder 
n=8 
 
Psychosis 
n=22 
 
Other mental 
issues 
n=21 
 
Alcohol in 
combination 
15 
(30.0) 
0 
(0.0) 
50 
(34.7) 
1 
(20.0) 
2 
(25.0) 
13 
(59.1) 
8 
(38.1) 
Amphetamines 
1 
(2.0) 
0 
(0.0) 
1 
(0.7) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Anti-depressants 
21 
(42.0) 
2 
(50.0) 
69 
(47.9) 
4 
(80.0) 
3 
(37.5) 
6 
(27.3) 
9 
(42.9) 
Anti-epileptics 
2 
(4.0) 
0 
(0.0) 
3 
(2.1) 
0 
(0.0) 
0 
(0.0) 
1 
(4.5) 
0 
(0.0) 
Anti-Parkinson’s 
1 
(2.0) 
0 
(0.0) 
1 
(0.7) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Anti-psychotics 
13 
(26.0) 
2 
(50.0) 
23 
(16.0) 
0 
(0.0) 
1 
(12.5) 
7 
(31.8) 
5 
(23.8) 
Cocaine 
2 
(4.0) 
0 
(0.0) 
3 
(2.1) 
0 
(0.0) 
0 
(0.0) 
1 
(4.5) 
0 
(0.0) 
Ecstasy-type drug 
2 
(4.0) 
0 
(0.0) 
1 
(0.7) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(4.8) 
Heroin/morphine 
12 
(24.0) 
0 
(0.0) 
21 
(14.6) 
1 
(20.0) 
1 
(12.5) 
4 
(18.2) 
3 
(14.3) 
Hypnotics/sedatives 
27 
(54.0) 
3 
(75.0) 
68 
(47.2) 
2 
(40.0) 
4 
(50.0) 
16  
(72.7) 
9 
(42.9) 
Methadone 
1 
(2.0) 
1 
(25.0) 
5 
(3.5) 
0 
(0.0) 
1 
(12.5) 
0 
(0.0) 
2 
(9.5) 
Other opiates/opioid 
analgesics 
26 
(52.0) 
3 
(75.0) 
72 
(50.0) 
2 
(40.0) 
6 
(75.0) 
13  
(59.1) 
9 
(42.9) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death. The case total 
sums to greater than the total number of cases since an individual may have more than one disorder. Cells highlighted in:       
indicate the drug most frequently implicated for each mental health problem. 
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9.4 The Islands (Guernsey, Jersey and the Isle of Man), 2008-2012 
Of the cases reported to the Programme for the Islands between 2008 and 2012, 19/42 (45.2%) 
were noted as having some form of mental health problem. These included bipolar disorder; 
depression; personality disorder; psychosis; and other unspecified mental health issues. 
 
Among all cases diagnosed with mental health issues, 31.6% (6/19) were diagnosed with 
depression; 15.8% (3/19) were known to be psychotic; 10.5% (2/19) had a diagnosis of 
borderline personality disorder; 5.3% (1/19) were suffering from bipolar disorder; and 42.1% 
(8/19) of them were known to suffer from unspecified mental health issues. Drug addict status 
was known in 15 cases with mental health disorders, 46.7% (7/15) of which were known to have 
a history of dependence or drug use. 
 
The majority (4/6) of those diagnosed with depression and all three who suffered from psychosis 
committed suicide (one of these also had a diagnosis of borderline personality disorder). 
 
Table 9.4 shows the principal psychoactive substances implicated in death. In people suffering 
from depression they were anti-depressants (5/6), followed by other opiates and opioid 
analgesics (4/6). In the deaths of those listed with psychosis the main substances implicated 
were other opiates and opioid analgesics (2/3). In cases suffering from personality disorders the 
only substances implicated were anti-depressants (1/2), and heroin/morphine (1/2). Among 
individuals with other mental issues, alcohol in combination with other drugs was the main 
substance implicated (3/8). 
 
 
Table 9.4: Psychoactive substances implicated alone and in combination in percentage of 
cases diagnosed with specific mental health problems  
Psychoactive substance 
implicated alone 
and in combination 
Depression 
n=6 
(n, %) 
Psychosis 
n=3 
(n, %) 
Personality 
disorders n=2 
(n, %) 
Other 
mental 
issues n=8 
(n, %) 
 
Alcohol in combination 
 
1 (16.7) 0 (0.0) 0 (0.0) 3 (37.5) 
 
Anti-depressants 
 
5 (83.3) 1 (33.3) 1 (50.0) 2 (25.0) 
 
Anti-psychotics 
 
0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 
 
Heroin/morphine 
 
2 (33.3) 0 (0.0) 1 (50.0) 2 (25.0) 
 
Hypnotic/sedatives 
 
1 (16.7) 1 (33.3) 0 (0.0) 2 (25.0) 
 
Methadone 
 
0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 
 
Other opiates/opioid 
analgesics 
4 (66.7) 2 (66.7) 0 (0.0) 2 (25.0) 
Note: Bipolar disorder is not reported in the table because of the absence of substances implicated in the death. 
Column totals may sum to more than 100% since more than one substance may be implicated in a death. Cells 
highlighted in:       show the drug most frequently implicated per mental health issue. 
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Prison 
9.5 England 2012 
In 2012, 15 individuals reported to the Programme were noted as having been in prison at some 
point in their lives, 11 of whom died as a result of accidental poisoning. The majority were male 
(14/15, 93.3%); White (11/15, 73.3%); unemployed (9/15, 60%); with 73.3% (11/15) of them 
known drug users. When reported, the most common causes of detention were drug-related 
offences such as dealing. 
 
The principal substances implicated in death, alone or in combination, were: heroin/morphine 
(8/15, 53.3%); other opiates/opioid analgesics (6/15, 40.0%); methadone (5/15, 33.3%); and 
alcohol in combination with other drugs (5/15 cases, 33.3%) (Table 9.5). 
 
Table 9.5: Psychoactive substances implicated in cases with prison history, England 2012 
 
Drug category Number (%) of cases 
where substance implicated 
TOTAL 15 (100.0) 
Alcohol in combination 5 (33.3) 
Amphetamines 2 (13.3) 
Anti-depressants 3 (20.0) 
Anti-epileptics 1 (6.7) 
Anti-psychotics 1 (6.7) 
Cocaine 2 (13.3) 
Heroin/morphine 8 (53.3) 
Hypnotic/sedatives 4 (26.7) 
Methadone 5 (33.3) 
Other opiates/opioid 
analgesics 
6 (40.0) 
Note: column totals may sum to more than 100% since more than one substance may be 
implicated in a death 
 
9.6 Wales 2008-2012 
Between 2008-12, 11 individuals reported to the Programme had been in prison at some point 
during their life, all of whom had died as a result of accidental poisoning. The majority were male 
(10/11); White (8/11); unemployed (10/11); and with a history of drug addiction or use (6/11). 
Where known, the most common reasons for detention were drug-related offences such as drug 
dealing. 
 
The substance most frequently implicated was heroin/morphine (10/11) (Table 9.6). 
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Table 9.6: Psychoactive substances implicated in cases with prison history, Wales 2008-
2012 
Drug category Number (%) of cases 
where substance implicated 
TOTAL 11 (100.0) 
Alcohol in combination 1 (9.1) 
Amphetamines 1 (9.1) 
Anti-depressants 1 (9.1) 
Cocaine 1 (9.1) 
Heroin/morphine 10 (90.9) 
Hypnotic/sedatives 3 (27.3) 
Methadone 4 (36.4) 
Note: column totals may sum to more than 100% since more than one substance may be 
implicated in a death 
 
9.7 Northern Ireland 2008-2012 
Between 2008-2012, 10 of the individuals who died in Northern Ireland and were reported to the 
Programme had been in prison at some point in their life. All were male; the majority were White 
(8/10); five were unemployed; and six were known drug users or addicts. 
 
Half of those with prison history had heroin/morphine implicated in their deaths; with 
hypnotics/sedatives and other opiates/opioid analgesics involved in 4/10 cases (Table 4.4). 
 
The most frequent underlying cause of death in individuals with prison history was accidental 
poisoning (5/10). 
 
 
Table 9.7: Psychoactive substances implicated in cases with prison history, Northern 
Ireland 2008-2012 
Drug category Number (%) of cases 
where substance implicated 
TOTAL 10 (100.0) 
Alcohol in combination 2 (20.0) 
Amphetamines 1 (10.0) 
Anti-depressants 2 (20.0) 
Heroin/morphine 5 (50.0) 
Hypnotic/sedatives 4 (40.0) 
Other opiates/opioid 
analgesics 
4 (40.0) 
Note: column totals may sum to more than 100% since more than one substance may be 
implicated in a death 
 
 
9.8 Islands 2008-2012 
 
In the Islands between 2008 and 2012, details of only two individuals were provided with 
information on their prison history. Both cases were male and from Jersey. One had been 
released a matter of hours prior to his death, and other opiates/opioid analgesics were a 
contributing factor. The other individual was a suspected drug dealer known to police due to 
heavy alcohol use. The principal substance implicated in his death was heroin/morphine. 
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Hepatitis and HIV/AIDS 
9.9 England 2012 
In 2012, a total of 43 cases were identified as being infected with hepatitis: 35 cases with 
hepatitis C; five cases with hepatitis B; and three cases with unspecified chronic hepatitis. 
The majority of individuals infected with hepatitis C were male (29/35, 82.9%). Addict status was 
known in 29 cases, all but one of which had a history of dependence or drug use. The main 
underlying cause of death for this group was accidental poisoning (20/35, 57.1%), whilst for 5/35 
cases (14.3%), hepatitis C was reported as a contributing factor in their deaths. The principal 
substances implicated in death were alcohol in combination (15/35, 42.9%); methadone (13/35, 
37.1%); and heroin/morphine (11, 31.4%). Hepatitis C can be contracted through the use of 
contaminated needles, and among the individuals who were diagnosed with hepatitis C, of those 
with known drug use status (29/35), all but one were known to use drugs. Among these 28 drug 
users, 11 cases (39.3%) were known to be injecting. Table 9.9.1 summarises the drugs 
implicated in the deaths of all those reported as infected with some form of hepatitis. 
 
Table 9.9.1: Psychoactive substances implicated in cases with hepatitis C, hepatitis B and 
other hepatitis, England 2012 
 
Drug category Hepatitis C 
(n, %) 
Hepatitis B 
(n, %) 
Other hepatitis 
unspecified  
(n, %) 
TOTAL 35 (100.0) 5 (100.0) 3 (100.0) 
Alcohol in 
combination 
15 (42.9) 3 (60.0) 2 (66.7) 
Amphetamines 2 (5.7) 0 (0.0) 0 (0.0) 
Anti-depressants 4 (11.4) 0 (0.0) 1 (33.3) 
Anti-psychotics 2 (5.7) 0 (0.0) 0 (0.0) 
Cocaine 6 (17.1) 2 (40.0) 0 (0.0) 
Ecstasy-type drug 1 (2.9) 0 (0.0) 0 (0.0) 
Heroin/morphine 11 (31.4) 2 (40.0) 2 (66.7) 
Hypnotics/sedatives 5 (14.3) 2 (40.0) 1 (33.3) 
Methadone 13 (37.1) 3 (60.0) 1 (33.3) 
Other opiates/opioid 
analgesics 
10 (28.6) 1 (20.0) 0 (0.0) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death 
 
A total of 8 individuals who died in England in 2012 were reported to NPSAD as suffering from 
HIV/AIDS. All were male, and where the addict status was known (7/8), the majority of cases 
(6/8) were reported to have a past drug addict history. Half of the known drug users used intra-
venous (IV) drugs. The main underlying cause of death was accidental poisoning (3/8, 37.5%), 
and the principal substances implicated in death were: heroin/morphine (3/8); other 
opiates/opioid analgesics (3/8); and alcohol in combination with other drugs (3/8) (Table 9.9.2). 
 
Table 9.9.2: Psychoactive substances implicated in cases with HIV/AIDS, England 2012 
Drug category 
Number of cases where 
substance implicated (%) 
TOTAL 8 (100.0) 
Alcohol in combination 3 (37.5) 
Amphetamines 1 (12.5) 
Anti-psychotics 1 (12.5) 
Cocaine 2 (25.0) 
Heroin/morphine 3 (37.5) 
Methadone 2 (25.0) 
Other opiates/opioid analgesics 3 (37.5) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death 
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9.10 Wales 2008-2012 
 
Between 2008-2012, a total of 8 cases were reported as having been positive for hepatitis C, 
two of whom were known to be using IV drugs. 
 
The majority were male (5/8); all were White; most were unemployed (7/8); and with previous 
drug use or addiction (7/8). The main underlying cause of death for this group was accidental 
poisoning (7/8). Substances implicated in the deaths, either alone or in combination, were 
heroin/morphine (4/8); methadone (3/8); hypnotic/sedatives (3/8); alcohol in combination with 
other drugs (3/8); and anti-depressants (1/8).  
 
9.11 Northern Ireland 2008-2012 
 
Between 2008-2012 a total of three individuals were described as having contracted hepatitis C, 
two of whom were confirmed to be IV users of drugs. All were male; drug addicts; and died as a 
result of accidental poisoning. Heroin/morphine was implicated in combination with other drugs 
in all three deaths. 
 
There was one case, a male, reported between 2008-12 as suffering from HIV/AIDS. Death 
resulted from poisoning of undetermined intent, and it was not known if he was a user of IV 
drugs. 
 
9.12 The Islands 2008-2012 
 
Only one case from Jersey between 2008-12 was identified as being infected with hepatitis C, 
who had also contracted HIV and developed AIDS. It was not known if this female case used IV 
drugs, but death resulted from intentional self-poisoning. 
 
Section 2: Drug Strategy cases, England 2012 
 
This section discusses other issues of the English cases reported to NPSAD meeting the 
definition used by the Government for monitoring its Drug Strategy (DS), covering information 
such as mental health issues; hepatitis or HIV/AIDS infection; and previous prison history. The 
figures presented here at to be regarded as the minimum due to the nature of the reporting 
system. 
 
9.13 Mental Health Issues 
 
The abuse of drugs or the addiction to them is a problem often linked to mental health issues, 
and of the DS cases reported to the Programme, 145 were noted as having some form of mental 
health issue. Among people listed as suffering from some form of mental illness, males 
accounted for 62.1%; and the majority were aged 35-54 years (56.6%). Of the 104 cases with 
drug use status provided to the Programme, the majority (59/104, 56.7%) were known drug 
addicts or users (Table 9.13.1) 
 
Of the DS cases reported as diagnosed with mental health issues, 87 were suffering from 
depression; 37 had an anxiety disorder (including post-traumatic stress disorder and obsessive 
compulsive disorder); 14 were psychotic (including schizophrenia); 11 were diagnosed with a 
personality disorder; 11 had bipolar disorder; three had an eating behaviour disorder; two were 
reported as having a behavioural disorder; and 40 were diagnosed with other unspecified mental 
issues (Table 9.13.2). 
 
Amongst those who were diagnosed with some form of mental illness and who were also known 
drug users, the most frequent manner of poisoning was accidental (46/55, 83.6%), followed by 
undetermined (5/55, 9.1%), and intentional (4/55, 7.3%). In contrast, those inviduals who were 
confirmed as non-drug users, the proportions of their deaths attributed to the different manners 
of poisonings greatly contrasted those of the known drug users, with just 48.9% (22/45) of their 
deaths resulting from accidental poisoning, followed by intentional (14/45, 31.1%) and 
undetermined (9/45, 20.0%) (Figure 9.13.3). 
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Of those listed with depression, the most common implicated drugs were other opiates/opioid 
analgesics (38/87, 43.7%) and heroin/morphine (31/87, 35.6%). Suicide accounted for 18.4% 
(16/87) of the deaths of those diagnosed with depression. In people with a diagnosis of anxiety, 
the principal implicated substance was heroin/morphine (18/37, 48.6%). The principal 
substances implicated for the other mental health issues are summarised in Table 9.13.4. 
 
 
 
 
Table 9.13.1: Demographic details of mental issues cases, DS England 2012 
Variable Category Number (%) 
TOTAL  145 (100.0) 
Gender Male 90 (62.1) 
Female 55 (37.9) 
Age group 15-24 5 (3.4) 
25-34 28 (19.3) 
35-44 44 (30.3) 
45-54 38 (26.2) 
55-64 24 (16.6) 
65 & older 6 (4.1) 
Drug addict 
status 
Yes 59 (40.7) 
No 45 (31.0) 
Not known 41 (28.3) 
 
Table 9.13.2: Epidemiology according to mental issues cases, DS England 2012 
 Gender 
(n, %) 
Age group at death 
(n, %) 
Drug use/addiction 
history (n, %) 
Specific 
mental 
issue 
(Total 
cases) 
M F 
15-24 
 
25-34 
 
35-44 
 
45-54 
 
55-64 
 
65+ 
 
Yes 
 
No 
 
Not 
known 
 
Anxiety 
Disorder 
(37) 
20 
(54.1) 
17 
(45.9) 
1 
(2.7) 
6 
(16.2) 
13 
(35.1) 
8 
(21.6) 
7 
(18.9) 
2 
(5.4) 
18 
(48.6) 
9 
(24.3) 
10 
(27.0) 
Behavioural 
disorder 
(2) 
2 
(100.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(50.0) 
1 
(50.0) 
0 
(0.0) 
0 
(0.0) 
1 
(50.0) 
0 
(0.0) 
1 
(50.0) 
Bipolar 
Disorder 
(5) 
4 
(80.0) 
1 
(20.0) 
0 
(0.0) 
1 
(20.0) 
2 
(40.0) 
2 
(40.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
2 
(40.0) 
3 
(60.0) 
Depression 
(87) 
49 
(56.3) 
38 
(43.7) 
4 
(4.6) 
16 
(18.4) 
24 
(27.6) 
21 
(24.1) 
16 
(18.4) 
6 
(6.9) 
37 
(42.5) 
29 
(33.3) 
21 
(24.1) 
Eating 
Disorder 
(3) 
1 
(33.3) 
2 
(66.7) 
1 
(33.3) 
1 
(33.3) 
1 
(33.3) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
3 
(100.0) 
Other 
mental 
issues 
(40) 
26 
(65.0) 
14 
(35.0) 
0 
(0.0) 
10 
(25.0) 
11 
(27.5) 
13 
(32.5) 
5 
(12.5) 
1 
(2.5) 
15 
(37.5) 
11 
(27.5) 
14 
(35.0) 
Personality 
Disorder 
(11) 
6 
(54.5) 
5 
(45.5) 
0 
(0.0) 
2 
(18.2) 
5 
(45.5) 
1 
(9.1) 
3 
(27.3) 
0 
(0.0) 
5 
(45.5) 
3 
(27.3) 
3 
(27.3) 
Psychosis 
(14) 
11 
(78.6) 
3 
(21.4) 
1 
(7.1) 
1 
(7.1) 
5 
(35.7) 
4 
(28.6) 
3 
(21.4) 
0 
(0.0) 
7 
(50.0) 
4 
(28.6) 
3 
(21.4) 
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Figure 9.13.3: Manner of death of cases with mental health issues and known drug use 
status, DS England 2012 
 
Table 9.13.4: Psychoactive substances implicated alone and in combination in 
percentage of cases diagnosed with specific mental health problems, DS England 2012 
 
 Mental health problem (n, %) 
Psychoactive 
substance implicated 
alone and in 
combination 
 
Anxiety 
(37) 
 
Behaviour 
disorder 
(2) 
 
Bipolar 
disorder 
(5) 
 
Depression 
(87) 
 
Eating 
disorder 
(3) 
 
Personality 
disorder 
(11) 
 
Psychosis 
(14) 
 
Other 
mental 
issues 
(40) 
 
Alcohol in 
combination 
15 
(40.5) 
1  
(50.0) 
0  
(0.0) 
25  
(28.7) 
1  
(33.3) 
4  
(36.4) 
1 
 (7.1) 
16 
(40.0) 
Amphetamines 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
1  
(1.1) 
0  
(0.0) 
1  
(9.1) 
1  
(7.1) 
0  
(0.0) 
Anti-depressants 
12 
(32.4) 
0  
(0.0) 
1  
(20.0) 
20 
 (23.0) 
1  
(33.3) 
2  
(18.2) 
4  
(28.6) 
14 
(35.0) 
Anti-epileptics 
1  
(2.7) 
0  
(0.0) 
0 
 (0.0) 
1  
(1.1) 
0  
(0.0) 
1 
 (9.1) 
0  
(0.0) 
0  
(0.0) 
Anti-Parkinson’s 
0 
 (0.0) 
0  
(0.0) 
0 
 (0.0) 
0  
(0.0) 
0 
 (0.0) 
0  
(0.0) 
1  
(7.1) 
0 
 (0.0) 
Anti-psychotics 
5 
(13.5) 
0 
 (0.0) 
2  
(40.0) 
4  
(4.6) 
0 
 (0.0) 
1  
(9.1) 
4  
(28.6) 
4 
(10.0) 
Cannabis 
0 
 (0.0) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
1  
(9.1) 
1  
(7.1) 
0  
(0.0) 
Cocaine 
3  
(8.1) 
0 
 (0.0) 
0  
(0.0) 
4  
(4.6) 
0 
 (0.0) 
1  
(9.1) 
1  
(7.1) 
3 
 (7.5) 
Ecstasy-type drug 
0  
(0.0) 
0  
(0.00 
0  
(0.0) 
0 
 (0.0) 
0  
(0.0) 
0  
(0.0) 
1  
(7.1) 
2  
(5.0) 
GHB/GBL 
0  
(0.0) 
0 
 (0.0) 
0  
(0.0) 
1 
 (1.1) 
0  
(0.0) 
0  
(0.0) 
0 
 (0.0) 
1  
(2.5) 
Heroin/morphine 
18 
(48.6) 
1  
(50.0) 
2  
(40.0) 
31  
(35.6) 
1  
(33.3) 
5  
(45.5) 
4  
28.6) 
13 
(32.5) 
Hypnotics/sedatives 
10 
(27.0) 
0  
(0.0) 
2  
(40.0) 
19 
 (21.8) 
1  
(33.3) 
1 
 (9.1) 
4  
(28.6) 
16 
(40.0) 
Methadone 
5 
(13.5) 
1  
(50.0) 
0  
(0.0) 
13  
(14.9) 
0 
 (0.0) 
2  
(18.2) 
3 
 (21.4) 
4 
(10.0) 
Other opiates/opioid 
analgesics 
17 
(45.9) 
2 
(100.0) 
2  
(40.0) 
38  
(43.7) 
1 
 (33.3) 
5 
 (45.5) 
4  
(28.6) 
18 
(45.0) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death. The case total sums to greater 
than the total number of cases since an individual may have more than one disorder. Cells highlighted in:      indicate the drug most frequently 
implicated for each mental health problem. 
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9.14 Prison 
 
Of the Drug strategy (DS) cases reported to the Programme for 2012, 15 had previously been in 
prison. The majority were male (14/15, 93.3%); White (12/15, 80.0%); unemployed (10/15, 
66.7%); and with past drug-addict history (11/15, 73.3%). When reported, the most common 
causes of detention were drug possession and dealing. 
 
The substances most frequently implicated in death either alone or in combination, were: 
heroin/morphine (8/15, 53.3%); alcohol (6/15, 40.0%); and other opiates/opioid analgesics (6/15, 
40.0%) (Table 9.14). 
 
The primary underlying cause of death in individuals with prison history was accidental poisoning 
(12/15, 80.0%). 
 
Table 9.14 Psychoactive substances implicated in cases with prison history, DS England 
2012 
Drug category Number (%) of cases 
where substance implicated 
TOTAL 15 (100.0) 
Alcohol in combination 6 (40.0) 
Amphetamines 2 (13.3) 
Anti-depressants 2 (13.3) 
Anti-epileptics 1 (6.7) 
Anti-psychotics 1 (6.7) 
Cocaine 2 (13.3) 
Heroin/morphine 8 (53.3) 
Hypnotic/sedatives 5 (33.3) 
Methadone 5 (33.3) 
Other opiates/opioid 
analgesics 6 (40.0) 
Note: column totals may sum to more than 100% since more than one substance may be 
implicated in a death 
 
9.15 Hepatitis and HIV/AIDS 
 
In 2012, a total of 38 DS cases were reported as infected with hepatitis: 30 with hepatitis C; five 
with hepatitis B; and three with unspecified chronic hepatitis. Of those infected with hepatitis C, 
the majority were male (25/30, 83.3%) and known drug users or addicts (23/30 cases, 76.7%). 
 
The main underlying cause of death for this group was accidental poisoning (22/30, 73.3%). The 
principal substances implicated in death were heroin/morphine (14/30, 46.7%); methadone 
(14/30, 46.7%); and alcohol alone or in combination (14/30, 46.7%) (Table 9.15.1). In 9/35 cases 
(25.7%) hepatitis C was reported as a contributory factor of death. Hepatitis C is frequently 
associated with IV drug use, and among the individuals who had hepatitis C and whose drug use 
status was known, almost all were known to be drug users (23/24, 95.8%), and nine of these 
were known to use IV drugs. The implicated drugs data for the three different forms of hepatitis 
reported are summarised in Table 9.15.1. 
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Table 9.15.1: Psychoactive substances implicated in cases with hepatitis C, hepatitis B 
and other hepatitis, DS England 2012 
Drug category Hepatitis C 
(n, %) 
Hepatitis B 
(n, %) 
Other hepatitis 
unspecified  
(n, %) 
TOTAL 30 (100.0) 5 (100.0) 3 (100.0) 
Alcohol in 
combination 
14 (46.7) 4 (80.0) 1 (33.3) 
Amphetamines 2 (6.7) 0 (0.0) 0 (0.0) 
Anti-depressants 4 (13.3) 1 (20.0) 0 (0.0) 
Anti-psychotics 2 (6.7) 0 (0.0) 0 (0.0) 
Cocaine 7 (23.3) 3 (60.0) 1 (33.3) 
Ecstasy-type drug 1 (3.3) 0 (0.0) 0 (0.0) 
Heroin/morphine 14 (46.7) 3 (60.0) 3 (100.0) 
Hypnotics/sedatives 6 (20.0) 3 (60.0) 1 (33.3) 
Methadone 14 (46.7) 3 (60.0) 1 (33.3) 
Other opiates/opioid 
analgesics 
11 (36.7) 2 (40.0) 0 (0.0) 
Note: column totals may sum to more than 100% since more than one substance may be implicated in a death 
 
A total of four DS cases for 2012 were reported as suffering from HIV/AIDS, all of whom were 
male and White, with three known to use drugs, with one of these known to use IV drugs. The 
substances implicated in their deaths are summarised in Table 9.15.2. 
 
 
Table 9.15.2: Psychoactive substances implicated in cases with HIV/AIDS, DS England 
2012 
Drug category 
Number of cases where 
substance implicated (%) 
TOTAL 4 (100.0) 
Alcohol in combination 3 (75.0) 
Anti-depressants 2 (50.0) 
Anti-psychotics 1 (25.0) 
Cocaine 2 (50.0) 
Heroin/morphine 2 (50.0) 
Hypnotic/sedatives 2 (50.0) 
Methadone 1 (25.0) 
Other opiates/opioid 
analgesics 2 (50.0) 
Note: column totals may sum to more than 100% since more than one substance may be 
implicated in a death 
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Appendix 1: The National Programme on Substance Abuse 
Deaths (NPSAD) 
Aims and objectives 
The Programme’s principal aim is to reduce and prevent drug-related deaths in the UK due to 
the misuse of drugs, both licit and illicit, by collecting, analysing, and disseminating information 
on the extent and nature of death.  
The Programme’s objectives are to: 
 Collect and collate drug-related mortality data 
 Develop and maintain a computerised surveillance system  
 Identify substances implicated in drug-related deaths – including new drugs and new 
combinations 
 Monitor and examine patterns and trends, e.g. geographic, demographic, substances 
implicated in death, method of death 
 Act as an early warning system for new trends in mortality and drug misuse 
 Use data as an indicator to estimate the prevalence of substance-related problems and 
assess the hazards associated with substance abuse 
 Collaborate with relevant agencies in research on substance-related mortality locally, 
nationally and internationally  
 Inform and facilitate discussion on the prevention of drug-related deaths, whether accidental 
or intentional 
 Provide data for local and national drug abuse policy formulation and programme planning 
 Disseminate information on drug-related mortality to the scientific community, clinicians, 
policy makers and other interested parties 
 
Surveillance data management 
Data collated for this programme is stored on the NPSAD Coroners’ database which was 
established in 1997. Its purpose is to provide information for the Programme’s surveillance 
system of monitoring drug-related deaths reported by Coroners, procurators fiscal and other 
agencies.   
Data collection 
All Coroners in the UK (see Appendix 3) are issued with copies of the standard data collection 
form (see Appendix 4). They are invited to complete the forms on all deaths that meet the criteria 
described in this report (see Appendix 2) and return them to the NPSAD team at St. George’s, 
University of London for coding and entry onto the database.  
Data submission is mostly directly on paper by Coroners or their staff. Forms are submitted 
when inquests are complete. Manual extraction of data by team members is undertaken at some 
Coroners’ courts.  
A monitoring process is undertaken to ascertain the quality of the information received from 
Coroners, as well as the extent to which all relevant cases are being identified and submitted. 
This assists in further improving the quality of the various outputs that the Programme seeks to 
provide. 
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Data entry and coding 
To enable comparison with various national and international datasets all causes of death have 
been coded according to the International Classification of Diseases (ICD-10). This is an 
international standard for the classification of diseases and health-related problems published by 
the World Health Organisation (1992). The online version (ICD-10 2010) has been employed for 
coding all substances implicated in death separately according to its therapeutic drug category, 
i.e. hypnotics/sedatives, anti-depressants, opiates, etc. 
The ‘intentionality‘ of deaths based on the Coroner’s verdict and/or or other additional 
information employing ICD-10 codes is inadequate for informing interested parties as to whether 
certain categories of drug-related deaths can be prevented.  
Whilst the ‘cause’ of death (as given in the preceding section) is concerned with the disease or 
injury responsible for the lethal sequence of events, the ‘manner’ of death explains how the 
cause of death arose, i.e. a natural or violent death. The categories for ‘manner of death’ have 
been adopted from the UK practice (Explore Forensics http://www.exploreforensics.co.uk/the-
four-manners-of-death.html) with the additional categories for those where intentionality is 
unclear or manner of death is impossible to determine: natural, accidental, suicidal, homicidal, 
undetermined, and unclassified/not specified. Verdicts of ‘dependence on drugs’ or ‘non-
dependent abuse of drugs’ are regarded as ‘accidental’. The ‘manner of death’ is derived from 
information such as the verdict or ‘finding’, history of drug misuse or dependence, post mortem 
drugs, and other information; and is based on the interpretation of the death by NPSAD and 
clinical presentation/profile of the individual case. 
Statistical analysis 
Due to the nature of the information collected by the programme, i.e. drug-related deaths as 
reported by the Coroners, this is an observational study. Hence, statistical methods employed 
are based on proportions. The data were analysed using IBM ® SPSS™ Statistics for Windows 
version 19. 
Data Storage 
The anonymised data-set for Coroners is held on a SPSS database for analysis.  All data held, 
whether electronic or paper, is stored securely and treated as confidential.  Access is restricted 
to Programme staff; only aggregated and anonymised data are released to third parties. 
Quality Assurance of Data 
The Programme has given consideration as to how it can ensure the quality, accuracy and 
comprehensiveness of the data collected in order to improve both the quality of information 
collected and to establish if all relevant cases are being identified and notified. Following a pilot 
phase in 2008-9, a programme of visits to a sample of geographically representative Coroners’ 
areas in England and Wales was undertaken in 2009-10.  
Such surveys help to establish the extent to which cases are being correctly identified. This 
makes it possible to extrapolate from the deaths notified by participating areas to the expected 
number of cases if all Coroners were reporting all cases, thereby providing a much more precise 
estimate of drug-related deaths (DRDs) for policy and intervention planning. 
This activity also provides insights into the quality and accuracy of the information submitted to 
the Programme, and has provided a firm basis for a process of audit in the future, thereby 
ensuring the consistent validation of the Programme’s surveillance work. This work also 
facilitates the drawing up of detailed guidance for Coroners and their staff in identifying and 
reporting relevant cases to NPSAD.  
The methodology used for this study was to select and examine completed inquests for deaths, 
available in Coroners’ offices, occurring in 2008. A statistically representative sample of 150 
DRDs reported to the Programme was drawn for the quality assurance aspect based on cases 
reported by Coroners in England and Wales.  
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To ascertain the accuracy of case identification and reporting, a 10% sample of records was 
drawn randomly from files for all completed inquests (for whatever reason) for each selected 
Coroner’s area. A total of 375 such completed inquests on all types of death in 2008 were 
examined.  
Geographical representativeness was based on selecting one Coroner’s area in each of the ten 
Strategic Health Authority (SHA) areas in England and two in Wales. For England there was a 
two-stage sampling process. In the first stage, three Coroners’ areas from each SHA area was 
selected on the basis of the highest number of inquests completed. The second stage consisted 
of randomly selecting one of these three areas for investigation.  
The key findings from this survey show that the information received by the Programme from 
Coroners is consistent with the Coronial inquest file papers. This exercise did not identify any 
‘false positives’ i.e. any over-reporting.  
In 2008 five cases, where one or more controlled drugs or psychoactive substances were 
mentioned, were not reported to NPSAD. An extrapolation of these five cases projects an 
increase of 50 in the number of reported cases from Coroners in England and Wales in 2008. 
The degree of under reporting in both the 2007 and 2008 cases is comparable (3.9% and 3.3% 
respectively). This underlines the consistency in reporting. 
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Appendix 2: Definitions of drug-related death 
 
NPSAD definition 
An NPSAD case is defined as a relevant death where any of the following criteria are met at a 
completed inquest, fatal accident inquiry or similar investigation: 
 One or more psychoactive substances* directly** implicated in death; 
 History of dependence or abuse of psychoactive drugs;  
 Presence of Controlled Drugs*** at post mortem; or 
 Cases of deaths directly due to drugs but with no inquest. 
  
Alcohol is included only when implicated in combination with other qualifying drugs, as are 
solvents.  
 
* ‘Psychoactive’ substances are those having a direct effect on perception, mood, cognition, 
behaviour or motor function. Typically these include opiates and opioid analgesics, hypnotics, 
sedatives, anti-depressants, anti-epileptics, anti-psychotics, hallucinogens, and stimulants (such 
as amphetamines and cocaine) and “legal highs”. 
 
** ‘Directly implicated’ means that drugs were considered by the Coroner or other person 
investigating the death to have been instrumental in the coming about of the deceased’s death 
(e.g. through poisoning or intoxication), or causing their powers of reasoning and/or perception 
to be so affected as to induce them to take risks which they would not have done had they been 
sober (e.g. thinking they could fly). 
 
*** ‘Controlled Drugs’ are those drugs specifically classified by the Misuse of Drugs Act 1971 as 
amended by subsequent legislation.  Controlled drugs include opioids, cocaine, amphetamines, 
cannabis, GHB, hallucinogens and most benzodiazepines.  
 
Who is a drug abuser/dependent? 
A drug abuser/dependent case is defined as one with a history of substance abuse where one or 
more of the following criteria are met: 
 Reported as a known illicit drug user by the Coroner, based on evidence obtained at 
inquest; 
 Prescribed substitute medication for drug dependence; 
 Presence of an illicit drug at post mortem, where not prescribed; or  
 Presence of any additional information on the Coroner’s report suggestive of a history of 
drug abuse, and where such a history fulfils ICD-10 criteria: (F11-F16 and F19, using the 4-
code subdivisions of .0 (acute intoxication), .1 (harmful use), and .2 (dependence 
syndrome). 
 
“Drug misuse” definition 
 
Cause of death categories included in the headline indicator of ‘drug misuse’ deaths used to 
monitor progress against the Government’s drug strategy are defined in terms of ICD-10 codes 
and Controlled Drug Status.  The relevant codes from ICD-10 are given in brackets. 
 
The definition comprises two types of deaths: 
 
a) deaths where the underlying cause of death has been coded to the following categories of 
mental and behavioural disorders due to psychoactive substance use (excluding alcohol, 
tobacco and volatile solvents): 
(i) opioids (F11); 
(ii) cannabinoids (F12); 
(iii) sedatives or hypnotics (F13); 
(iv) cocaine (F14); 
(v) other stimulants, including caffeine (F15); 
(vi) hallucinogens (F16); and 
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(vii) multiple drug use and use of other psychoactive substances (F19) 
 
b) deaths coded to the following categories and where a drug controlled under the Misuse of 
Drugs Act 1971 was mentioned on the death record: 
(i) Accidental poisoning by drugs, medicaments and biological substances (X40–X44); 
(ii) Intentional self-poisoning by drugs, medicaments and biological substances (X60–X64); 
(iii) Poisoning by drugs, medicaments and biological substances, undetermined intent (Y10–14); 
(iv) Assault by drugs, medicaments and biological substances (X85); and 
(v) Mental and behavioural disorders due to use of volatile solvents (F18) 
 
Notes: 
1. Deaths coded to opiate abuse which resulted from the injection of contaminated heroin 
have been included in the indicator. This differs from the approach taken in Scotland, 
where these deaths have been excluded. This is because the General Register Office 
for Scotland (GROS) is able to identify deaths which occurred as a result of the use of 
contaminated heroin, whereas in England and Wales, these deaths cannot be readily 
identified. In practice, in England and Wales, they will only be included where the drug 
was mentioned on the death record and the death was coded to one of the ICD codes 
on the ONS database of drug-related poisonings and not to an infection code. 
 
2. Specific rules were adopted for dealing with compound analgesics which contain 
relatively small quantities of drugs listed under the Misuse of Drugs Act, the major ones 
being dextropropoxyphene, dihydrocodeine and codeine. Where these drugs are 
mentioned on a death record, they have been excluded if they are part of a compound 
analgesic (such as co-proxamol, co-dydramol or co-codamol) or cold remedy. 
Dextropropoxyphene has been excluded on all occasions, whether or not paracetamol 
or a compound analgesic was mentioned. This is because dextropropoxyphene is rarely, 
if ever, available other than as part of a paracetamol compound. However, codeine or 
dihydrocodeine mentioned alone were included in the indicator. This is because they 
are routinely available and known to be abused in this form. This approach is taken by 
both the Office for National Statistics and the General Register Office for Scotland. 
 
3. Drugs controlled under the Misuse of Drugs Act 1971 include class A, B and C drugs. 
 
Definition used by SCDEA 
 
Deaths reported to the SCDEA by Scottish police forces are those which meet the definition 
used by the Association of Chief Police Officers (Scotland) – “where there is prima facie 
evidence of a fatal overdose of controlled drugs. Such evidence would be recent drug misuse, 
for example controlled drugs and/or a hypodermic syringe found in close proximity to the body 
and/or the person is known to the police as a drug misuser although not necessarily a notified 
addict.”  Thus, most suicides in Scotland will be excluded. 
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Appendix 3: Coroners’ jurisdictions in England and Wales, 2012 
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Key to jurisdictions  
North East  
101 – Darlington and South Durham  
102 – North Durham  
103 – Hartlepool  
104 – North Northumberland  
105 – South Northumberland  
106 – Teesside  
107 – Gateshead and South Tyneside  
108 – Newcastle upon Tyne  
109 – North Tyneside  
110 – Sunderland  
 
North West 
201 – Cheshire  
203 – South and East Cumbria  
204 – North and West Cumbria  
205 – Manchester (city)  
206 – Manchester North Coroners   
207 – Manchester South  
208 – Manchester West  
209 – Blackburn, Hyndburn and Ribble Valley  
210 – Blackpool and Fylde  
211 – East Lancashire  
212 – Preston and West Lancashire  
213 – Sefton, Knowsley and St Helens  
214 – Liverpool  
215 – Wirral  
 
Yorkshire and the Humber  
301 – East Riding and Hull  
302 – North Lincolnshire and Grimsby  
303 – York City  
304 – North Yorkshire - East  
305 – North Yorkshire - West  
306 – South Yorkshire - East  
307 – South Yorkshire - West  
308 – West Yorkshire - East  
309 – West Yorkshire - West  
 
East Midlands  
401 – Derby and South Derbyshire  
402 – North Derbyshire  
403 – Leicester and South Leicestershire  
404 – North Leicestershire and Rutland  
406 – Central Lincolnshire  
408 – South Lincolnshire  
409 – Northamptonshire  
410 – Nottinghamshire  
 
West Midlands 
501 – Herefordshire  
502 – North Shropshire  
503 – South Shropshire  
504 – Staffordshire South  
505 – Stoke-on-Trent and North Staffordshire  
506 – Telford and Wrekin  
507 – Warwickshire  
508 – Birmingham and Solihull  
509 – Black Country  
510 – Coventry  
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512 – Worcestershire  
 
East of England  
601 – Bedfordshire and Luton  
602 – North and East Cambridgeshire  
603 – South and West Cambridgeshire  
604 – Essex and Thurrock  
605 – Hertfordshire  
607 – Norfolk  
609 – Peterborough  
610 – Southend on Sea  
611 – Suffolk 
 
London  
701 – City of London [not visible]  
702 – East London  
703 – Inner London North  
704 – Inner London South  
705 – Inner London West  
706 – North London  
707 – South London  
708 – West London  
 
South East  
801 – Berkshire  
802 – Brighton and Hove  
803 – Buckinghamshire  
804 – East Sussex  
805 – Central Hampshire  
806 – North East Hampshire  
807 – Portsmouth and South East Hampshire  
808 – Southampton and New Forest  
809 – Isle of Wight  
810 – Central and South East Kent  
811 – Mid Kent and Medway  
812 – North East Kent  
813 – North West Kent  
814 – Milton Keynes  
815 – Oxfordshire  
816 – Surrey  
817 – West Sussex  
 
South West  
901 – Avon  
902 – Cornwall  
903 – Exeter and Greater Devon  
904 – Plymouth and South West Devon  
905 – Torbay and South Devon  
906 – Bournemouth and Eastern Dorset  
907 – Western Dorset  
908 – Gloucestershire  
909 – Isles of Scilly  
910 – Eastern Somerset  
911 – Western Somerset  
912 – Wiltshire and Swindon  
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Wales  
1001 – Bridgend and Glamorgan Valleys  
1002 – Cardiff and Vale of Glamorgan  
1003 – Carmarthenshire  
1004 – Central North Wales  
1005 – Ceredigion  
1006 – Gwent  
1007 – Neath and Port Talbot  
1008 – North East Wales  
1009 – North West Wales  
1010 – Pembrokeshire  
1011 – Powys  
1012 – City and County of Swansea 
(Map and list reprinted with permission, under the Open Government Licence (OGL), from the  Coroners 
Statistics 2012 England and Wales. Ministry of Justice Statistics Bulletin) 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/2/ 
Northern Ireland 
Comprising the whole of Northern Ireland 
 
Scotland Police Force areas 
Argyll & Clyde 
Central Scotland Police 
Dumfries & Galloway Constabulary 
Fife Constabulary 
Grampian Police 
Lothian & Borders Police 
Northern Constabulary 
Strathclyde Police 
Tayside Police 
The Islands Jurisdictions 
Guernsey, Jersey and the Isle of Man 
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Appendix 4: NPSAD data collection form 
The National Programme on Substance Abuse Deaths (NPSAD) 
NOTIFICATION OF DRUG-RELATED DEATHS 
 
Section I Demographic information 
Deceased forename(s): _____________________________   Gender:   Male     Female 
 
Family name: ____________________Other names known by: _______________________ 
 
Date of birth: ______/______/______ Place of birth: ________________________________ 
 
Usual address: ______________________________________________________________ 
 
_____________________________________________Postcode:  __________________________ 
 
Ethnicity (tick one only) 
 White   Pakistani   Black African   Other, specify_________  
 Chinese  Bangladeshi   Black Caribbean  Not known 
 Indian   Black other, specify ______________   
 
Occupational status (tick one only) 
 Employed (manual)   Unemployed    Retired  
 Employed (non-manual)  Childcare/houseperson  Student/pupil 
 Self employed   Invalidity/sickness   Other, specify_________  
 Not known 
 
Living arrangements (tick one only) 
 Alone    Self and children   No fixed abode  
 With partner    With parent(s)  Other, specify_______________ 
 With partner & children  With friend(s)  Not known 
 
 
Section II Details of death 
 
Date of death: _______/_______/_________   
 
Place of death: (tick one only) 
 Home   Residential premises (.e. hotel)   In custody  
 Place of work   Street or highway    Place of recreation/sport 
 Treatment centre  Educational establishment   Hospital 
 Other place, specify________________________________________________________ 
 
Cause(s) of death (as given on the death certificate) 
 
1(a) _______________________________________________________________________ 
(b) _______________________________________________________________________  
  (c) ________________________________________________________________________ 
2 _________________________________________________________________________ 
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The National Programme on Substance Abuse Deaths (NPSAD) 
 
 
Toxicology 
Please list drugs and alcohol present at post mortem   (in order of importance, if known) 
 
 Drug/alcohol Level   Drug/alcohol Level 
  B T U   B T U 
1     4     
2     5     
3     6     
B = Blood; T = Tissues; U = Urine 
 
Section III  Coroner’s verdict   
 
 
 
 
Section IV  Background information 
Recent history of drug use and other relevant information: e.g. evidence of injecting drug 
use; evidence of ‘crack’ use; recently released from prison or discharged from treatment 
programme; psychiatric history; known to alcohol/drug services; length of use; poly-substance 
user; known health problems associated with substance misuse; last 24 hours of life (if 
known), time police summoned, any drugs paraphernalia, etc.: 
 
 
 
 
 
 
 
 
Was the deceased on prescribed psychoactive medication?  Yes  No  Not known 
If yes, please list drugs:  
1 _______________________________      2 ___________________________ 
3 _______________________________        4 ___________________________ 
5 _______________________________  6 ___________________________                          
 
Was the deceased a drug addict or known drug abuser?   Yes  No  Not known 
 
 
Section V Coroner’s details 
 
Coroner’s name: __________________________Date inquest completed: ____/_____/_____ 
Jurisdiction: __________________________________ Office: _______________________ 
Signature: ___________________________________ Date: _______/________/________ 
 
Please send completed form to:  
 
National Programme on Substance Abuse Deaths (NPSAD) 
    International Centre for Drug Policy 
    St George’s, University of London 
   FREEPOST LON 10141,  
London SW17 0BR 
 
For general enquiries: Tel 020 8725 5522 
            Email icdp@sgul.ac.uk 
 
This form is available electronically 
 
